Poly(lactide-co-glycolide) devices for drug delivery by Campbell, Christopher
 1 
Poly(lactide-co-glycolide) Devices 
for Drug Delivery 
 
 
Christopher S. J. Campbell 
 
Doctor of Philosophy 
 
University of Bath 
Department of Chemical Engineering and  
Department of Pharmacy and Pharmacology 
 
September 2008 
 
 
 
COPYRIGHT 
Attention is drawn to the fact that copyright of this thesis rests with its author. A 
copy of this thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with the author and they must not 
copy it or use material from it except as permitted by law or with the consent of the 
author. 
 
This thesis may be made available for consultation within the University Library and 
may be photocopied or lent to other libraries for the purposes of consultation. 
 
 
 
 2 
Abstract 
Ovarian cancer is one of the five most common causes of cancer death in women in 
the USA and UK. It is usually diagnosed when it is well established beyond the 
ovary in the peritoneum. Intravenous injection of cisplatin is a common palliative 
therapy for ovarian cancer patients. Intraperitoneal therapy has been shown to 
improve survival for patients. Poly(lactide-co-glycolide) (PLGA) is a biodegradable 
polyester which has been proven safe for medical implantation. PLGA microspheres 
or fibres have been considered in this work as depots for delivering intraperitoneal 
cisplatin directly to the tumour site. The aims of this work were (1) to develop 
microsphere depot formulations with improved drug release profiles compared to 
previous work. (2) Novel cisplatin containing solid and hollow fibres were to be 
developed and investigated as alternative structures for depot devices. (3) The drug 
release profiles were to be examined using mathematical models to allow rational 
comparison of the devices. The suitability of different mathematical models was also 
considered.  
 
Cisplatin undergoes a ligand exchange in the presence of water, forming a potent 
electrophile. This charged cisplatin species readily forms DNA-platinum adducts. 
These adducts are thought to be the major mechanism of toxicity to cancer cells. 
Charged cisplatin also binds other nucleophiles in cells. Cisplatin binding to other 
cellular components reduces the amount of cisplatin available for DNA attack. 
Irreversible protein binding influences cisplatin pharmacokinetics compared to other 
drugs. Therefore, an additional aim of this project was (4) to investigate irreversible 
binding of cisplatin to non-DNA targets, such as cisplatin binding to protein. 
 
The surfaces of all implanted medical devices are susceptible to bacterial attachment. 
Bacteria are able to survive on implants in a hostile environment-resistant slow 
growth mode. A further aim of this thesis was (5) to investigate attachment of 
bacteria to PLGA depots. 
 
Cisplatin containing PLGA 50:50 and 65:35 microspheres were prepared using less 
toxic solvents than those manufactured elsewhere while achieving equivalent release 
profiles. The particle size distributions of batches of microspheres were measured 
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using laser scattering. Batches had median diameters of 25-66 µm. Cisplatin 
containing PLGA 65:35 solid fibres and hollow fibres were fabricated by spinning 
polymer dissolved in organic solvent into a water bath where solidification (phase 
inversion) occurred. A novel method was developed for drug delivery applications 
that included a freeze drying step that maximized encapsulation of the drug. This 
method may be suitable for improving the drug loading of any fibres used to 
encapsulate water soluble drugs. The drug loading of solid (15 %) and hollow (27 %) 
fibres produced by this method was higher than the best drug loading of PLGA 
microspheres (10 %) produced in this work and elsewhere. Cisplatin release profiles 
for all three depot structures were determined using atomic absorption spectroscopy 
(AAS). The devices were also examined using scanning electron microscopy and 
backscattering electron imaging. 
 
Semi-empirical and mechanistic models derived from Fick’s laws of diffusion were 
successfully used to model the data. The diffusivity of cisplatin in microspheres was 
lowest in microspheres at 4×10-11 cm2 s-1. The diffusivity of cisplatin in PLGA 65:35 
hollow fibres was calculated as 3×10-10 cm2 s-1 using a model derived from Fick’s 
second law. Using Higuchi kinetics the diffusivity of cisplatin in PLGA solid fibres 
was shown to be similar to the diffusivity cisplatin is hollow fibres. The porous 
structure of solid and hollow fibre matrix produces more rapid diffusion than occurs 
in the solid matrices of microspheres. 
 
Cisplatin binding to bovine serum albumin (BSA) was determined by combining 
protein precipitation using cold ethanol with acid digestion and AAS. Cold ethanol 
precipitation was equivalent to ultrafiltration, the gold standard for removing BSA 
from solution. Cold ethanol precipitation is here established as a suitable method for 
in vitro investigation of irreversible protein binding phenomena. The rate of 
irreversible cisplatin binding to protein was found to be 6±1×10-5 s-1 in vitro. First 
order models were successfully used to model in vitro data of dynamic cisplatin 
release and protein binding systems to an acceptable level of accuracy. 
 
Staphylococcus epidermidis is an important pathogen associated with long term 
implanted polymeric devices such as intravenous catheters. S. epidermidis was 
observed to rapidly bind to PLGA microspheres and fibres in vitro. Attached cell 
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numbers can be reduced by freeze-drying or exposure to 70 % ethanol for 60 
seconds. Increasing the amount of depot present increased the number of cells 
bound. Although bacterial attachment to depot devices does occur, surveillance 
information of commercial PLGA implants suggests that the infection rates are low 
(<5 %). 
 
In conclusion, cisplatin containing PLGA 65:35 solid and hollow fibres represent a 
novel, reproducible formulation for encapsulating higher amounts of cisplatin for an 
equivalent mass of excipient than other polymer formulations. The fibres developed 
in this study were able to maintain elevated concentrations of unbound cisplatin in 
the presence of a biological matrix for approximately 100 hours in vitro. 
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Abbreviations 
AAS Atomic absorption spectroscopy 
AIC  Akaike’s information criterion 
ATP7A Copper-transporting P-type ATPase 7A 
BSA Bovine serum albumin 
CD20 Non-glycosylated phosphoprotein CD20 
cfu Colony forming units 
CTR1 Copper-transporting membrane protein 1 
DCM Dichloromethane 
DMF N,N-Dimethyl formamide 
ERCC1—XPF Excision repair cross complementing 1—xeroderma   
 pigmentosum, complementation group F complex 
GnRH Gonadotropin-releasing hormone 
IP Intraperitoneal 
IV Intravenous 
LC50 Concentration of a chemical that is lethal to 50 % of a defined 
 group of animals (mg ml-1) 
LD50 Dose of a chemical that is lethal to 50 % of a defined group of 
 animals (mg) 
NER Nucleotide excision repair 
NMP N-methyl-2-pyrrolidone 
PBS Phosphate buffered saline 
PGA Poly(glycolide) 
PLA Poly(lactide) 
PLGA Poly(lactide-co-glycolide) 
PVA Poly(vinyl alcohol) 
rpm Revolutions per minute 
TSA Tryptone soya agar 
TSB Tryptone soya broth 
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Nomenclature 
A Exposed area of a membrane (cm2). 
AB Constant to be determined for solution of Bessel’s equation. 
AW Aggregated constant for pharmacokinetic model. 
a  Radius of solid fibre or inner radius of hollow fibre (cm). 
α Positive roots of Bessel function. 
αW Root of pharmacokinetic polynomial. 
BB Constant to be determined for solution of Bessel’s equation. 
BW Aggregated constant for pharmacokinetic model. 
b  Outer radius of hollow fibre (cm). 
β Random errors. 
βW Root of pharmacokinetic polynomial. 
C Concentration (mg ml-1). 
C(r, t) Concentration in solution at (r) at time = t (mg ml-1). 
C(x, t) Concentration in solution at (x) at time = t (mg ml-1). 
C(x, y, z, t) Concentration in solution at (x, y, z) at time = t (mg ml-1). 
C(0) Starting concentration in solution at time = 0 (mg ml-1). 
Cs Solubility of the drug in the solvent (mg ml
-1). 
c Intercept of linear model describing bacterial attachment to  
 microspheres. 
c12 Rate constant of transfer from aqueous (W1) to peripheral (W2) 
 compartment (s-1). 
c21 Rate constant of transfer from peripheral (W2) to aqueous (W1)
 compartment (s-1). 
cel Rate constant of elimination total cisplatin from central 
 compartment (W1) (s-1). 
count Cell count of colony forming units which made weak 
 interactions with microspheres (cfu ml-1). 
D Apparent diffusivity of drug in homogeneous matrix (cm2 s-1). 
DW Dose (mg). 
d Coefficient of linear model describing influence of initial 
 culture concentration on bacterial attachment to microspheres. 
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dd Coefficient of linear model describing the influence of 
 arbitrary dilution of bacterial culture. 
∆C∆t Change in concentration over small time. 
e Coefficient of linear model describing influence of mass of  
 microspheres present on bacterial attachment to microspheres. 
f Coefficient of linear model describing influence of additional 
 wash step on bacterial attachment to microspheres. 
g Centripetal acceleration of a centrifuge equivalent to the 
 acceleration due to earth’s gravity (9.8 m s-1) 
h Theoretical distance in Higuchi kinetics describing depth into 
 a slab from which drug has begun eluting. 
init Initial concentration of bacteria (cfu ml-1). 
j(r, t) Flux of material is the rate of transfer per unit area of section  in 
 the direction r (mg cm-2). 
j(x, t) Flux of material is the rate of transfer per unit area of section  in 
 the direction x (mg cm-2). 
j12 Rate constant of transfer of unbound cisplatin from central (U1) 
 to peripheral (U2) compartment (s-1). 
j21 Rate constant of transfer of unbound cisplatin from peripheral 
 (U2) to central (U1) compartment (s-1). 
jel Rate constant of elimination unbound cisplatin from central 
 compartment (U1) (s-1). 
k Release constant using Higuchi kinetics (mg cm-2 s-0.5). 
k21 Rate constant of release from X2 into X1 compartment of two 
 compartment model (s-1). 
k31 Rate constant of fast release from X3 into X1 compartment of 
 three compartment model (s-1). 
k41 Rate constant of slow release from X4 into X1 compartment of 
 three compartment model (s-1). 
kb Protein-drug binding constant (s
-1). 
λi Roots of the denominator polynomial, Q(s), in general partial 
 fraction theorem. 
M(t) Amount of drug released at time = t (mg). 
M(∞)  Total drug (released after large time) (mg). 
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M2(∞) Total drug in depot X2 compartment of two compartment model 
 (mg). 
M3(∞) Total drug in depot rapidly released from X3 compartment of 
 three compartment model (mg). 
M4(∞) Total drug in depot slowly released from X4 compartment of 
 three compartment model (mg). 
mass Mass of microspheres (bacterial attachment studies) (mg). 
n An integer. 
P A point defined using rectangular (x, y, z) or polar (r, θ, z) 
 coordinates. 
P(·) Numerator polynomial in general partial fraction theorem. 
p Number of parameters used in a model when calculating AIC.  
Q(·) Denominator polynomial in general partial fraction theorem. 
R Microsphere radius (cm). 
R(·) A function of radius, r. 
r Radial distance of a point, P from z in polar space (cm). 
s Standard notation used in Laplace operations. 
σ 2 Variance. 
T(·) A function of time, t. 
t Time (s or h). 
θ Angle from z axis to point, P, in polar space. 
U1 Concentration of unbound cisplatin in central compartment 
 (µg ml-1). 
U2 Concentration of unbound cisplatin in peripheral compartment 
 (µg ml-1). 
U3 Concentration of unbound cisplatin in peritoneal compartment 
 (µg ml-1). 
u An undefined variable. 
V Volume of matrix containing drug (ml). 
W1 Concentration of total cisplatin in central compartment 
 (µg ml-1). 
W2 Concentration of total cisplatin in peripheral compartment 
 (µg ml-1). 
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W3 Concentration of total cisplatin in protein bound compartment 
 (µg ml-1). 
wash Number of wash steps (bacterial attachment studies). 
X(·) A function of length, x. 
X1 Concentration in solution compartment following drug release 
 (mg ml-1). 
X2 Concentration in depot compartment for two compartment 
 model (mg ml-1). 
X3 Concentration in rapid release compartment of three 
 compartment model (mg ml-1). 
X4 Concentration in slow release compartment of three 
 compartment model (mg ml-1). 
x Distance in rectangular space. 
y Distance in rectangular space perpendicular to x. 
z Distance in rectangular space perpendicular to x and y and in 
 polar space. 
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1 Introduction 
1.1 Need for Implantable Drug Release Devices 
Modern medicine is able to cure many diseases that were at one time fatal. Some 
diseases can only be treated toxic drugs which have severe side effects in the patient. 
To reduce harm to patients such drugs may be administered slowly. This allows the 
patient to recover from the side effects of the drug at the same time as treating the 
condition. Drugs can be administered as courses of pills, injections or infusions over 
hours, days or weeks. This ensures that the effective concentration of the drug in the 
blood is reached without causing the plasma concentration of the drug to rise to toxic 
levels. 
 
An estimated 6.7 million people die of cancer every year globally (Parkin et al., 
2005). Cancer is difficult to prevent, although risks can be reduced by lifestyle 
choices, such as not smoking. Cancer is often difficult to diagnose at an early stage 
as there may be few early symptoms. Cancer drugs are extremely toxic (section 
1.3.2) and have limited efficacies for some patients. Cycles of dosing are required for 
sufficient drug exposure while minimizing the severe side effects. Resident catheters 
can be used to extend drug delivery duration to several days or weeks. Yet 
hospitalising patients for extended periods during distressing illness is unpopular 
with patients and expensive. 
 
Implantable drug release devices can prolong drug exposure at the tumour site and 
minimise maximum blood plasma concentration of the drug. Depot formulations are 
currently used for treating some types of tumour (section 1.5.4.4). A depot of 
chemotherapeutics could improve therapy for other types of cancer. This thesis 
investigates the possibility of using biodegradable polyesters to act as a depot for 
platinum drugs, such as cisplatin, for treating ovarian cancer. 
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1.2 Thesis Outline 
This thesis is divided into chapters which outline experimental investigations. 
Delivery of platinum containing chemotherapeutics to ovarian cancer is considered 
as a good example of an opportunity for slow release therapy using implantable 
devices. Section 1 reviews current drug delivery technologies with a focus on 
platinum therapy for ovarian cancer. Section 2 gives details of the experimental and 
statistical methods used for this work. Experimental results and discussion are 
presented in Section 3 with overall conclusions in Section 4.  
 
Section 1 examines the mode of action of platinum therapy for ovarian cancer. It 
discusses strategies for reducing the toxicities associated with cisplatin therapy. 
Mathematical analysis of diffusion from drug delivery devices is reviewed. Bacterial 
contamination of implants is also considered. Section 2 describes the manufacture of 
microspheres, solid fibres and hollow fibres used in this work. Descriptions of 
device analysis methods used are included. Methods used for studying attachment of 
Staphylococcus epidermidis to PLGA devices are presented. Section 3 gives details 
of results of physical analysis of PLGA devices and studies of release kinetics. The 
binding of cisplatin to biological materials is investigated. The attachment and 
removal of bacteria from PLGA devices is considered. 
1.3 Cancer Treatment 
1.3.1 Cancer 
Cancer is a major cause of death among populations which have affordable 
healthcare to control infectious diseases. In the United States an estimated 23 % of 
deaths were due to cancer in 2004, second only to heart disease as the most likely 
cause of death (Jemal et al., 2007). 
 
Cancer is the collective term for the 200 or so diseases which occur when healthy 
body cells are freed from the restrictions of the cell cycle. To grow and maintain a 
functioning organism, control of cell proliferation must be absolute. Cells which 
detect that they are damaged commit suicide (apoptosis) and the immune system 
continuously purges the body of questionable cells. Three types of change occur in 
cells which become tumours. Cells must be immortalised, growing indefinitely. They 
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must be transformed meaning they no longer require the normal cell growth factors 
which would otherwise control them. They must also be able to undergo metastasis 
whereby cells are able to form colonies in other parts of the body (Lewin, 2000). In 
addition, tumour cells must not be immunogenic so avoid destruction by the immune 
system (Shankaran et al., 2001). Once growth is no longer constrained, the cells are 
able to infiltrate other organs, disrupting them and ultimately resulting in death of the 
patient.  
 
Cancers develop from the stem cells of the parent tissue. As an organ may consist of 
many tissues, most organs have several types of cancer associated with them. 
Cancers are classified by the tissue or organ of origin, morphological appearance of 
the tumour and spread (progression) of the disease. Although molecular 
classification of tumours may become possible, for example using genetic 
microarrays (Golub et al., 1999), these technologies are not yet mature. 
 
Figure 1: Estimated annual cancer deaths in the US for 2007 by site of cancer.  
Ovarian cancer (grey bar) is responsible for 2.7 % of all cancer deaths. Data from Jemal et 
al., 2007. 
 
Figure 1 shows estimated numbers of cancer deaths for the United States for 2007 
for tumours originating at different sites. Cancers of the respiratory and digestive 
systems account for 35 % of new cases of cancer a year and are responsible for 54 % 
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of deaths. Non-melanoma skin cancers are not included in the cancer rate estimates 
as they are rarely fatal and are not reliably reported by some medical practices. The 
incidence and death rates for individual organs can be quite different. Cancer of the 
pancreas accounts for 3 % of new cases but 6 % of cancer deaths. Breast cancer 
accounts for 12 % of new cases but only 7 % deaths. The raised awareness of this 
disease and the relative ease of screening may be responsible for the relatively high 
relative survival rate of this disease. Ovarian cancer accounts for 1.6 % of new cases 
but 2.7 % of deaths (Jemal et al., 2007). 
 
Different types of malignant tumours have characteristic disease progressions 
whereby if they are not destroyed or removed in the early stages will spread through 
adjacent tissues and form secondary colonies (metastases) around the body. 
Metastases are often well dispersed throughout the body, making surgical removal 
impossible. 
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Figure 2: Five year survival of patients with cancers at different sites by progression 
of disease in the US between 1996 and 2002.  
Local disease is constrained within the parent tissue. Survival is higher as affected tissue 
may be surgically removed. Regional disease has spread beyond originating tissue. 
Advanced disease is characterised by secondary metastases in distant organs. Data from 
Jemal, et al., 2007. 
 
Figure 2 compares the five year survival of cancer patients by site and disease 
progression. Prognosis is better for patients if the disease is recognised during its 
early stages. Survival from skin cancer is good; 80 % of patients are diagnosed 
during the early stages, allowing the tumour to be excised. Up to 99 % of patients 
diagnosed with local melanoma survive for at least five years. Although survival 
from localised ovarian cancer is good with up to 93 % of patients surviving for at 
least five years only 19 % of tumours are detected at the early stage. Prognosis is 
extremely poor for pancreatic cancer. Only 7 % of tumours are detected while the 
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tumour remains localized and just 20 % of these patients survive for five years 
following diagnosis. For other patients the survival rate is lower still. 
 
As there are a diverse range of diseases that fall under the umbrella term, cancer, the 
best approach to treatment varies considerably. Surgery, radiotherapy and 
chemotherapy are all useful treatment options and may be used alone or in 
combination. The best treatment for each case depends on the type of cancer, disease 
progression, and whether the tumour is a solid mass or dispersed through one or 
more tissues. In addition, more aggressive therapies may not be appropriate for 
patients who have been weakened by other diseases or old age. In cases where 
several methods have similar therapeutic value patient may choose treatments based 
on risks and severity of side effects.  
1.3.2 Chemotherapy 
Not all tumours can be easily surgically removed or damaged using focussed 
radiation. Chemotherapy is a successful alternative approach which aims to destroy 
cancer cells throughout the body. It is particularly useful when the tumour is in close 
proximity to sensitive vital organs which would be excessively damaged by invasive 
surgery or high doses of radiation. 
 
Pathogenic microorganisms can be selectively targeted because they are sufficiently 
different from their host that they have markers and metabolic pathways not shared 
with humans. Drugs that bind to foreign proteins or block foreign enzymes will not 
harm the patient. A significant difficulty with extending this approach to cancer is 
that while invaders such as bacterial pathogens can be targeted using differences 
from host cells there are few markers for most cancers. Silver bullet approaches aim 
to solely target cancer cells. Gene therapy may be possible using a cancer cell 
targeted viral vector which is only able to replicate in telomerase expressing cells 
(Wirth et al., 2003). Most silver bullet techniques are still many years away from the 
clinic. Antibody based therapy has been used successfully to deliver radioisotopes to 
non-Hodgkin’s lymphoma which expresses the CD20 antigen (Witzig et al., 2002). 
Antibody-based approaches are naturally limited to cancers expressing the relevant 
antigens.  
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Traditional chemotherapeutics dramatically increase survival rates for some cancers 
but are highly toxic and are used with the aim of destroying the tumour before the 
patient. There are three major classes of chemotherapeutic strategies.  
 
• Antimetabolites are small molecules which have a similar structure to normal 
cell metabolites, most commonly nucleotides. They inhibit cellular 
machinery when recruited by enzymes, generally inhibiting DNA replication, 
preventing cell division. 
• DNA-affecting compounds cause direct damage to DNA through oxidative 
damage or chemical modification. Alternatively cell division machinery is 
attacked through interactions with microtubules or topoisomerases causing 
entry into apoptosis. 
• Cellular protein targeting molecules bind to enzymes or cell surface proteins 
and reduce the proliferation of cells expressing the target. 
 
Each strategy has associated toxicities. In addition, patients may experience different 
symptoms determined by properties of the drug, pathways of metabolism, and 
whether there is an immune response to the treatment. The rate of drug clearance and 
rate of metabolism will also affect the severity of the side effects. The toxicities of 
some common chemotherapeutics associated with diseases such as lung, testicular 
and ovarian cancers are severe. 
 
For adenocarcinoma, the most common lung cancer, surgical removal of early stage 
disease is the preferred treatment. Unfortunately only a third of patients have disease 
that can be treated in this way. Surgery for these early stage patients improved 
chance of surviving five years from 6-22 % with no treatment to 32-63 % in the 
United States in 1995 (Fry et al., 2000). Prognosis is poor for patients with advanced 
disease. Patients with distant metastases only survive for an average six months 
without chemotherapy. Patients with advanced lung cancer treated with cisplatin-
docetaxel or gemcitabine-docetaxel chemotherapy survive for a median ten months 
(Georgoulias et al., 2001). Two thirds of lung cancer patients are given radiotherapy, 
chemotherapy or a combination. These treatments offer a small but significant 
survival advantage.  
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Docetaxel is a DNA-affecting compound which interferes with cell division. 
Paclitaxel was the first taxane discovered of this class and was initially extracted 
from the bark of the Pacific yew tree. Docetaxel was developed as a replacement; it 
is a semi-synthetic taxane which is derived from the more common European yew 
tree. Taxanes bind to tubulin which stabilises assembled microtubules. This causes 
an accumulation of microtubules, which initiates apoptosis. Major DNA breaks dues 
to apoptosis can be observed three days following treatment (Fabbri et al., 2006). As 
microtubules must be regulated in all dividing cells healthy stem cells are also 
affected by taxanes.  
 
Gemcitabine is an example of an antimetabolite. It is a pyrimidine nucleoside 
analogue prodrug which is phosphorylated in the cell and incorporated into DNA 
during DNA synthesis. Once it has been incorporated DNA polymerase is unable to 
proceed and the proof-reading enzymes cannot remove it, resulting in apoptosis 
(Plunkett et al., 1995). As DNA must be replicated by all dividing cells healthy stem 
cells are also affected by this treatment. 
 
Side effects of both docetaxel and gemcitabine include myelosuppression, nausea 
and vomiting, muscle and joint pain, constipation or diarrhoea, mild hair loss, 
peripheral nerve damage, disorders of the skin and nails, fatigue and liver damage.  
 
In the 1970s the best treatment for testicular cancer was bleomycin with vinblastine. 
This was improved by adding cisplatin (section 1.4) and replacing vinblastine with 
etoposide. These improvements dramatically improved survival from testicular 
cancer. 
 
Bleomycin is a DNA-affecting compound which directly damages DNA. It is a 
glycopeptide antibiotic which is believed to cause DNA cleavage by chelating metal 
ions to catalyse the production of superoxide and hydroxide free radicals. Oxidative 
damage affects all body tissues in addition to cancer cells. The lungs suffer extreme 
damage and severe scarring can impair lung function which is thought to be fatal in 
up to 3 % of patients (Jones and Vasey, 2003). 
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Vinblastine is a DNA-affecting alkaloid that binds to tubulin, promoting spiral 
aggregation of tubulin rather than microtubule formation. Cells become arrested in 
the M phase of the cell cycle as they cannot form mitotic spindle and the kinetochore 
and therefore cannot divide.  
 
Etoposide is a non-alkaloid toxin which inhibits topoisomerase II. Like vinblastine 
and other inhibitors of cell division, etoposide damages stem cells in addition to 
cancer cells. Side effects include myelosuppression, nausea and vomiting, muscle 
and joint pain, constipation or diarrhoea, mild hair loss, peripheral nerve damage, 
disorders of the skin and nails, fatigue and liver damage. 
 
Alkylating agents were the best chemotherapeutics available for treating ovarian 
cancer in the 1960s. Cisplatin (section 1.4) was introduced in 1973. Carboplatin 
(section 1.5.1) was introduced in the 1980s. Paclitaxel was first used in the 1990s 
and replaced cyclophosphamide after survival advantage was shown (McGuire et al., 
1996). Doxorubicin has also been used for treating ovarian cancer. 
 
Cyclophosphamide is a nitrogen mustard alkylating agent pro-drug which is oxidised 
by cytochrome P450s in the liver into its active form (Hengstler et al., 1997). The 
active metabolite forms DNA cross-links resulting in cell cycle arrest and entry into 
apoptosis. Aldehyde dehydrogenase converts activated cyclophosphamide into a less 
toxic form. Cyclophosphamide is therefore most toxic to cells with low 
concentrations of this enzyme. 
 
Doxorubicin is a DNA-affecting anthracycline antibiotic which intercalates DNA 
and inhibits DNA, RNA and protein synthesis (Momparler et al., 1976). 
Cardiotoxicity is the dose limiting toxicity. Other toxicities include nausea and 
vomiting, myelosuppression and hair loss. 
 
Development of novel classes of chemotherapeutics is one approach to cancer 
treatment. However, the pipeline of bringing new drugs to market is agonizingly 
slow. Drugs typically take ten years after identification of a suitable lead to approval. 
The drug must be economically viable, safe and effective. Even successful drugs 
may not be widely available to patients if they are too expensive.  
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An alternative approach is to reduce the toxicity of existing compounds and optimize 
the path of delivery of the drug or drugs. Since each type of cancer poses unique 
challenges, the best method of drug delivery should be considered for each type of 
disease. 
1.3.3 Ovarian Cancer 
Ovarian cancer is the fourth most common cause of cancer death in women in the 
United Kingdom with around 6000 new cases diagnosed each year. In the United 
States it is the fifth most common cause of cancer death with 22,400 new cases 
diagnosed each year (Jemal et al., 2007). The majority of cases are malignancies of 
the ovarian epithelium in post-menopausal women. In younger patients malignancies 
are frequently germ-cell tumours. Around 5-10 % cases are hereditary; these are 
generally due to inherited mutations in tumour suppressor genes. Such cases occur 
around 10 years earlier (Holschneider and Berek, 2000).  
 
Ovarian cancers are derived from three different types of parent tissue. The most 
common are surface epithelial-stromal tumours are from ovarian surface lining cells. 
Sex cord-stromal tumours are derived from hormone producing cells and may 
continue to express oestrogen and inhibin (La Marca and Volpe, 2007). Germ cell 
tumours are the most common type of tumours in young women or girls. As there 
are a range of cancer types it is likely that no single marker will be discovered; early 
diagnosis is difficult. 
 
Stage Summary Five Year Survival (%) 
I Cancer confined to one or both ovaries. 82-93 
II Includes pelvic extensions. 51-70 
III Includes peritoneal metastases. 17-37 
IV Distant metastases. 12-25 
 
Table 1: Staging of ovarian cancer and five year survival rates by stage from 
Holschneider et al, 2000. 
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Ovarian cancer is usually asymptomatic in the early stages of the disease. If it is 
diagnosed at stage I while restricted to the ovaries (Table 1) prognosis is very good 
with five-year survival rates of 82-93 % (Holschneider and Berek, 2000). At stage II 
the cancer has begun to spread into the pelvis but is still difficult to detect. Three 
quarters of cases are diagnosed with advanced disease. Normally ovarian cancer is 
diagnosed at stage III when cells have proliferated into the peritoneum. The tumour 
cells form a plaque across the diaphragm and omentum which blocks lymph drainage 
of the peritoneum. Without drainage the abdomen swells as the volume of tumour 
cell containing fluid (ascites) increases. By the time symptoms have appeared it is 
impossible to remove all of the tumour cells by surgery. Five-year survival is much 
lower at 17-37 %. If disease is not diagnosed before stage IV, where metastases have 
spread to peripheral sites around the body, survival falls to 12-25 % (Holschneider 
and Berek, 2000).  
 
Most patients require a combination of surgery and chemotherapy. An initial surgical 
operation to investigate the stage of the disease is common to allow accurate staging 
of the disease. Surgery is carried out to remove the ovaries and visible tumour mass 
in the peritoneum is also often removed (cytoreduction or debulking). Work by 
Eisenkop et al. revealed a 62 month median survival of 139 patients with advanced 
ovarian cancer following removal of all visible tumour (Eisenkop et al., 1997).  
 
The prognosis of disease is worse once cancer cells have escaped from the ovary, are 
present in both ovaries, are well differentiated or have unusual numbers of 
chromosomes (aneuploidy) (Trope et al., 2000). The disease is also likely to relapse 
in older patients or if malignant cells are present in the ascites. 
 
Radiotherapy is not suitable as a first line therapy as the tumour cells are well 
dispersed around the abdomen by the time of diagnosis. Evidence that radiotherapy 
is useful for consolidating treatment following chemotherapy (Petit et al., 2006, 
Sorbe, 2003) or for salvage therapy following chemotherapy (Morton and Thomas, 
1996) is not conclusive. 
 
Intravenous cisplatin or carboplatin is a popular choice for treating ovarian cancer, 
often with paclitaxel (section 1.4.4). 
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1.4 Cisplatin 
1.4.1 Properties of Cisplatin 
The cell growth inhibiting effects of platinum complexes were discovered by 
Rosenberg et al. in 1964. Active platinum salts were accidentally created in a cell 
culture experiment by electrolysis of a platinum electrode (Rosenberg et al., 1965). 
The most active compound, cis-dichlorodiammine platinum (II) which came to be 
known as cisplatin, was shown to reduce animal tumour mass. Cisplatin is a deep 
yellow powder when solid. It is slightly soluble in water with a limit of solubility in 
the range 1.0-2.4 mg ml-1 depending on temperature (de Kroon et al., 2005, Burger et 
al., 2002). The diffusivity of cisplatin in water has been estimated as 6×10-6 cm2 s-1 
(Saltzman and Radomsky, 1991). Cisplatin is poorly lipophilic; its lipophilicity 
parameter, logPoct, is -2.3±0.05 (Hall et al., 2004). After development and trials Food 
and Drug Administration approval was granted in 1978 under the name Platinol.  
1.4.2 Pharmacokinetics of Cisplatin 
Cisplatin is usually administered by intravenous infusion (section 1.4.4). For 
determining cisplatin pharmacokinetics, acid digestion of samples is used to break 
down biological molecules present. The platinum concentration is then determined 
without interference from the sample matrix. This technique has good sensitivity for 
determining low platinum concentrations. In this way the pharmacokinetics of 
cisplatin can be calculated from the total cisplatin concentration. 
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Figure 3: Mean plasma cisplatin concentration following cisplatin infusion. 
Infusion duration 15 min. Data from Erlichman et al., 1987. 
 
Figure 3 shows typical cisplatin pharmacokinetics following a single bolus infusion 
of cisplatin over 15 min (Erlichman et al., 1987). Following cisplatin administration 
the drug becomes dispersed in the blood and quickly reaches equilibrium with well 
perfused tissues such as the lungs and liver. The drug is then distributed through the 
rest of the body (except the brain which is kept separate by the blood-brain barrier). 
This is modelled as transfer of drug into the peripheral compartment. The peripheral 
compartment represents fatty tissues and other tissues which have a poor blood 
supply. The distribution into these tissues takes longer to reach equilibrium. Drug 
molecules enter the peripheral compartment at a concentration determined by the 
partition coefficient of the drug in that tissue when the concentration of drug is high 
in the blood. Drug in the peripheral compartment will slowly diffuse back into the 
blood as the drug is eliminated from the central compartment. This causes the blood 
plasma concentration of total cisplatin falls in a biphasic manner. 
 
Two (Korst et al., 1998) and three compartment (Erlichman et al., 1987) models 
have been used for describing cisplatin pharmacokinetics. The two compartment 
model is an adequate model for the behaviour of total plasma cisplatin. This model 
requires two assumptions; firstly, that the body can be treated as the two separate 
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well perfused and poorly perfused compartments. Secondly, that drug is only 
transported between the compartments and eliminated as a diffusion-limited first 
order process with no active transport. These assumptions are acceptable as long as 
the model produces useful, predictive results. 
 
 
Figure 4: Pharmacokinetic model of total cisplatin in the body following intravenous 
injection.  
A bolus of cisplatin, DW is injected into the central compartment with volume V. The 
concentration in the central compartment, W1, is determined by the rates of transport of 
cisplatin, c12, c21 and cel, into and out of that compartment. 
 
Figure 4 shows a two compartment pharmacokinetic model where an initial dose, 
DW, is injected into the blood of a patient, becoming rapidly mixed throughout the 
whole volume, V, of the central compartment. The concentration of cisplatin in the 
central compartment, W1, is determined by the rate of transfer into, c12, and out of, 
c21, the peripheral compartment, the concentration of cisplatin in the peripheral 
compartment, W2, and the rate constant for elimination, cel. The elimination rate 
constant comprises of drug elimination by the kidneys and removal of the drug from 
the circulation by reactions with drug targets or other metabolism. 
 
112
1
1221 WcWcWc
dt
dW
el−−=  
(1) 
 
21
2
2112 WcWc
dt
dW
−=  
(2) 
 
Rate equations (equations 1 and 2) can be determined for this two compartment 
model (Figure 4). From the rate equations the predicted concentration of cisplatin in 
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the central compartment (which includes the blood), equation 3, can be derived 
(Appendix B). 
 
( ) ( )tBtAW WWWW ⋅−+⋅−= βα expexp1  (3) 
 
The concentration of drug in the blood can be predicted from equation 3 if the 
empirical constants AW, BW, αW, and βW are known. Assuming the two compartment 
model shown in Figure 4, the transport constants, c12, c21 and cel, can be linked to AW 
and BW. 
 
For many drugs the two compartment model is a good tool for predicting drug 
exposure. Such drugs reversibly bind to plasma proteins and are released from 
binding, maintaining a constant unbound:bound ratio as unbound drug is cleared. 
Cisplatin binding to proteins is effectively irreversible. Although the amount of 
cisplatin present in the blood decreases relatively slowly with a half-life of 58-96 h 
(Sweetman, 2004) this does not represent the total amount of cisplatin available for 
cancer cell killing. The total cisplatin plasma concentration includes unbound and 
protein-bound cisplatin. 
 
Cisplatin in aqueous solution undergoes a reversible ligand exchange of a chloride 
ion for water. The forward reaction is described as aquation. A potent charged 
electrophile is formed. The aquated cisplatin species readily form DNA-platinum 
adducts. These adducts are thought to be the major mechanism of toxicity to cancer 
cells (section 1.4.3). However, aquated cisplatin species will also form adducts with 
other nucleophiles in the blood and in cells. When the chloride concentration is high 
(>50 mM), the equilibrium is towards uncharged cisplatin (Cheung et al., 1987, 
Wenclawiak and Wollmann, 1996). As the concentration of chlorine is 84-122 mM 
in blood, the concentration of aquated cisplatin is low. However, the equilibrium is 
displaced towards aquation by the removal of aquated cisplatin. Aquated cisplatin 
binds to plasma nucleophiles, shifting the equilibrium. There is no significant 
dissociation following binding (Sullivan and Krieger, 1992).  
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Figure 5: Pharmacokinetic model of unbound cisplatin in the body following 
intravenous injection incorporating protein binding.  
A bolus of cisplatin, DW is injected into the aqueous compartment with volume V. The 
concentration of unbound cisplatin in the central compartment, U1(t), is determined by the 
rates of transport of cisplatin, j12, j21 and jel, and kb into and out of that compartment. In 
addition, clearance of unbound cisplatin occurs in the peripheral compartment, U2. 
 
Figure 5 shows a two compartment model treating protein binding as an additional 
source of elimination. In this model the concentration of unbound cisplatin in the 
plasma, U1(t), is determined by kb and jel. In addition, cisplatin is also cleared by 
protein binding from the peripheral compartment. Ovarian cancer occurs in the 
ovaries and peritoneum which is well perfused with blood and can be modelled as 
part of the central compartment. Alternatively, the peritoneum can be modelled as a 
separate compartment (section 1.6.3). 
 
The model for U1 has the same form as equation 3 but the parameters incorporate 
the protein binding constant, kb. The disadvantage of this model is that because 
αW·βW depends on four constants, the values of the parameters cannot easily be 
determined. In addition, this model does not take into account protein binding of 
cisplatin in the peripheral compartment. Increasing the number of compartments may 
improve the physiological description of the model but may not improve the 
usefulness of the model. It is important to consider that the amount of toxicity to the 
tumour may not correspond to the exposure to total cisplatin, but instead, the 
exposure to unbound cisplatin (section 1.4.3). Unbound cisplatin has a half-life of 
1.3 h (Urien and Lokiec, 2004). 
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1.4.3 Intracellular Action of Cisplatin 
Cisplatin is thought to enter cells by a combination of passive diffusion and 
facilitated diffusion (Kartalou and Essigmann, 2001). Passive diffusion of cisplatin 
across the cell membrane is likely to be slower than for other small molecules due to 
the slightly polar nature of the molecule (Kelland, 2007). The polarity is caused by 
the small positive charge on the ammonia the small negative charge on the chlorine 
group. In addition, the hydrogen bonds between the ligands and the water molecules 
of the hydration shell will also reduce the rate of diffusion across the cell membrane. 
Dissolved cisplatin undergoes a ligand exchange reaction, called aquation, where a 
chloride ion is replaced with a water molecule (Figure 6). This exchange creates a 
positively charged ion called aquated cisplatin. Aquated cisplatin is unable to cross 
cell membranes since lipid membranes are a good barrier to ions. CTR1 (copper-
transporting membrane protein 1) is the main protein responsible for delivering 
copper into cells (Lee et al., 2001). Mounting evidence suggests that copper 
transporters, such as CTR1 and chaperones mediate cisplatin uptake (Ishida et al., 
2002). High intracellular concentrations of copper cause ATP7A (copper-
transporting P-type ATPase 7A) to be delivered to the surface membrane, causing 
copper efflux (La Fontaine and Mercer, 2007). It has been shown that increased 
expression of ATP7A corresponds with tumour resistance (Samimi et al., 2003).  
This evidence suggests that cisplatin is transported into and out of the cell via the 
copper homeostasis machinery. 
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Figure 6: Mechanism of cisplatin tumour toxicity.  
Cisplatin enters the cell by facilitated and passive diffusion where it is rapidly hydrolysed 
(aquation) to form a strongly electrophilic charged species. If aquated cisplatin is not 
removed by binding to proteins it selectively binds guanine residues in the DNA. Blockade of 
DNA and RNA polymerase causes the cell to enter programmed cell death (Kartalou and 
Essigmann, 2001, Kelland, 2007). 
 
The physiological chloride concentration in blood plasma is ~100 mM. The presence 
of nucleophiles in blood will increase the rate of aquation by removing the charged 
species from solution. Nonetheless, cisplatin remains relatively stable in extracellular 
matrices due to the excess chloride ions present (Sweetman, 2004). Once cisplatin 
has entered the cell the lower chloride level (~4 mM) means that the equilibrium is 
shifted towards aquation (Figure 6). Cisplatin hydrolysis therefore occurs at a faster 
rate inside cells (Reedijk, 2003). A potent electrophile is formed in the cell at 
8×10-5 s-1 (Knox et al., 1986, Wenclawiak and Wollmann, 1996). Aquation of the 
platinum group creates the highly reactive electrophile that will attack surrounding 
nucleophiles such as sulphydryl groups in proteins or nitrogen donor atoms on 
nucleic acids, especially guanine. 
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Cisplatin is able to form two covalent cross-links in the DNA strands. In vitro studies 
show that 90 % of DNA-cisplatin adducts are between adjacent guanine residues or 
between guanine-adenine (Eastman, 1986). It is likely that the mono-aquated 
platinum binds the DNA and the cross-link occurs subsequently (Eastman, 1986). 
Intra-strand cross-links are thought to be major disrupting lesions. Guanine-guanine 
cross-links have been shown to cause kinks in a DNA strand (Takahara et al., 1996). 
Morphological changes to DNA will disrupt interactions between DNA and the 
nuclear machinery. High levels of DNA damage cause replicating cells to enter the 
apoptosis pathway rather than division (Kartalou and Essigmann, 2001). It is thought 
that DNA-cisplatin adducts cause cell division to become blocked in G2 before the 
start of mitosis (Sorenson, 1990). Cells which do not enter mitosis within a few days 
enter apoptosis and die. 
 
This gross DNA damage can be very effective at cell killing and can completely kill 
tumours. Cisplatin/etoposide/bleomycin combination therapy for testicular cancer 
achieves cure rates of between 80 % (Einhorn, 2002) and 95 % (Kartalou and 
Essigmann, 2001). This cure rate is so high because testicular cancer is 
hypersensitive to cisplatin. Testicular tumour cells exhibit low XPA (xeroderma 
pigmentosum, complementation group A) protein concentration. This causes low 
ERCC1—XPF (excision repair cross complementing 1—xeroderma pigmentosum, 
complementation group F complex) levels (Kelland, 2007) which means that 
nucleotide excision repair (NER) is defective and the adducts cannot be removed. 
The accumulation of damage triggers apoptosis. For other tumours, such as ovarian 
cancer, which are not repair-defective the cure rate is much lower. 
 
Severe dose-limiting toxicities include hearing loss (ototoxicity), damage to the 
kidneys (nephrotoxicity) and epithelium of the gastrointestinal tract (mucositis), and 
immunosuppression. In addition nausea and vomiting can be so bad in the first 
month of therapy that patients sometimes consider withdrawing from treatment. The 
cost of anti-emetics alone can be more than the chemotherapeutics. Patients may also 
experience hair loss. 
 
Cisplatin is thought to kill cells by trapping cells in G2 of cell division. This is 
achieved through the formation of DNA-cisplatin adducts. This would suggest that 
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cisplatin toxicity should be restricted to dividing cells. However, there is evidence 
that systemic toxicity is not solely due to DNA-cisplatin adducts. Additional 
mechanisms of toxicity in non-dividing cells have been proposed. 
 
When aquated cisplatin reacts with glutathione, the conjugate can be metabolised to 
toxic thiols. Investigations into nephrotoxicity in kidney samples suggest that the 
production of thiols is involved in cisplatin-induced kidney damage. Townsend et 
al., 2003 inhibited the enzymes which metabolise cisplatin-glutathione adducts to 
unstable reactive thiols in kidney proximal tubule cells. This halved toxicity to the 
cells (Townsend et al., 2003). This suggests that the metabolites may be more toxic 
than cisplatin to systemic, non-dividing cells and be the primary cause of 
nephrotoxicity. Patients’ are protected from severe nephrotoxicity during intravenous 
cisplatin therapy by being kept well hydrated before and during treatment (Hayes et 
al., 1977). 
 
It has also been proposed that the platinum group directly catalyses the production of 
free radicals. Cisplatin induced ototoxicity (hearing loss) may be caused by 
production of reactive oxygen species. Electron paramagnetic resonance detects the 
spins on free radicals. This technique has been used to show direct evidence of free 
radical formation by cisplatin in the presence of cochlear material (Clerici et al., 
1996).  
 
The main mechanism of cisplatin toxicity is cisplatin-DNA adduct formation.  
Mitosis is prevented in dividing cells which triggers apoptosis. Alternative pathways 
may be a significant source of toxicity, causing cell death in healthy non-dividing 
cells. 
1.4.4 Cancer Treatment with Cisplatin 
Cisplatin is a successful therapeutic that has improved survival for many patients 
with lung, neck, head, testicular and ovarian cancers. Cisplatin chemotherapy 
improved the complete cure rate for testicular cancer from 5-10 % with original 
therapy to at least 80 % today (Einhorn, 2002). 
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Figure 7: Five year survival for ovarian and testicular cancer patients since 1971. 
Percentage of patients with ovarian (grey bars) and testicular cancer (white bars) in the UK 
who survived for five years following diagnosis during the 1970s and 1980s (Office for 
National Statistics, 1995). 
 
Cisplatin is also used to treat ovarian cancer with significant but less impressive 
results than for testicular cancer (Figure 7). The addition of cisplatin to 
cyclophosphamide-doxorubicin therapy increased the proportion of patients that 
showed a partial or complete response to therapy from 48 % to 76 % (Omura et al., 
1986).  
 
A typical course of cisplatin consists of at least six cycles of cisplatin solution, a 
dose of 75 mg m-2 which is typically ~120 mg per patient. This is administered 
intravenously at 1.0 mg ml-1 in saline solution with hydration before and after 
delivery. This saline solution has a high chloride concentration to keep the cisplatin 
in the inactive form for as long as possible during delivery. Dose is reduced in 
patients with low kidney function (a glomerular filtration rate of less than 
55 ml min-1). This dose is administered every 21 days as long as the tumour shows 
response (Graham and Falk, 2005). Hydration with up to two litres of fluid before 
treatment and infusion with excess fluid containing an osmotic diuretic such as 
mannitol diminishes the extent of the kidney damage (Sweetman, 2004). 
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1.4.5 Failure of Cisplatin Treatment  
Relapses following treatment are due to tumour resistance to cisplatin. If the tumour 
is not completely destroyed by the first treatment then mutations may appear which 
confer resistance against cisplatin toxicity making further treatment ineffective. 
Further cisplatin treatment has reduced effectiveness. There is no standard treatment 
and prognosis is poor. Some resistant cell lines have been shown to be able to 
tolerate fifty times more platinum-DNA adducts. Failure of therapy can occur by a 
number of mechanisms before and after toxic platinum-DNA adducts have been 
formed. 
 
Before binding has occurred cisplatin availability can be modulated by the tumour. 
Cisplatin is a polar molecule which enters cells slowly. Uptake is influenced by 
sodium and potassium ion concentrations, pH, presence of reducing agents and 
transporters.  
 
The amount of cisplatin entering and leaving the cell are strongly influenced by the 
copper homeostasis machinery (section 1.4.1). Loss of the copper transporter, CTR1 
by tumour cells increases resistance to cisplatin. CTR1 negative cells have low 
accumulation of cisplatin. Tumour cell populations treated with cisplatin undergo a 
reduction in CTR1 levels (Kelland, 2007). In addition, an increase of the copper 
efflux transporter ATP7A increases resistance of tumour cells to cisplatin. 
 
Some resistant cell lines remove platinum-DNA adducts four times faster than 
sensitive cells (Eastman and Schulte, 1988). In addition, treated populations show 
increased glutathione which sequesters cisplatin before it can bind to the DNA. This 
conjugate can be transported out of the cell by the ATP-dependent glutathione 
S-conjugate export pump (Kartalou and Essigmann, 2001). 
 
Following binding, the efficacy of the adducts in causing cell death can be reduced 
by a number of pathways. DNA repair and removal of adducts or tolerance to 
adducts increases tumour resistance. Nucleotide excision repair (NER) removes 
incorrect or damaged nucleotides. Evidence for this mechanism can be seen in cell 
lines where increased NER coincides with increased cisplatin resistance (Kelland, 
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2007). ERCC1-XPF is the protein complex that makes the incision for this pathway. 
Small inhibiting RNA for ERCC1 increases sensitivity of tumour cells to cisplatin 
(Kelland, 2007). 
1.5 Reducing Cisplatin Toxicity 
1.5.1 Cisplatin Analogues 
The rate of release of reactive platinum can be changed by changing the ligand to 
reduce the rate of aquation to form the active species. The analogues carboplatin and 
oxaliplatin are successful chemical alternatives to cisplatin that have higher lethal 
concentrations for 50 % of patients (LC50s), but which require higher concentrations 
to reach an equivalent effective dose. 
 
 
 
Figure 8: (a) Cisplatin and its analogues, (b) Carboplatin and (c) Oxaliplatin. 
 
The dose limiting toxicity for carboplatin is immune suppression. For oxaliplatin it is 
damage to the peripheral nerves which connect the central nervous system with the 
rest of the body (peripheral neuropathy), possibly due to blockade of sodium 
channels in sensory neurons (Wilson et al., 2002). 
 
Cisplatin rapidly becomes aquated by a substitution of a chloride ion for water with a 
rate constant of 8×10-4 s-1 at 37°C (Wenclawiak and Wollmann, 1996). Carboplatin 
aquation has a rate constant of the order of 10-6 s-1 (Knox et al., 1986). The 
differences in rate of DNA adduct formation of cisplatin and carboplatin are similar 
orders of magnitude to the differences in aquation rates, suggesting that aquation is 
rate limiting. The bidentate cyclobutanedicarboxylato group of carboplatin 
hydrolyses at a rate of 10-5 s-1 after adduct formation. This is faster than before DNA 
binding and correlates with the rate of interstrand adduct formation of DNA bound 
carboplatin. The slower rate of aquation of carboplatin means that there is less 
irreversible binding of carboplatin to plasma components.  
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Although carboplatin may exhibit less severe toxicities, prolonged exposure may 
lead to allergy-like reactions. In a study by Markman et al., 1999, episodes of 
hypersensitivity to carboplatin were found to be rare in patients who have received 
fewer than six courses of carboplatin with no episodes occurring among 205 patients 
at risk. Hypersensitivity was more frequent in patients who had more than six 
courses with 22 episodes among 83 patients at risk (Markman et al., 1999). This 
increase in risk of hypersensitivity with repeated exposure suggests that carboplatin 
may not be suitable for sustained release for extended periods. Cisplatin 
hypersensitivity reactions are believed to occur but at a rate of 1-5 % patients when 
administered alone (Von Hoff et al., 1979, Zweizig et al., 1994). 
 
In a study of 417 patients given cisplatin or carboplatin alongside cyclophosphamide 
(section 1.3.2) no significant differences in response (57 % and 59 %) and median 
survival (100 weeks and 110 weeks) were found (Swenerton et al., 1992). The main 
finding from such trials are that carboplatin exhibits more acceptable toxicities than 
cisplatin (Alberts et al., 1992) rather than significant improvement of response for 
either drug. 
 
Oxaliplatin, trans-cyclohexane-1,3-diamineoxalato platinum (II), is a tetravalent 
platinum compound. Oxaliplatin also hydrolyses slower than cisplatin with a rate 
constant of the order of 10-6 s-1 at 25°C (Gao et al., 2003). Some experimental 
tumours which are resistant to the divalent cisplatin and carboplatin are not resistant 
to oxaliplatin. This may be due to the bulky diaminocyclohexane ring remaining 
following adduct formation. Resistance to platinum adducts can be due to repair of 
the DNA strand or bypass of the damaged site by the replication machinery. The 
incorporation of the larger blockade may reduce access of repair and replication 
proteins by steric hindrance. As nephrotoxicity is low, hydration is not required with 
oxaliplatin treatment. Around 15-18 % of patients show allergic reactions to 
oxaliplatin; allergies can develop from first exposure but symptoms tend to be mild 
(Fu et al., 2006). 
 
The development of cisplatin analogues continues with many promising candidates 
entering late phase trials. Satraplatin may shortly be approved for treatment of 
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hormone-refractory prostate cancer. Picoplatin is a promising candidate for treating 
small-cell lung cancer. 
1.5.2 Regional Delivery 
Chemotherapy drugs are extremely toxic (section 1.3.2) and typically have narrow 
therapeutic windows. Intravenous injection is systemic, exposing the whole body to 
the chemotherapeutic agent during treatment. Regional drug delivery aims to create 
high drug concentrations at the tumour site and lower concentrations throughout the 
rest of the body than by intravenous injection. Drugs with high ratios of toxicity to 
efficacy are described as having high therapeutic indices. Regional delivery 
increases the therapeutic index of a drug by increasing the dose that can be safely 
delivered while reducing the toxicity to the rest of the body. A high therapeutic index 
is important because there is variability in the reaction of each patient to a certain 
dose of drug. A safe dose for one patient could be fatal for another. Patients are less 
likely to suffer extreme side effects if there is a wide margin of safety. 
 
Ovarian cancer is difficult to diagnose in the early stages and is normally diagnosed 
by the symptoms of stage III of the disease, especially ascites. By this stage a tumour 
plaque has formed a coating on the surface of the diaphragm and omentum and is 
effectively impossible to remove by surgery. Soluble anti-tumour drugs have a low 
residence time in the peritoneum. Much work has been focussed on attempting to 
increase the retention of chemotherapeutics in the peritoneum, potentially increasing 
efficacy and reducing side-effects. Intraperitoneal (IP) therapy is an attractive 
method for treating ovarian cancer. A catheter is passed directly into the peritoneal 
cavity and aqueous cisplatin delivered in a large volume (generally two litres) of 
saline. 
 
Injecting cisplatin into the peritoneal cavity of rats produced IP cisplatin 
concentrations ten to twenty times higher than serum levels. However, cisplatin only 
penetrated 1-2 mm into tumour nodules despite the improved exposure (Los et al., 
1990). This suggests that IP delivery is only suitable for patients who have had 
debulking surgery to remove the majority of the tumour nodules. Prolonging 
exposure of drug to the peritoneum may allow progressive penetration into tumour 
nodules as the tumour progressively dies back. 
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Ovarian cancer spreads through the lymphatic and venous systems in addition to the 
peritoneum (Burghardt et al., 1991). Chemotherapy targeting solely the peritoneum 
may be insufficient for treating the disease. 
 
There have been eight clinical trials investigating the effect of IP cisplatin as a first 
line therapy. Clinical trials accept patients with diseases at a range of stages of 
progression and treat them with differing treatments. Even if the selection criteria for 
the study are very strict, there is still great variability in survival times of patients 
following diagnosis. These factors mean that detecting a real change in overall 
survival using an alternative treatment requires a large number of patients to reliably 
determine the distributions of survival of the two groups. Many trials do not have 
enough patients do detect differences in survival that could not be attributed to 
chance. These trials do not have sufficient statistical power to make rigorous 
assessments of the treatment of interest. The most statistically sound way to 
determine the affect of a treatment is perform a meta-analysis on the aggregated the 
results of every relevant randomised trial. By examining the survival of a very large 
number of patients from many studies significant differences can be identified, if 
present. There have been eight studies including intraperitoneal platinum agents as a 
first line therapy: 
 
• Alberts et al., 1996 found that intravenous (IV) cyclophosphamide or with IV 
or IP cisplatin chemotherapy  showed prolonged median survival. Abdominal 
pain was worse for IP patients but other side effects such as low white blood 
cell count and tinnitus were reduced under IP therapy (Alberts et al., 1996). 
• Armstrong et al., 2006 compared IV paclitaxel and IV cisplatin with IV 
paclitaxel followed by IP cisplatin and IP paclitaxel. IP therapy improved 
survival although the dosing schedules and toxicities were higher (Armstrong 
et al., 2006). 
• Gadducci et al., 2000 compared epidoxorubicin and cyclophosphamide with 
IV or IP cisplatin. IP therapy showed a slight but not significant improvement 
in survival (Gadducci et al., 2000). 
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• Kirmani et al., 1995 compared both cisplatin and cyclophosphamide 
delivered by IV or IP infusion. No significant differences were found 
between the groups (Kirmani et al., 1995). 
• Markman et al., 2001 compared IV cisplatin and paclitaxel with IV 
carboplatin, IP cisplatin and paclitaxel. IP cisplatin improved progression 
free survival but bone marrow suppression was more severe (Markman et al., 
2001). 
• Polyzos et al., 1999 compared IV cyclophosphamide combined with either 
IV or IP  carboplatin. Differences in survival between the groups were not 
significant (Polyzos et al., 1999). 
• Yen et al., 2001 compared IV cyclophosphamide plus adriamycin or 
epirubicin with or without an additional dose of IP cisplatin. Differences in 
survival between the groups were not significant  (Yen et al., 2001). 
• Zylberberg et al., 1986 compared a multidrug cocktail of adriamycin, 
fluorouracil, bleomycin, vincaleublastin, ifosfamide and cisplatin delivered 
either entirely IV or in part IP. Results were not significant due to low patient 
numbers (Zylberberg et al., 1986). 
 
A meta-analysis of the eight studies investigating intraperitoneal cisplatin or 
carboplatin as an addition to standard treatment following surgery has shown an 
improvement in survival (Jaaback and Johnson, 2006). Hazard ratio is a metric for 
comparing two treatments. To identify if a new regime of chemotherapy increases 
the survival for one group of patients compared to another, the median survival of 
the standard treatment group is divided by the median survival of the trial group. A 
ratio of significantly less than one suggests an improvement in treatment. If the ratio 
is one then there is no improvement using the trial regime. If the ratio is greater than 
one then the trial regime is more toxic than any improvement due to treatment 
effects. 
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Figure 9: Meta-analysis of the effect of intraperitoneal (IP) cisplatin on time to death 
of ovarian cancer patients.  
Hazard ratio of chemotherapy with and without IP cisplatin is 0.8, favouring IP delivery. Grey 
boxes show relative weights of trials. From Jaaback and Johnson, 2006. 
 
Figure 9 shows the hazard ratios of chemotherapy with or without IP platinum 
therapy. The combined hazard ratio is 0.8 (95 % confidence intervals 0.7-0.9) in 
favour of IP cisplatin. This means that including IP cisplatin in chemotherapy for 
ovarian cancer prolongs survival for some patients.  
 
A theoretical advantage of cisplatin for IP therapy over analogues such as 
carboplatin is its low molecular mass. During IP therapy transfer of cisplatin into the 
tumour is diffusion limited. This is because the drug is delivered directly to the site 
of action so does not need to be transported to the site of action. The tumour nodules 
are bathed with chemotherapeutic rather than being delivered through the 
bloodstream. The inverse relationship between diffusion and solute mass has been 
confirmed using rat models in which ten-fold concentrations of carboplatin were 
required to reach an equivalent penetration to cisplatin (Los et al., 1991). In addition, 
the increased stability of carboplatin may allow sufficient time for the peritoneal and 
serum concentrations to reach equilibrium before any advantage of peritoneal 
administration is able to occur. 
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1.5.3 Prolonged Delivery 
Prolonged drug delivery over hours, days or weeks may offer improvement in 
efficacy of disease treatment with a reduction of side effects. Prolonged delivery of 
doxorubicin, for example, has been shown to cause less heart failure at high 
cumulative doses (450 mg m-2) compared to bolus delivery for breast carcinoma 
patients (Hortobagyi et al., 1988).  
 
There are several strategies for prolonged delivery of drugs. The most widely used is 
intravenous (IV) catheter. A catheter feeds to a major blood vessel and drugs are 
passed into the bloodstream by injection into an external port such as a Hickman line 
or a subcutaneous port such as BardPort®. The main reason for failure of treatment 
by this route is either infection of the implant (section 1.7.1) or blockage of the 
catheter line. Prolonged delivery may be achieved using daily low doses or 
continuous infusion. Daily doses offer less fluctuation in patient drug plasma 
concentration than less frequent bolus injections but there will still be variability. 
Continuous infusion can be used to achieve stable drug plasma concentrations but 
requires connection to an external pump. This requires hospitalisation for the 
duration of delivery which carries associated costs and may be distressing for the 
patient. 
 
 
Figure 10: The effect of cisplatin on blood urea nitrogen. 
Blood urea nitrogen is an indicator of renal impairment. Dose administered by single (●) or 
intermittent (at arrows) bolus (o) injection. Control was intermittent bolus of 0.9 % saline 
solution (x). Adapted from Nagai and Ogata, 1997. 
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Tests of dosing schedules in a rat model showed a negation of severe nephrotoxicity 
using doses administered over four days rather than a single bolus injection (Figure 
10). This was achieved despite having an equivalent exposure to the drug by 
comparison of areas under the concentration against time curves (Nagai and Ogata, 
1997). 
 
Tumour response to drugs may be cell cycle dependent. The major mechanism of 
cisplatin toxicity depends on blockading cells in the G2 phase of the cell cycle 
(section 1.4.3). By maintaining high concentrations of cisplatin for prolonged 
periods of time, a larger proportion of the population of tumour cells will be exposed 
at the relevant part of the cells cycle. Cisplatin which has not become protein bound 
is the critical concentration to be maintained (section 1.4.2). Since protein binding is 
effectively not in equilibrium for cisplatin, unlike for other drugs, it is important that 
prolonged delivery is able to maintain therapeutic unbound cisplatin levels. 
 
In a pilot clinical study Chen et al., 1990 administered cisplatin at 10 mg m-2 day-1 
over 14 days with anthracycline antibiotic, aclarubicin. Diuretics were not used. The 
mean plasma level of unbound cisplatin was 0.4-1.3×10-6 mg ml-1 during infusion 
compared to a total platinum concentration of 0.2-1.2 mg ml-1 (Chen et al., 1990). 
Following the end of infusion the level of unbound platinum dropped significantly 
over the following 12 hours while the total platinum did not decrease appreciably. 
This study suggests that unbound cisplatin concentrations can be maintained during 
prolonged drug delivery. 
 
These studies suggest that prolonged delivery of cisplatin may offer reduced toxicity 
compared to IV delivery of a single bolus. Prolonged release can also be achieved by 
sustained release from a drug depot (section 1.5.4). Sustained release of cisplatin 
from implantable microspheres or fibres offers the reduced toxicity of prolonged 
delivery. In addition, the risks associated with resident catheters and costs of 
extended hospitalization are avoided. 
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1.5.4 Depot Formulation 
1.5.4.1 Polymers for Drug Delivery 
Both continuous infusion and regional delivery of cisplatin can be shown to be 
advantageous; these advantages can be exploited by formulating the drug with a 
polymer excipient for slow release therapy. A solid depot system can be injected 
directly to the site of action, the peritoneum, to which the drug will be released over 
the course of several weeks. As there will be no resident catheter the risk of infection 
is far lower than by intravenous infusion. The depot contains the entire dose for the 
treatment cycle minimising the number of health personnel interventions required for 
treatment. 
 
Choice of polymer is important in depot design. Besides having very low toxicity, 
interactions of the drug with the polymer matrix must also be understood. The 
properties of both polymer and drug determine whether it will remain active upon 
formulation and at what rate it will be released under physiological conditions. The 
profile of release should match the required regime of the treatment. An ideal 
candidate for drug delivery would have low toxicity during its entire life cycle in the 
patient. Real world considerations mean that the entire process of manufacture must 
be affordable to patients and provide a good rate of return to investors. 
 
Drug release from the depot will occur by diffusion from the matrix. The matrix 
must become wetted to allow the drug to become solubilised. Wetting will occur as 
water penetrates the depot. Differences in dynamics of the hydration front influences 
drug release (Jamzad et al., 2005). Matrix degradation may also be required to 
increase the permeability of the matrix. Pores in the polymer will further complicate 
rates of drug release. 
 
As the diffusivity of the drug in the polymer affects the rate of diffusion controlled 
release, the choice of polymer will determine release kinetics. To the author’s 
knowledge, diffusivity of cisplatin has not been reported for any polymer matrices. 
Polymer selection has been based on empirical observations of release. The 
diffusivity will also change with time as the polymer degrades. Diffusion of small 
molecules occurs at a higher rate in lower molecular mass polymer matrices 
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(Braunecker et al., 2004). This is because glass transition temperature of a polymer is 
usually higher when the molecular mass is higher. The closer the environmental 
temperature is to the glass transition temperature, the higher the long-range mobility 
of the polymer chains. Lower molecular mass polymer chains will be more mobile 
than higher molecular mass polymer chains at a fixed temperature. More mobile 
polymer chains will allow faster diffusion of small molecules in that matrix. Other 
factors such as the size and shape of the polymer device, the rate of polymer 
hydrolysis, and the physiological conditions to which the device is exposed will have 
an effect on the rate of release. 
 
Concerted efforts have been made to exploit biodegradable polymers as slow release 
delivery devices for a range of proteins, peptides and other pharmaceuticals. These 
systems have advantages and disadvantages; a delivery system which is excellent for 
one pharmaceutical may be of no value for another. Polymers of interest are 
generally preferred to already be commonly used for some medical purpose. Dextrin 
is used clinically in dialysis solutions. A dextrin-doxorubicin conjugate with a drug 
loading of 8-12 % by weight degraded by enzymes in the plasma over seven days 
releasing oligosaccharide conjugated doxorubicin species (Hreczuk-Hirst et al., 
2001). The breakdown products of this polymer are non-toxic and non-enzymatic 
degradation is very low so the formulation is stable. Conjugating sugars to cisplatin 
however is likely to be difficult, expensive and reduce drug efficacy. 
 
Cisplatin has been encapsulated in liposomes with the aim of either triggering drug 
release at the tumour site, or anticipating direct fusion of the liposomes with tumour 
cells. Iga et al., 1991 fabricated cisplatin liposomes with a drug loading of 13 %. 
Using an implanted heater to disrupt the liposomes, they demonstrated targeted 
release in a mouse model (Iga et al., 1991). Elevated internal temperatures are 
painful for patients and the technique was not developed further. An improved 
method of liposome fabrication yielded nanocapsules with a drug loading as high as 
49 % by weight (Burger et al., 2002). At 37°C drug was released more rapidly than 
from typical polyester microsphere formulations. The first order release constant 
(section 1.6.2) of these liposomes has been calculated here to be approximately 
3×10-5 s-1, higher than the release constant of four published microsphere 
formulations (section 1.5.4.5) analysed in section 3.4.1. These capsules were more 
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toxic to cancer cells in vitro than drug in solution, possibly due to direct delivery of 
cisplatin into the cells by liposome-cell fusion. A possible drawback of liposome 
formulation could be preferential uptake of these submicron particles by phagocytic 
immune cells, potentially leading to higher immunosuppression than standard 
cisplatin chemotherapy. 
 
Responsive drug release systems have been investigated, in which the drug is 
released in the presence of a stimulus such as pH, temperature change, or electric 
field strength. Unfortunately these polymers are frequently toxic and do not degrade 
in the patient so must be left in place or surgically removed (Jeong et al., 1997). 
Responsive polymers are not especially advantageous for treating ovarian cancer 
where a constant release of cisplatin is required rather than release at a rate relating 
to an additional parameter. 
 
Some attempts have been made to prolong the time that the drug depot remains in 
circulation in the blood. Colloidal poly(ethylene glycol)-poly(aspartic acid) 
copolymer micelles containing 39 % by weight cisplatin showed prolonged blood 
residence. These submicron particles (28 nm) did not appear to be preferentially 
taken up by the spleen but accumulated in liver tissue at three times the 
concentration of the tumour (Nishiyama et al., 2003). Pegylation has also been used 
to reduce detection of  liposomes by the immune system (Newman et al., 1999) but 
suffered from leaching of polyethylene glycol before complete release. 
 
Lactic acid and glycolic acid polymers and copolymers have a number of 
characteristics making them suitable for depot delivery (section 1.5.4.2) and have 
investigated as a promising excipient for cisplatin (section 1.5.4.5). Rational 
improvements to drug release profiles from polymer depots can be made using 
mathematical models (section 1.6). 
1.5.4.2 Poly(lactide-co-glycolide) 
Poly(lactide-co-glycolide) (PLGA) is an aliphatic, biocompatible polyester. It 
hydrolyses in water to produce lactic acid and glycolic acid which may be 
metabolised by the body or excreted. Lactic acid has a chiral centre which has some 
influence on the physical properties of its polymers (and the chemical properties of 
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its degradation properties). When the polymer is manufactured from at or close to 
100 % glycolic acid or enantiomerically pure lactic acid, the polymer may 
demonstrate semi-crystalline character. For other lactide:glycolide ratios the random 
sequence of backbone prevents regular, crystalline structures from forming. 
Similarly, a racemic mixture of D- and L-lactic acid will introduce sufficient 
disorder into the polymer chain that semi-crystalline behaviour will not be observed. 
PLGA is generally manufactured from the racemic mixture of D- and L-lactic acid. 
PLGA is therefore usually an amorphous solid at room and physiological 
temperatures. By using PLGA with intermediate lactide:glycolide ratios there is a 
reduction in the risk of crystalline regions forming during the processing or 
degradation of the devices, thus reducing the risk of device fracture. 
 
There are a number of routes for PLGA polymerisation. The most common method 
of manufacture is under high pressure using stannous octoate as a catalyst. Glycolic 
acid is very reactive and so may form side products during PLGA synthesis. The 
molecular mass and composition of the chains determine the physical properties of 
the polymer. Lactic and glycolic acid polymers can also be blended to increase the 
range of properties available. 
 
 
Figure 11: Log observed degradation rate against pH of lactic acid oligomers (de 
Jong et al., 2001). 
 
Experiments with immobilised PLA oligomers showed acid catalysed ester 
hydrolysis below pH 4 and base catalysed hydrolysis above pH 4 (de Jong et al., 
2001). This is suggested by the change of end terminal hydrolysis with pH shown in 
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Figure 11 with a typical observed rate of hydrolysis of 10-7-10-6 s-1. This range of 
degradation rate is in accord with observations that microspheres made from PLGA 
50:50 with molecular mass 21 kDa degrade at a rate of 5×10-7 s-1 (Tracy et al., 1999). 
 
 
Figure 12: Proposed mechanism of base catalysed ester hydrolysis (de Jong et al., 
2001). 
 
The proposed mechanism for base catalysed ester hydrolysis is shown in Figure 12. 
The nucleophilic hydroxyl end group attacks the second carbonyl leading to the 
formation of a six-membered ring as an intermediate (b). A base interacting with the 
hydroxyl end group increases the nucleophilicity of the oxygen atom, catalysing the 
reaction (de Jong et al., 2001). Lactide rapidly hydrolyses to lactic acid in water. 
This model may be relevant at physiological pH as the number of end groups 
increases. It should be noted that glycolide does not have the steric hindrance of the 
additional methyl group and so PLGA chains may also undergo standard ester 
hydrolysis at these residues. 
 
 55 
 
Figure 13: Reaction scheme showing acid catalysed hydrolysis of PLGA.  
Brackets represent continuation of polymer chain. 
 
Figure 13 shows acid catalysed hydrolysis of an ester bond of a PLGA chain (a) 
based on the text-book model of ester hydrolysis. Hydrolysis is initiated by 
protonation of the carbonyl; this increases its electrophilicity (c). This facilitates 
nucleophilic attack by water (d). A proton is transferred to generate a good leaving 
group (e). The equilibrium is driven towards ester hydrolysis when water is in 
excess. Ester hydrolysis can occur at any point along the polymer chain resulting in 
PLGA chains and oligomers of varying length. 
 
Hydrolysis will continue, releasing lactic and glycolic acid monomers for 
metabolism. D-lactic acid is the biologically preferred isomer and is rapidly 
metabolised (at a rate of 950 mg kg-1 h-1 in rats without increasing blood lactate) and 
although L-lactate is poorly metabolised it is rapidly excreted (Cori and Cori, 1929). 
As the structures degrade fragments of the microspheres may be cleared by 
phagocytes. 
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Lactide and glycolide polymers have been in use in medicine since the 1960s as 
biodegradable sutures (Cutright et al., 1971). They have also been used for 
orthopaedic applications. Bone fracture fixing pins hold damaged bone in place and 
allow the bone to bear increasing load as it is repaired and the pin subsequently 
dissolves (Muggli et al., 1999). Interference screws are used during reconstructive 
anterior cruciate ligament surgery to secure the graft in the femur and tibia. PLA 
interference screws have allowed successful repair without need for second surgery 
(Bach et al., 2002). Suture anchors are used to fix sutures firmly in place during 
reattachment of soft tissue to bone. Biodegradable sutures have similar strength to 
metal anchors but do not need to be removed (Warme et al., 1999). An additional 
advantage of polymer orthopaedic implants over metal implants is that they do not 
prevent magnetic resonance imaging of the repair site. PGA and PLGA have also 
been used as tissue scaffolds for smooth muscle cells (Kim et al., 1999) and bone 
marrow stromal cells (Kim et al., 2005). Biodegradable polyesters have also been 
used extensively for drug delivery systems (section 1.5.4.4) which have also been 
shown to be biocompatible (Anderson and Shive, 1997). 
 
 
Figure 14: Drug release profiles of theophylline from PGA. 
PGA had molecular weights of 6 kDa (o), 13 kDa (●), 24 kDa (▲) and 36 kDa (□). Adapted 
from Braunecker et al. 2004. 
 
Figure 14 shows release of theophylline from PGA pellets with a range of molecular 
weights. Drug release was faster from PGA pellets with lower molecular weight 
(Braunecker et al., 2004). For systems in which the scale of drug release corresponds 
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to the scale of polymer degradation the release profile may be adjusted by rational 
selection of polymer excipient with an appropriate molecular weight. By controlling 
how the polyester is deposited, well defined structures can be formed (such as 
microspheres or hollow fibres) which release drugs at a predictable rate. 
 
Properties of Ideal Polymer for Drug 
Delivery 
Properties of PLGA for delivering 
cisplatin 
Non-Toxic  Non-toxic 
Not antigenic or inflammatory  Negligible 
Readily excreted, non-toxic metabolites  Metabolised or excreted 
High drug loading to minimise excipient  Moderate (10 %) 
Formulation simple   Optimisation ongoing 
Financial viability  Excipient currently on market 
 
Table 2:  Table comparing the ideal properties of polymers for drug delivery and the 
properties of PLGA for delivering cisplatin. 
 
Table 2 summarises the suitability of PLGA as a slow release excipient for cisplatin. 
As well as being a safe polymer it is also possible to develop the system by 
controlling the lactide:glycolide ratio, molecular mass and device structure, allowing 
a tailored delivery profile. 
1.5.4.3 PLGA Microspheres  
PLGA microspheres have been fabricated by a range of routes (Watts et al., 1990), 
commonly by dissolving the polymer in an organic solvent, creating an oil phase. Oil 
and water mixtures will disperse spontaneously, forming an emulsion of droplets less 
than one micrometre in diameter if the interfacial tension is reduced to zero by an 
emulsifying agent. Most PLGA microspheres have been manufactured by agitation 
of an oil in water suspension where the interfacial tension is greater than zero. PLGA 
microsphere formation occurs in two stages. The first is the suspension step. Initially 
a dope of polymer dissolved in an organic solvent is dispersed in an aqueous 
medium (or continuous phase) using a mechanical homogeniser (Niwa et al., 1993, 
Araki et al., 1999, Tamura et al., 2002, Huo et al., 2005, Matsumoto et al., 2005) or 
ultrasonication (Ishihara et al., 2005). A suspending agent, such as poly(vinyl 
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alcohol) (PVA), is used to lower the interfacial tension between the oil and water. 
The dope is immiscible with the aqueous medium so an oil in water suspension is 
formed. Mixing must be continuous to maintain the suspension. The suspension step 
can also be carried out using an immiscible oil instead of water as the continuous 
phase (Ike et al., 1992, Fujiyama et al., 2003). A potential hazard of oil in oil 
suspension is that more toxic contaminants are present in place of water. This 
additional oil must be carefully removed from the final formulation. Water-soluble 
molecules have been incorporated in microspheres by a double emulsion step of 
water in oil followed by oil in water (Okada, 1997). 
 
The second step is extraction of the polymer solvent leaving spherical droplets of 
polymer. A high concentration of solvent plasticizes the polymer, decreasing the 
glass transition temperature of the polymer. The lower the glass transition 
temperature of the polymer, the more the polymer chains move at the temperature of 
manufacture. Initially, the solvent is able to rapidly diffuse out of the oil phase into 
the aqueous phase. As more solvent is extracted, the oil phase becomes a 
progressively poorer solvent the polymer chain becomes less extended in solution 
(Artursson et al., 1990), interacting more with other PLGA chains and the glass 
transition temperature increases. As the glass transition temperature increases, the 
polymer chains move less, reducing the diffusivity of the solvent in the oil phase. 
This decreases the rate at which the solvent is extracted. The outer layer of the 
droplet solidifies first, leaving a molten centre. Depending on how long the droplet is 
exposed to water the droplets of polymer may completely harden as the remaining 
solvent dissolves away or retain a viscous liquid centre. Evaporation of the solvent 
from the reaction vessel allows additional hardening of the microspheres (although 
this will be reduced for solvents with higher boiling points). This reverse-phase (or 
oil in water) technique gives a normal distribution of micrometre-scale spheres 
(microspheres) rather than haphazard structures formed by uncontrolled 
precipitation. 
 
All factors which effect the destabilization processes of the solvent/polymer 
suspension and interactions between the oil and aqueous phases will influence 
particle formation. Creaming or sedimentation are destabilization effects  which are 
determined by the difference between the density of the solvent and the continuous 
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phase, the radius of the droplets, and the viscosity of the mixture. Particles may 
aggregate, increasing the destabilization of the suspended droplets, even if they do 
not coalesce due to their hard surfaces. The solubility of the solvent in the 
continuous phase and the volatility of the solvent will determine the rate of diffusion 
of the solvent into the continuous phase by altering the concentration gradient 
microsphere formation and so the size and porosity of the particles. The choice of 
continuous phase, solvent, polymer, suspending agent, drugs and any other additives 
will alter the electrical charge on the surface of the suspended droplets (or Zeta 
potential) which will alter the behaviour of the suspension. In addition, factors such 
as method and degree of agitation of the emulsion, , ratio of polymer to solvent, ratio 
of solvent to external phase, temperature of all phases, humidity, dimensions of the 
mixing vessel and so on will have some effect on the nature of the microspheres 
formed.  
 
Water (with suspending agent such as polyvinyl alcohol) is preferred as a suitable 
continuous phase due to its low cost and lack of toxicity. 
 
Dichloromethane (DCM) is a solvent of PLGA commonly used for microsphere 
manufacture. It has a low boiling point of 40°C (Appendix A) which means that 
most of the solvent will be removed during the solvent evaporation step in 
microsphere production. DCM is a class 2 solvent according to the International 
Conference on Harmonisation which means that the concentration should be limited 
to 600 ppm (ICH Q3C (R3), 2005).  
 
Replacing DCM in microspheres should lead to less chance of toxicity due to 
accidental high levels resulting from a fault during manufacture. PLGA nanospheres 
have been made using a mixture of acetone and methanol as the PLGA solvent 
(Kawashima et al., 1998).  
 
Ethyl acetate is a suitable replacement solvent for microsphere production. The 
solubility of ethyl acetate in water is 8.4 g in 100 g water at 20°C(Altshuller and 
Everson, 1953). Destabilization process that increase the tendency of a suspension to 
separate. Differences in density can cause creaming or sedimentation of the oil 
phase. For example, DCM has a density of 1.3 g cm-3 (Appendix A), suggesting that 
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sedimentation effects may be partially responsible for destabilizing the suspension of 
DCM in water. The density of ethyl acetate is close to that of water, reducing the 
destabilizing effect on the suspension. The most appealing attribute of ethyl acetate 
is low toxicity. Ethyl acetate is a class 3 solvent as it is less toxic with an LD50 three 
times higher than that of DCM (Appendix A). Ethyl acetate concentration should be 
minimised by good manufacturing practice but is less hazardous for medical 
applications than DCM. This improved safety rating makes it better to take to the 
clinic and so is preferred for manufacture of microspheres. 
1.5.4.4 Market Approved PLGA Microspheres 
A number of PLGA implantable microsphere formulations are currently in clinical 
use. Decapeptyl SR® (licensed as Trelstar Depot® in the US) is a PLGA 
microsphere formulation licensed by the British regulatory body (the Medicines and 
Healthcare products Regulatory Agency) in January 2002. PLGA technology was 
developed by Debio R.P., Switzerland and is manufactured by a solvent-free method. 
The active ingredient is triptorelin acetate, a gonadotropin-releasing hormone 
(GnRH) analogue at 2 % drug loading. Lupron Depot® is an equivalent PLA matrix, 
administered as a subcutaneous or intramuscular  injection, which releases 
leuprolide, another GnRH analogue at 10 % drug loading for treating prostate cancer 
(Okada, 1997, TAP Pharmaceutical Products Inc., 2003). 
 
The mechanism of action is the same for both products. At higher than normal 
concentrations these GnRH agonists suppress rather than stimulate sex hormone 
(such as testosterone and oestrogen) production by desensitising the pituitary gland. 
The resulting reduction of testosterone reduces stimulation of prostate cancer tumour 
cells. Similarly, inhibiting oestrogen release ends stimulation of endometriosis or 
painful fibroids in the uterus. Decapeptyl SR® may also be administered to delay 
early onset (precocious) puberty. Both Decapeptyl SR® and Lupron Depot® are 
available in formulations that release for one or three months.  
 
Leuprolide is a relatively large molecule (molecular mass 1209.4 g mol-1). The 
molecular mass of the PLA used for Lupron Depot® is low (15 kDa) but the 
hydrophobicity of PLA acts to control the drug release. These two factors allow 
sustained release of the drug for up to three months. Polyesters are especially well 
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suited to hormone delivery as the agents are active at low concentrations and the 
mechanism of action is required over prolonged periods. 
 
Risperdal Consta® is a PLGA microsphere formulation of risperidone for 
intramuscular injection. Risperidone is a common antipsychotic for treating 
schizophrenia. It is a receptor antagonist with an inhibitory constant in the 
nanomolar range for four key neurotransmitter receptors, although the precise 
mechanism of action is uncertain. This formulation consists of PLGA 75:25 and has 
38 % drug loading (Janssen Pharmaceutical Products Inc., 2006). Risperidone is 
released following initial polymer degradation between weeks three and eight 
following injection. Risperdal Consta® is useful clinically as it increases patient 
compliance while providing a useful dosing schedule and can extend the period over 
which treatment is effective. 
 
Although risperidone is a relatively small molecule (molecular mass 410.5 g mol-1) 
the release is controlled by the high lactide:glycolide ratio and high molecular mass 
(90 kDa) of the PLGA used in the formulation. 
 
The success of these formulations suggests that there would be acceptance of a 
similar formulation of cisplatin microspheres by physicians and patients. It also 
suggests that microspheres are financially viable provided that they offer advantages 
over alternative therapies. 
1.5.4.5 Cisplatin Microspheres 
Injecting cisplatin microspheres directly into the peritoneum has advantages over IV 
delivery of particles. IP microspheres would have lower exposure to phagocytic cells 
in the liver and spleen. Formulation of cisplatin into microspheres also changes the 
rate of platinum delivery. Rather than IV infusion over a few hours, cisplatin can be 
released over days. A depot of drug in microspheres can produce high drug exposure 
at the treatment site. In addition, the maximum plasma concentration of drug is 
reduced. No external access is required once the microspheres have been injected. 
 
Ike et al., 1992 made PLA microspheres with 4 % cisplatin loading. This formulation 
released 85 % of the cisplatin after one day. They also found that larger beads (2 mm 
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diameter) released cisplatin more slowly and this rate was dependent on the 
polydispersity of the molecular mass of the PLA (Ike et al., 1992). 
 
Araki et al., 1999 produced PLA-albumin cisplatin microcapsules with a cisplatin 
loading of 8.5 %. The formulations produced were less toxic and less effective than 
an equivalent dose of cisplatin as a solution (Araki et al., 1999). This observation 
could be explained by assuming that a proportion of the cisplatin dose became 
inactivated by binding to albumin in the formulation. Reduced toxicity of the 
albumin and cisplatin containing formulation supports the hypothesis that unbound 
cisplatin is the active species for tumour cell killing (section 1.4.3). 
 
Hagiwara et al., 1993 prepared cisplatin loaded PLA microspheres by an oil in oil 
emulsion method with a loading of 9 %. Release profile of the formulation was 40-
50 % burst release followed by 20-30 % slow release of cisplatin over the following 
three weeks (release profiles not shown). These microspheres had an LD50 almost 
twice as high as cisplatin solution in mice. The microspheres were used to treat a 
mouse model of ovarian cancer which had a mean survival time of 21±5 days if left 
untreated. Comparing cisplatin solution at 2.5 mg kg-1 to cisplatin microspheres at 
5 mg kg-1 survival was increased from 28±7 to 35±10 days (Hagiwara et al., 1993a). 
These doses correspond to 19 % and 21 % of the LD50 respectively. 
 
These microspheres were then used in a pilot study of 13 patients with malignant 
ascites resulting from gastric, colon or pancreatic cancer. Cancer cells were cleared 
or reduced in 12 of the patients but there was negligible improvement in survival 
time due to a lack of treatment for other tumours distributed around the body 
(Hagiwara et al., 1993b). These results suggest that this approach is not suitable as a 
sole method of treatment for gastric, colon or pancreatic cancer. For these diseases 
the tumour cells are not entirely contained within the peritoneal cavity. For ovarian 
cancer however, many patients will only have small tumour nodules (<0.5 mm 
diameter) which will largely be confined to the peritoneal cavity. Subsequent 
preparations by the same group were reported as cisplatin PLGA 75:25 microspheres 
by oil in oil emulsion with a drug loading of 3 %. There was a 21 % burst release 
and 95 % release over two weeks (Fujiyama et al., 2003). 
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Kumagai et al., 1996 prepared cisplatin PLGA microspheres with a drug loading of 
5 % (release profiles not shown). When implanted into rats the microspheres had an 
LD50 which was four times higher than cisplatin solution. The microspheres were 
used to treat a rat model of ovarian cancer; untreated rats had a mean survival time of 
9±3 days. The LD50 of cisplatin solution for the rats was 14 mg kg
-1 and 53 mg kg-1 
for cisplatin microspheres. Comparing cisplatin solution at 2.4 mg kg-1 (the 
equivalent of a clinical dose) with a dose of 9.6 mg kg-1 cisplatin in microspheres 
survival of rats was increased from 48±23 to 74±18 days. This is a valid comparison 
as these doses correspond to 17 % and 18 % of the LD50 of solution and microsphere 
formulation respectively (Kumagai et al., 1996).  
 
Tamura et al., 2002 compared cisplatin distribution following injection with IP 
cisplatin solution and IP or subcutaneous PLA microspheres containing 5 % 
cisplatin. As expected the peak concentration of cisplatin was much higher following 
cisplatin treatment than microsphere treatment (Tamura et al., 2002).  
 
Huo, et al., 2005 made PLGA 75:25 microspheres of 5-30 µm by solvent evaporation 
of DCM in PVA solution. These were injected into healthy rabbits. These 
microspheres were found to accumulate in the lung (Huo et al., 2005). By 
comparison with other cisplatin microsphere formulations it is likely that the claimed 
drug loading of 17 % is an overestimate. As only 70 % of the claimed total loading 
was released after 28 days with a negligible rate of release it is likely that the true 
drug loading was closer to 12 %. 
 
Matsumoto, et al. 2005 made PLA and PLGA 50:50 microspheres by 
homogenisation of the polymer with DCM and cisplatin in PVA solution and solvent 
evaporation (Matsumoto et al., 2005).  
 64 
 
Author Polyester Molecular 
Weight (kDa) 
Dope 
Solvent 
Continuous 
Phase 
Ike, 1992 PLA 12 DMF Castor Oil 
Araki, 1999 PLA 20 DCM PVA 
Fujiyama, 2002 PLGA 75:25 17 DMF Paraffin 
Tamura, 2002 PLA 9 + 22 DCM PVA 
Huo, 2005 PLGA 75:25 20 “ “ 
Matsumoto, 2005 PLA/PLGA 50:50 20 + 20 “ “ 
 
Table 3: Polyester and solvents used for manufacture published cisplatin 
microspheres. 
 
Table 3 summarises the polymer, dope solvent and continuous phase of published 
cisplatin microspheres. Cisplatin microspheres have been examined as a formulation 
for chemotherapy. Little effort has been made to rigorously characterize the release 
kinetics of such sustained release formulations. A brief analysis of these 
formulations may allow meaningful comparisons to be made. Other hurdles still to 
be overcome are the reproducibility of cisplatin release and scale-up of production 
and a demonstration that the formulation can provide a significant improvement in 
treatment over current standard therapy.  
1.5.4.6 Microsphere Phagocytosis 
Foreign bodies are detected by the immune system even if they do not elicit an 
immune response. Small particles such as polymer microspheres are well known to 
be cleared by phagocytes (Tabata and Ikada, 1988). Nanocapsules have been used to 
deliver drugs to treat pathogens which are resident within phagocytic cells and so 
hard to treat by conventional means. For example PLGA microspheres of 4 µm 
diameter have even been used to deliver drugs to phagocytic cells (Prior et al., 2002). 
PLGA microspheres as large as 10 µm have even been used as a medium for an 
experimental vaccine for cattle and was shown to be well phagocytosed by antigen 
presenting cells (O’Brien and Guidry, 1996). This means that PLGA microspheres 
below 10 µm could accentuate damage to the immune system compared to venous 
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administration. A PLGA delivery system should have released most of its drug load 
before becoming small enough to be phagocytosed. 
 
Avgoustakis et al. introduced cisplatin PLGA-mPEG nanospheres (0.1-0.2 µm) into 
the bloodstream of model animals and demonstrated that a proportion of the particles 
appeared to be evading the immune system. These particles were designed to 
accumulate in solid tumours. Unfortunately, the drug loading was very low at just 
0.1 % by weight. In addition the mPEG was shed faster than the PLGA particles 
degraded which may expose phagocytic cells to high doses of cisplatin (Avgoustakis 
et al., 2002). 
1.5.4.7 Disadvantages of Depot Formulation 
An important disadvantage of depot formulations is the difficulty of recovering the 
large quantity of drug implanted. Even if the general risk of poor response to a 
treatment is low the consequences of unexpected toxicity can be severe. Cisplatin 
causes major dose related toxicity including cumulative nephrotoxicity, 
immunosuppression, ototoxicity, nausea and vomiting. Under current dosing the 
kidney is protected by pre-treatment hydration and diuresis. Nephrotoxicity may be 
less severe under the lower peak cisplatin concentrations associated with slow 
release. Immunosuppression and ototoxicity increase with extended dosing 
schedules. In addition anaphylactic-like reactions have been reported (Brunton et al., 
2005).  
 
When the patient undergoes sudden side effects it may be clinically necessary to 
withdraw treatment. If a month’s dose of drug has been administered then this may 
not be feasible. With microsphere formulations, it may be good practice to 
administer a standard IV solution dose of drug before committing to the treatment 
with a depot system. Alternatively implanted fibres have similar release profiles but 
can be more easily removed in case of adverse reactions to the therapy. 
 
Another potential drawback that needs to be investigated is the effective 
bioavailability of drugs which are released slowly. Many drugs exhibit reversible 
binding to plasma proteins. Cisplatin is continually removed from solution by 
irreversible binding to nucleophiles in cells and in the plasma During slow release 
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concentrations will remain low and with a large portion of the active drug being 
sequestered by peritoneal fluid nucleophiles, the effective concentration may be 
further lowered. 
1.5.4.8 PLGA Fibres 
Rather than dispersing polymer in an organic solvent in an aqueous medium to create 
droplets, a stream of polymer can be extruded into the aqueous medium to create a 
continuous fibre of polymer. A dope of PLGA dissolved in NMP with powdered 
drug as a suspension can be extruded from a needle or spinneret (Perera and Tai, 
2006) into a water bath. The NMP is extracted into the water leaving a coagulated 
PLGA fibre containing encapsulated drug.  
 
For manufacturing fibres the solvent must be very soluble to allow a skin to rapidly 
form, creating the fibre structure. The most suitable solvent for manufacturing fibres 
is n-Methyl-2-Pyrrolidone (NMP) (Appendix A). This is a class 2 solvent meaning 
that the concentration should be controlled. Residual NMP should be maintained 
below 4840 ppm when used to manufacture polymer excipients (ICH Q3C (R3), 
2005).  
 
A spinneret is a spinning orifice with two concentric needles. Polymer dope is 
extruded through the outer orifice and water through the inner orifice. The polymer 
then enters the water bath as a continuous stream with solvent diffusing out of the 
nascent fibre into the water bath and the fibre bore.  
 
Polyethersulphone (Wang et al., 1996, Qin and Chung, 1999) and polyimide 
(Wallace et al., 2006) hollow fibres have been used for gas or liquid separation. 
PLGA hollow fibres have been used for bone tissue engineering (Ellis and 
Chaudhuri, 2006) and as nerve tract guidance channels (Wen and Tresco, 2006). 
PLGA fibres have also been used as coronary stents (Tamai et al., 2000).  
 
Solid or hollow polymer fibres may also be of interest for drug delivery. Depot 
morphology influences release behaviour. Fibres may exhibit improved drug release 
characteristics. A potential disadvantage of fibres is that they may cause pain to 
patients if implanted due to their larger size and are more difficult to administer since 
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they cannot be injected. An advantage of fibres over microspheres is that fibres can 
more easily be recovered from the patient in the event of severe adverse reactions to 
the drugs. Another advantage of fibres is that fibre extrusion may readily be adapted 
into a continuous process allowing scale-up, whereas microspheres must be made by 
a batch process. 
1.6 Modelling Drug Release 
1.6.1 Mathematical Models 
Slow release drug delivery devices release their payload at a rate that is determined 
by the physical characteristics of the drug, matrix and solvent. Although many 
groups have shown interest in developing sustained release formulations for cisplatin 
release (full review in section 1.5.4.5), few have reported meaningful results of 
analysis of release kinetics. To allow comparisons between formulations, 
mathematical models can be fitted to drug release data. These fits are sometimes 
based on theory that allows general predictions to be made about the behaviour of 
the devices. 
 
Mathematical models can increase understanding of physical systems. Empirical 
models make fewer assumptions but do not make predictions about the underlying 
process. Simple empirical models such as averages or straight lines are useful for 
generalising trends in a system. More complex empirical models may reduce the 
residual error (the total difference between the values predicted by the model and the 
data) but do not allow extrapolation of the data or improve understanding of the 
system.  
 
A semi-mechanistic empirical model is an empirical model that can be usefully 
interpreted by relating the parameters to physical events. A rate constant only gives 
predictions under the experimental conditions in which it was deduced but does 
allow comparisons between formulations under the same conditions. If the 
experimental conditions are close to the conditions of interest (physiological 
conditions in the case of drug delivery) then useful predictions can be made. 
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Mechanistic models attempt to interpret data with physical significance. Calculating 
a diffusion coefficient can allow predictions of release profiles under conditions 
other than experimental conditions in which it was deduced. It should be noted that a 
mechanistic model is still a model. It may allow improved predictions to be made but 
it is not reality. A mechanistic model is only an interpretation of the system so 
predictions may differ from observations. 
1.6.2 Semi-Empirical Models 
First order models are used extensively for pharmacokinetic analysis. They are used 
for compartmental and non-compartmental analysis of patients during analysis of 
drug distribution, although the individual rates are usually treated as aggregated 
parameters (section 1.4.2). First order models are also appropriate for use as semi-
empirical models for studying drug release from depots. When a solid matrix 
containing a water soluble drug is introduced into an aqueous environment the drug 
will leach into the aqueous phase. The more that drug leaves the matrix means that 
the amount remaining to subsequently be released is reduced. Diffusion of a 
concentrated analyte can be assumed to dissipate away from the concentrated region 
assuming a favourable or irreversible equilibrium. It can be assumed that the driving 
force for mass transfer is proportional to the difference between the outer surface 
concentration and the concentration of analyte in an analyte-rich region (Glueckauf 
and Coates, 1947). For drug release from a depot under sink conditions the rate of 
drug release will be determined by the concentration of drug in the depot and the 
constant representing the rate of release. 
 
Rate equations are derived from simplified schematics of material transfer. The 
concentrations in each compartment, here depot and solution, can be derived by 
integrating the rate equations. 
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Figure 15: Two compartment drug release model. 
X2 is the amount of drug remaining in the depot. This is released at a concentration 
dependent rate k21. X1 is the amount of drug which has been released from the depot into 
the surrounding solution. 
 
Figure 15 shows the scheme of cisplatin release from a fibre (or microsphere), where 
X1 is the amount released, M2(∞) is amount of cisplatin in the depot which will be 
released after a long time and k21 is the rate of the release process. Initially (at time = 
0) all of the cisplatin, M2(∞), is in the fibre and none has been released into solution.  
 
2
1
21 Xk
dt
dX
⋅=  
(4) 
 
After the fibre is implanted it releases drug at a rate determined by the release 
constant and the concentration of drug remaining in the fibre (equation 4). 
Integrating the equations for the two compartments (described in Appendix C) 
produces the first order equation that describes the amount of drug present in the 
volume of each compartment. 
 
( ) ( )tkeMX 21121 −−⋅∞=  (5) 
  
( ) tkeMX 2122 −⋅∞=  (6) 
 
 
This release scheme is described by equation 5 and the remaining drug in the depot 
is described by equation 6. A single exponential, also known as the linear driving 
force (LDF) model (Sircar and Hufton, 2000), is simple to implement and so is 
widely used (Messaritakia et al., 2005, Machida et al., 2000). First order kinetics can 
be used to model drug release from solid matrices. An exponential release curve 
should give parameters which are true for each formulation under the corresponding 
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experimental conditions. The release constant represents the fraction of drug 
remaining in the depot released after a unit of time. Rate of release is proportional to 
the release constant (equation 4). The release constant, k21, can be used to compare 
how quickly drug is released from different formulations under the same conditions. 
 
For some depot formulations the initial burst of drug release can occur to a greater 
extent than predicted by a single exponential. As the apparent rate of release changes 
the previous model is no longer appropriate. Such an effect could be caused by a 
skewed distribution of drug crystals towards the surface of the depot such that drug 
is released faster than would be expected for homogenous distribution of drug in the 
matrix. A second exponential term can be added to represent the readily released 
drug. Adding parameters should always reduce the residual error of the model; a 
more complex model cannot be justified unless the improvement in predicting power 
justifies the reduction in degrees of freedom. 
 
 
Figure 16: Three compartment model showing release of two pools of drug in the 
fibre into solution.  
X3 and X4 are the amounts of cisplatin remaining in the fast and slow compartments of the 
device respectively. This is released at concentration dependent rates k31 and k41. X1 is the 
amount of cisplatin which has been released from the depot into the surrounding solution. 
 
Figure 16 shows the release scheme which in physical terms these represent a 
surface pool, M3(∞), of readily released cisplatin at rate k31 and a well dispersed 
pool, M4(∞), of slowly released cisplatin at a rate, k41. The sum of drug in both pools 
M3(∞) and M4(∞) is the total drug loading. 
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The amount of drug released can be derived from the rate equations (Appendix C) to 
give the model shown in equation 7.  
 
Empirical models are useful for describing release profiles. They are simple to 
implement and are robust to fit computationally. Their scope is limited to a 
quantitative understanding of the system. To attempt to examine the underlying 
physics of the systems mechanistic models are required. These are derived from 
Fick’s laws of diffusion and are described in sections 1.6.4 and 1.6.5. 
1.6.3 Cisplatin Release and Protein Binding 
Many drugs exhibit reversible binding to plasma proteins. This is not a mechanism 
of drug clearance because as drug in the plasma is eliminated, the equilibrium of 
bound to unbound drug is displaced towards unbound. Most drugs are effectively 
entirely cleared from the central compartment. This is a good approximation of total 
drug fate as drugs are usually eliminated by renal filtration or liver metabolism. The 
kidneys and liver are active in the central compartment. Since the entire absorbed 
dose is eventually eliminated from the central compartment the area under the 
concentration-time curve is independent of the rate of drug release (section 1.4.2).  
 
The peritoneum is usually considered as part of the central compartment. There is 
some evidence that concentrations of unbound cisplatin are higher in the peritoneum 
compared to the blood plasma during IP cisplatin release (Kumagai, et al., 1996). 
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Figure 17: Concentration of unbound cisplatin in (a) peritoneum and (b) plasma. 
Concentration of cisplatin measured following administration of cisplatin microspheres (▲) 
or cisplatin solution (o) (Kumagai et al., 1996). 
 
Figure 17 shows the concentration of cisplatin in the peritoneal fluid and the blood 
plasma that had not become protein bound. Cisplatin was measured following release 
from 9.6 mg kg-1 IP microspheres or 2.4 mg kg-1 IP cisplatin solution. Concentration 
of unbound cisplatin was higher in (a) the peritoneum than (b) the plasma at 
equivalent times. At 24 h the concentration of cisplatin was higher in the peritoneum 
of rats treated with microspheres than in those treated with cisplatin solution. The 
concentration of cisplatin is higher in the peritoneum than in the plasma which may 
justify the use of an additional compartment to describe the pharmacokinetics of 
sustained, regional delivery of cisplatin to pharmacokinetic models such as Figure 5. 
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Figure 18: Four compartment model for release of cisplatin from a fibre. 
A dose of cisplatin, M2(∞), is released from a fibre, X2, with a rate constant k23 into the 
peritoneum of a patient, U3. Cisplatin rapidly exchanges with the central compartment, U1, 
with rate constants j13 and j31 and becomes protein bound from central, peripheral and 
peritoneal compartments with rate constant kb. There is distribution with the peripheral 
compartment, U2 from the central compartment with rate constants j12 and j21.  
 
Figure 18 is an extension of Figure 5 incorporating a compartment for regional drug 
release (section 1.6.2) into the peritoneum and a compartment for sustained release 
(Figure 15) from an dose of drug, M2(∞), implanted microsphere or fibre depot. For 
this model, the rate of elimination of unbound cisplatin depends on the concentration 
of drug in the peripheral, peritoneal and central compartments, the protein binding 
constant, kb, and the elimination constant of unbound cisplatin, jel. The elimination 
constant jel includes renal filtration and binding of cellular or other non-plasma 
components. 
 
Regional delivery is able to increase the area under the concentration-time curve of 
that compartment to the drug relative to the central compartment, even if the overall 
residence time of the drug in the body is unchanged (Benet, 1985). Cisplatin 
becomes protein bound in the peritoneum as well as in the central and peripheral 
compartments. Unbound cisplatin concentration in the peritoneum can be measured 
experimentally if a patient has a catheter for ascites drainage. This may allow 
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correlations between plasma and peritoneal unbound cisplatin concentrations to be 
assessed. Therefore, the peritoneum is a valid compartment to incorporate into the 
pharmacokinetic model. The peritoneum has been treated as a separate compartment 
for carboplatin pharmacokinetics (Miyagi et al., 2005). 
 
Since the cisplatin-protein binding constant, kb, cannot be calculated from 
pharmacokinetic data (Appendix B), complex pharmacokinetic models such as 
Figure 18 could be solved by supplying fixed values for the model. For example, the 
determination of free cisplatin concentrations released from a fibre in the presence of 
protein would be useful for assessing the impact of protein binding in the 
performance of an IP cisplatin depot. 
 
 
Figure 19: Two compartment model for cisplatin release and protein binding. 
M2(∞) is the amount of cisplatin remaining in the fibre, X2, which is released at a 
concentration dependent rate with a rate constant k21. X1(t) is the amount of cisplatin which 
has been released from the fibre but which is subsequently removed by binding to BSA with 
rate constant kb. The unbound cisplatin in X1 corresponds to unbound cisplatin to which the 
patient is exposed. 
 
Rate equations for drug release from a depot such as a microsphere or fibre and 
protein binding following release can be derived from a two compartment model 
(Figure 19). The amount of drug remaining in the fibre decreases at a rate defined as 
k21. The rate of drug removed from the system is defined by kb. The predicted 
concentration in solution (equation 8) can be derived from these rate equations 
(Appendix D).  
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Initially the amount of cisplatin in the fibre, X2, is the drug loading, M2(∞), and 
there is no cisplatin in solution, X1. The concentration of cisplatin solution will 
initially increase as it is released from the depot. As the concentration of cisplatin 
increases, protein binding will occur faster. The concentration peaks when the 
amount of cisplatin being released equals the amount becoming bound. As the rate of 
drug release falls the concentration of cisplatin in solution will fall.  
 
Equation 8 will be appropriate for determining the concentration of drug in solution 
if a two compartment model was sufficient for analysing drug release in water. If the 
release profile is more complicated and required three compartment model treatment 
then an equivalent three compartment profile may be more appropriate. 
 
 
Figure 20: Three compartment model showing release of two pools of cisplatin from 
the fibre into solution and removal of cisplatin from solution by protein binding. 
M3(∞)+M4(∞) is the amount of cisplatin remaining in the fibre, X3+X4, which is released at a 
concentration dependent rate with a rate constants k31 and k41. X1(t) is the amount of 
cisplatin which has been released from the fibre but which is subsequently removed by 
binding to BSA with rate constant kb. The unbound cisplatin in X1 corresponds to unbound 
cisplatin to which the patient is exposed. 
 
From the rate equations of the three compartment model (Figure 20) the amount of 
cisplatin in solution in the presence of protein (equation 9) can also be derived 
(Appendix D).  
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This model may give better predictions if the release profile of the device deviates 
from single exponential release. As there are five parameters, this model will have 
fewer degrees of freedom than the two compartment model. Unless the additional 
parameters significantly improve the fit to the data the two compartment model will 
generally be preferred. 
1.6.4 Fick’s First Law Mechanistic Model 
Rather than analysing diffusion data, empirically mathematical modelling can 
incorporate characteristics of the physical process. This means that the diffusivity, a 
general parameter that describes the movement of a molecule through a defined 
matrix can be directly calculated. The movement of small molecules in a medium is 
governed by Fick’s laws of diffusion. Fick’s first law for diffusion in one dimension 
can be written as a rate equation where j(x, t) is the flux of material in the direction x, 
D is the diffusion coefficient, C(x, t) is the concentration and x is distance in one 
direction (equation 10).  
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x
txC
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∂
∂
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,
,  (10) 
 
The flux, j(x, t), is the rate of transfer per unit area of section of the matrix. The 
diffusion coefficient incorporates Brownian diffusion as well as mechanical 
restrictions to mobility such as tortuosity of the path of the small molecule out of the 
matrix. Because the model is derived assuming that the matrix is perfectly 
homogenous when it is actually heterogeneous, matrices made from the same 
material but with different structures may demonstrate different apparent 
diffusivities. This model also requires that the solute is homogenously dissolved in 
the matrix and elutes from the inert support. If instead the drug is encapsulated as 
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large aggregates with no direct contact between water and the drug, the drug will 
dissolve into the matrix as it is removed, maintaining the drug concentration at the 
maximum solubility of the drug in the matrix. In this case, the drug concentration is 
buffered by the crystals and the release profile may be expected to behave more like 
a mass transfer system (section 1.6.2). 
 
Kinetics based on Fick’s first law predicts that initial drug release is dependent on 
the square root of time. This model assumes that the homogeneous matrix contains a 
higher concentration of drug than the solubility of the drug in the bathing fluid and 
that the rate of dissolution of drug into the polymer is faster than the rate of diffusion 
of the drug in the matrix. The most common implementation in the field of drug 
delivery is Higuchi kinetics (Higuchi, 1961). Higuchi proposed that an infinitely 
thick flat membrane under perfect sink conditions can be used to represent initial 
release of drug from a polymer depot (Appendix E). The model assumes that the 
drug loading of the matrix is much higher than the solubility of the drug in the 
release medium. 
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Equation 11 is the Higuchi model where M(t) is the amount of drug released across 
the exposed area, A, after time t, D is the diffusivity of the drug in the matrix 
medium, M(∞)/V is the total amount of drug initially present in the matrix per unit 
volume and Cs is the solubility of the drug in the solvent.  
 
( ) tktM =  (12) 
 
The constants in the Higuchi model can be aggregated to give equation 12 which can 
be determined by fitting the model to drug release data where k is a constant relating 
to diffusion controlled release (equation 13). The Higuchi model makes a number of 
assumptions but effectively only has one parameter, k for a single sample under fixed 
conditions. It should be noted that k is not a rate constant and has the dimensions 
mg s-0.5. 
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From k, the Higuchi model can be used to estimate the diffusivity. The advantage of 
the Higuchi model is that it is defined by a single parameter, k, and may be fitted as a 
linear model as a function of the square root of time. The most significant flaw of 
this model is that it is only true for part of the release profile as the depot is not 
actually an infinite slab. It has been estimated that this transport equation is 
applicable to the first 60 % of drug release (Ritger and Peppas, 1987). In addition, 
the Higuchi model is only defined for one dimension and does not take device 
morphology into account.  
1.6.5 Fick’s Second Law Mechanistic Models 
To overcome the limitations of models derived from Fick’s first law, release models 
can instead be derived from Fick’s second law. Fick’s second law for diffusion states 
that the rate of change of concentration in a matrix is proportional to the rate of 
change of concentration gradient at that point. Drug delivery devices are three 
dimensional objects so Fick’s second law requires a solution in three dimensions. 
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Fick’s second law in three dimensions can be written in the form of equation 14 
where D is the diffusion coefficient, C(x, y, z, t) is the concentration and x, y, and z 
are locations in rectangular coordinates. It is assumed that the diffusivity is the same 
in every direction; such media are described as isotropic. Depending on the boundary 
conditions which define the morphology of the depot the diffusion model can be 
derived. From this the diffusivity can more accurately be estimated for spheres 
(section 1.6.5.1), solid cylinders (section 1.6.5.2), and hollow cylinders (section 
1.6.5.3). 
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1.6.5.1 Spherical Model 
The diffusivity and release profile of microspheres can be calculated by using the 
spherical Fickian model and assuming that the microspheres are perfect spheres with 
diameter equal to the median diameter of the sample. It is also assumed that as drug 
reaches the surface of the fibre it is instantly removed. Spherical matrices such as 
microspheres are symmetrical in three dimensions so treating x, y, and z as equal, 
Fick’s first law (equation 10) can be expressed in terms of r (equation 15) where C(r, 
t) is the concentration, D is the diffusivity and r is the radius.  
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This can be used to derive Fick’s second law (equation 14) in terms of r using finite 
element analysis (Appendix F). This technique considers the amount of material 
being released from the microsphere through a very thin spherical shell, which has 
an internal surface area of 4pir2 and external surface area 4pi(r+∆r)2. Since the 
amount passing through the shell equals the change in concentration across the shell 
multiplied by the volume of the shell, the change in concentration with respect to 
radius and time can be determined in terms of the flux across the shell (equation 16). 
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Substituting for Fick’s law (equation 15) produces the result of Fick’s second law for 
cylindrical coordinates (equation 17). 
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Substituting u = C(r, t)r, where u is the substituted variable, into equation 17 
produces equation 18, the equation for linear flow in one dimension (Crank, 1975).  
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There are four boundary conditions for this equation. Firstly, because u is the 
concentration multiplied by the radius, u = 0 when r = 0 at t > 0. Secondly, the 
microsphere is under sink conditions during release so u = 0 when r = a at t > 0 
where a is the radius of the microsphere. Thirdly, u = rC0 at t = 0 at 0 < r < a, where 
C0 is the constant surface concentration of drug. Finally, the sphere is initially at 
uniform concentration, C1. 
 
For a sphere the solution of Fick’s second law for drug release can be expressed as a 
Taylor series of exponentials (equation 19) as described by Crank, 1975, p91. 
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M(∞) is the total drug in the device which is completely released after infinite time. 
As sphere radius (R) is effectively a bulk parameter that will depend on the size 
distribution of the particles it should be combined with diffusivity (D) for parameter 
estimation. As n increases the output converges with the solution; the solution can be 
approximated using a high value for n. This mechanistic model can give information 
about the underlying process of the drug release from a spherical device. Unlike a 
Fick’s first law model it describes the profile even at long values of time (weeks). 
1.6.5.2 Solid Cylinder Model 
The diffusivity and release profile of solid fibres can be calculated by using the 
cylindrical Fickian model and assuming that the fibres are infinitely long, perfect 
cylinders with radius, a, equal to the mean radius of the fibre. It is also assumed that 
as drug reaches the surface of the fibre it is instantly removed. A long, cylindrical 
device such as a fibre can be analysed in polar coordinates by substituting x = r cos θ 
and y = r sin θ into equation 14 as shown by Figure 21. To describe point, P, at (x, y, 
z) the substitution defines P at (r, θ, z).  
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Figure 21: Polar coordinates. 
A point, P, in three dimensional coordinates (x, y, z) can also be described in polar 
coordinates by (r, θ, z), where x = r cos θ and y = r sin θ (Sten-Knudsen, 2002). 
 
The fibre is assumed to be radially homogenous for all angles of θ and along its 
length for all values of z. Therefore, concentration is treated as not being a function 
of z or θ so the terms in equation 20 can be excluded from the concentration profile. 
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As the only independent variable is the radius of the cylindrical surface, 
concentration is only a function of radius and time. Flux, from Fick’s first law 
(equation 15), is the same at every point on the cylindrical surface and is always 
perpendicular to the cylinder axis. As for spherical systems (section 1.6.5.1) Fick’s 
second law can be derived for cylindrical systems using finite element analysis (full 
derivation in Appendix G). An amount of material passes through a cylindrical ring 
with internal surface area 2pir∆z and external surface area 2pi(r+∆r)∆z. As above 
(section 1.6.5.1), this amount equals the change in concentration multiplied by the 
volume thereby allowing the change in concentration to be determined with respect 
to the flux. 
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Substituting for Fick’s law (equation 15) produces the result of Fick’s second law for 
cylindrical coordinates (equation 22) (Sten-Knudsen, 2002). 
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The method of separation of variables (as described by Crank, 1975, p17) can be 
used to solve this expression where time and space variables are convoluted. It is 
assumed that the time and space dimensions of C(r, t) has a solution that can be 
treated as two independent functions, R(r) and T(t), which can be multiplied together 
(equation 23).  
 
( ) ( ) ( )tTrRtrC =,  (23) 
 
These functions can be substituted into equation 22 to give equation 24. 
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Since R(r) is not a function of time and T(t) is not a function of radius, equation 25 
can be expressed as two separate ordinary differential equations. 
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As both sides are equal they can be treated as separate differential equations for time 
and space and solved by setting both sides equal to –α2D. Treating the time function 
of equation 25 as an ordinary differential equation allows the function T(t) to be 
defined (equation 26). 
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To solve the space function, R(r), for fibres to be determined –α2D is substituted into 
the other side of equation 26. 
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Equation 27 is in the form of a Bessel equation (Crank, 1975). 
 
( ) ( ) ( )rYBrJArR BB 00 ⋅+⋅=  (28) 
 
A Bessel equation has the solution given in equation 28 where AB and BB are 
constants, ( )rJ 0  is a Bessel function of the first kind of order zero, and ( )rY0  is a 
Bessel function of the second kind of order zero. These functions are damped but 
infinitely oscillating. 
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Figure 22: Bessel functions. 
Bessel function of the first kind of zero order, J0(aαn), (solid line) and of the second kind of 
zero order, Y0(aαn), (dashed line) calculated using R. The first ten in the infinite series of 
positive roots of J0(aαn) are shown in Table G1. 
 
Bessel functions of the first, J0, and second, Y0, kind of zero order have the form 
shown in Figure 22. A Bessel function of the first kind of order zero, ( )rJ 0 , has a 
defined value at r = 0. A Bessel function of the second kind of zero order, ( )rY0 , 
diverges at the origin which means that BB can be set to zero for physical models of 
solid fibres so that the result has physical meaning.  
 
( ) ( )rJArR B 0⋅=  (29) 
 
 
By combining the definitions of the time function (equation 26) and the space 
function (equation 29) gives the explicit solution, equation 30, which is defined 
when the boundary conditions are satisfied. The concentration, C(r, t) = C0 when 
r = a, for all time, t ≥ 0, and C(r, t) = C0 at 0 < r < a, when t = 0. 
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The boundary condition is satisfied by equation 30 as long as αn is the series of 
positive roots of the Bessel function of the first kind of zero order (equation 31) 
divided by a.  
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 For a long fibre where diffusion from the end of the fibre is negligible the solution 
of Fick’s second law for drug release can be expressed as a Taylor series of 
exponentials (equation 32) as described by Crank, 1975 p73. 
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The amount of drug released depends on fibre radius (a), diffusivity (D), total drug 
(M(∞)) and nα  which is the series of roots of Bessel’s equation of the first kind of 
order zero. The true value can be approximated using an arbitrarily large number of 
roots. 
 
The cylindrical model has been successfully used to determine the diffusivity of 
hydrocortisone in polycaprolactone (1.6×10-10 cm2 s-1), ethylene-vinyl acetate 
(1.2×10-11 cm2 s-1) and PVA terpolymer (4.3×10-12 cm2 s-1) (Fu et al., 1976). This 
model should also be able to describe the release of cisplatin from PLGA fibres. 
1.6.5.3 Hollow Fibre Model 
The diffusivity and release profile of hollow fibres can be calculated by using the 
cylindrical Fickian model determined as for a solid fibre in section 1.6.5.2 using 
equation 22. For a hollow fibre there are different boundary conditions that must be 
considered. It is assumed that the fibres are infinitely long, perfect hollow cylinders 
with inner radius, a, and outer radius, b. Continuing to assume sink conditions C(r, 
t) = 0 at t > 0 and r = a, or r = b. Fick’s second law (equation 22) is true between the 
outer and inner radius of the cylinder, a < r < b. Release of drug from a hollow 
cylindrical device such as a hollow fibre is described by equation 33 from Crank, 
1975, p83 (Appendix H). 
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Equation 33 predicts drug release from a hollow fibre with inner radius a and outer 
radius b where na  is a positive root of equation 34. 
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The Fickian model for the hollow fibre is useful for estimating the diffusivity of 
cisplatin in the fibre. The diffusivity should be more comparable between 
formulations than rate constants or other empirical measures. Quantitative 
predictions cannot be made in the same way from the empirical models. 
1.6.6 Model Comparison 
Statistical computing packages are able to greatly extend analysis of scientific data. 
Models can be fitted to the data and then compared to allow the most likely 
mechanism to be determined. Alternatively, different models can offer equally valid 
interpretations of the same dataset. Statistical testing provides objective measures for 
decisions to be made as to how well different models fit a dataset. 
 
( ) iii xfy εβ += ,  (35) 
 
A model (equation 35) representing data, yi can be described as being a function of 
its independent variable, xi, with model parameters, β, and also independent, 
randomly distributed errors, εi. A useful method of fitting non-linear models to data 
is by minimizing the sum of the squared residuals. 
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The differences between the data, yi, and the predicted values of the independent 
variable, f(β, xi) at each data point, from i = 1, …, n are the residuals. The minimum 
value of the sum of the squared residuals, S(β), is calculated by finding the points of 
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inflection where the gradient of equation 36 is zero. These equations must be solved 
numerically and in R this is achieved using a convergence criterion that minimizes 
the distance between the data point and the predicted value (Bates and Watts, 1981).  
 
Analysis of variance is an extended form of Student’s t-test. To determine whether a 
set of values are different from the whole population the ratio of between-group and 
within-group variance, the F statistic, is examined. When F is large the probability 
that the groups belong to the same population is low. If we are comparing models 
then a saturated linear model can be fitted and parameters removed until removing a 
parameter introduces a significant change. This approach can be used to compare 
models as better models will produce less variance in the residuals. The method is 
modified for categorical data and the technique is called analysis of covariance. 
 
Models can be selected by comparing how well the data is explained by the model 
with how many parameters are used in the model. Akaike’s Information Criterion 
(AIC) (Akaike, 1974) allows comparison of mathematical models of data by trading 
off the number of parameters used against the residual error.  
 
( )LpAIC ln22 −=  (37) 
 
AIC is calculated from statistical fitting parameters using equation 37; p is the 
number of parameters including the sum of squares, L is the likelihood function and 
2 is the numeric penalty for each parameter. AIC values can only be used to compare 
different models of a dataset, not between datasets. The model with the lowest AIC 
is preferred by this method. AIC can be used in conjunction with hypothesis testing 
methods such as analysis of variance/covariance during model comparison. The 
advantage of AIC is that unlike hypothesis testing there is no concern that the 
sequence of analysis will affect the results. 
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The likelihood of a model with parameters, β, with random errors distributed with 
variance σ 2 is calculated using equation 38. Comparison with equation 36 shows 
that minimizing the sum squared of the residuals maximises the likelihood of the 
model.  
1.7 Infection of Implants 
1.7.1 Infection 
Bacteria which manage to penetrate one of the physical barriers to entering the body 
are destroyed by the immune system. This effective system is generally only 
overcome when it is in a weakened state or by organisms which have specifically 
evolved to subvert its defences in some way. Even normal body cells are vigilant and 
send distress signals to the immune system or commit suicide if they detect that they 
are under attack. 
 
Any surface is susceptible to suffer bacteria attachment (Smith, 2005). Even if a 
surface is chemically resistant to bacterial attachment, small organic molecules will 
rapidly foul the surface in normal conditions. Microorganisms have a wide array of 
surface properties with differing surface charges and different degrees of 
hydrophobicity or hydrophilicity. A surface which has tailored physicochemical 
properties to be resistant to bacterial attachment cannot be resistant to every 
infectious organism. Even within a single species, mutants can show a range of 
affinities for a surface. Some Staphylococcus aureus mutants have been shown to 
attach to polystyrene surfaces although the wild type does not (Gross et al., 2001). 
Once a surface has become fouled with small molecules or other microorganisms, 
further surface infection can occur. Following initial attachment, the microorganisms 
secrete a matrix of biological polymers (such as polysaccharides and proteins) which 
is able to develop into a highly structured community including other species. Such a 
closely packed and firmly attached bacterial mass, or biofilm, matures into complex 
structure that protects the cells from the immune system and the effects of anti-
microbial agents. 
 
The problem of surface fouling is magnified in clinical situations. Implanted objects 
are frequently used for a variety of medical purposes such as mechanical repair, 
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introduction of medicines or drainage of fluids. Inert surfaces rapidly become 
covered with a conditioning film of biological material such as small molecules and 
host matrix proteins (Heilmann, 2003). The physicochemical characteristics of the 
surface as well as the environmental conditions will determine how quickly bacteria 
to which the surface is exposed may become attached. Bacteria can contaminate the 
implant during manufacture, handling, implantation or even from the bloodstream. 
The skin of healthcare workers and patients is a common source of bacteria. 
 
Environmental stresses trigger global gene regulators; these cascade to regulate 
bacterial virulence and so adopt a range of stress response phenotypes (Foley et al., 
1999). This means that stresses in the host bloodstream such as low iron availability 
and immune system attack trigger entry of bacteria into the slow-growth or dormant 
state preparing bacterial cells for hostile environments (Warner and Mizrahi, 2003). 
One stress response is an increase in production of polysaccharide intercellular 
adhesin which is involved in cell-cell binding, biofilm formation and attachment to 
biomaterials (Cramton et al., 2001). Stressed cells also demonstrate other 
characteristics such as low metabolic activity and can be said to enter a persister state 
(Brown and Smith, 2003) in which antibiotic resistance is many orders of magnitude 
higher than during growth stages (Keren et al., 2004). 
 
After initial reversible contact there is a phase of protein mediated strong binding. 
The cells produce a defensive matrix of extracellular polysaccharides to develop a 
biofilm. Rate of biofilm growth will depend on environmental conditions. In ideal 
conditions for bacterial growth severe encrustation can occur within 24 hours 
(Donlan, 2001).  
 
Bacteria encrusting surfaces and encased in biofilm have excellent resistance to the 
immune system, stressful conditions and antimicrobial treatments. Biofilms are 
medically important as the colony matures it sheds cells which may cause 
bacteremia. To avoid this risk catheters which become colonised by biofilm are 
generally removed (von Eiff et al., 2005). This would interrupt or end a catheter 
based IV slow release regime. 
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Coagulase-negative Staphylococci are gram-positive, human skin commensals. 
While normally harmless, they represent the most frequent causative agents of 
catheter and foreign body related infections. The majority (87 %) of bloodstream 
infections in intensive care units were caused by catheterisation and 39 % of these 
infections were coagulase-negative Staphylococci (compared to 12 % S. aureus) 
(Richards et al., 2000). S. epidermidis is the most successful of these species and is 
found in nearly 80 % of biomaterial related infections. S. epidermidis is able to 
colonise a medical implant prior to insertion, via a direct pathway between the skin 
to the implant (in the case of catheters) or from the blood following a subsequent 
wound. Cells in the biofilm mode of growth are difficult to control with antibiotics. 
Strains of S. epidermidis which do not form biofilm are not normally associated with 
disease. 
1.7.2 Bacterial Attachment to Implants 
Any form of implant for medical treatment may potentially suffer from colonisation 
by microorganisms. Before implementing a new method of treatment it is important 
to attempt to quantify the risks involved. Even objects prepared under perfectly 
aseptic conditions and a contamination free implantation can become subsequently 
infected by bacteria which have entered the body by another route, for example 
dental surgery. Normally these bacteria are rapidly destroyed by the immune system. 
If they are able to form a protective biofilm colony on an implant there is a danger of 
creating a centre for repeated infection. Clinically, polymer implants are known to 
occasionally become infected. Abscess formation following injection of Lupron 
Depot® suggests that the site of microsphere injection site becomes infected in up to 
5 % of cases (TAP Pharmaceutical Products Inc., 2003). Risperdal Consta® follow 
up data suggest that this figure may be lower at 0.1-1.0 % of doses (Janssen 
Pharmaceutical Products Inc., 2006). 
 
S. epidermidis is a good choice of experimental organism as it is easier to work with 
than the more pathogenic S. aureus while being medically relevant as a very 
common coloniser of implants. It is important to remember that no one set of 
physicochemical conditions will be repellent to all bacteria. In addition, the 
properties of the surface will never prove impregnable to colonisation because no 
surface is truly unadulterated. Organic material will coat any surface (Heilmann, 
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2003), especially in vivo where there are large quantities of protein and other organic 
molecules. 
 
Ideally all biopolymer devices would be manufactured under sterile conditions. If 
this is not possible then the PLGA device must be sterilized. Unfortunately the 
properties which make the polymer suitable for implantation become a hindrance to 
effective sterilization. Extreme conditions such as autoclaving will destroy the 
polymer. Gamma irradiation (Gilding and Reed, 1979), ethylene oxide and radio 
frequency glow discharge plasma (Holy et al., 2001) reduces the molecular mass of 
the polymer, potentially altering the release properties. Antibiotic cocktails can 
destroy certain classes of microbes but do not guarantee sterilization and may create 
further problems for patients with allergies.  
 
Ethanol solution, typically at 70 % is frequently used as an effective, broad-spectrum 
antiseptic. Ethanol has the advantage of having a relatively low toxicity and low cost 
although it is capable of causing tissue damage at high concentrations. Even 70 % 
ethanol treatment causes some damage to PLGA structures (Shearer et al., 2006) and 
cannot guarantee sterilization as it will not destroy some viruses and bacterial spores. 
In addition, bacteria living in the hostile (dry, nutrient-depleted) environment of 
microspheres are likely to be in a stress-resistant vegetative state even if they are not 
spore forming. 
 
Aseptic production and administration remains the best approach to disease 
prevention. Devices for sterile injection of microsphere are already used to prevent 
infection before implantation. If ethanol treatment can be shown to display 
reproducible effects on a device then it may be a suitable treatment method after 
production as a risk reducing measure to prevent inadvertent injection of infected 
implants. 
1.8 Aims and Objectives 
This review of the current state of ovarian cancer treatment shows that paclitaxel in 
combination with platinum drugs is the best treatment currently available. Second 
generation platinum agents have reduced side effects but have not yet been shown to 
improve survival. Intraperitoneal delivery has been shown to offer improved therapy 
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to ovarian cancer patients. Depot delivery of cisplatin to the peritoneum may offer 
further improvements in efficacy with reduced toxicity to patients with this disease. 
Findings from this thesis will also offer a review of mathematical tools available to 
rational investigation of diffusion controlled drug releasing depots. 
 
The aims of this research are to: 
 
1. Fabricate microspheres with improved release profiles compared to previous 
formulations.  
2. Manufacture novel fibres and assess as potential drug delivery devices. Solid 
and hollow fibres have not been widely studied as drug delivery devices.  
3. Apply mathematical models to the drug release profiles to allow rigorous 
comparison of formulations. Real datasets will also allow critical evaluation 
of the usefulness of empirical and mechanistic mathematical models. 
4. Investigate irreversible protein binding of cisplatin to proteins. As unbound 
cisplatin is thought to form the cytotoxic species, quantifying the amount of 
unbound cisplatin in solution is an important goal. 
5. Quantify bacterial attachment to drug depots using Staphylococcus 
epidermidis, a common implant pathogen. All surfaces are liable to bacterial 
attachment. Cisplatin is a toxic molecule which limits bacterial growth. Once 
the cisplatin payload has been released from a depot, the surface will serve as 
a potential focus for infection until the polymer has fully degraded. A method 
for comparing attachment of bacteria to different depots would be a useful 
tool for development of biomedical applications. 
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2 Experimental Methods 
2.1 Drug Release from Delivery Devices 
2.1.1 Materials 
Cisplatin powder was obtained from Lianyungang Unionrun Foreign Trade Co., 
Jiangsu, China. Poly(vinyl alcohol) (PVA) was purchased from Sigma-Aldrich 
(UK).  
 
Poly(lactide-co-glycolide) (PLGA) was obtained from Alkermes (Birmingham, 
Ohio, USA). Three different lactide:glycolide polymers were selected to allow 
comparisons of release rates from depots made from each. PLGA 50:50 (lot LP-178) 
had a molecular weight of 51-72 kDa. PLGA 65:35 (lot LX4-72) had a molecular 
weight of 90-140 kDa. PLGA 75:25 (LX4-74) had a molecular weight of 290 kDa.  
 
Analytical grade ethyl acetate, N-methyl-2-pyrrolidone (NMP), dichloromethane 
(DCM) and cyclohexane were from Fisher Scientific (UK). 
2.1.2 Manufacture of Microspheres 
Microspheres were fabricated by oil in water suspension precipitation (section 
1.5.4.3). A dope solution consisting of polymer dissolved in an organic solvent is 
homogenised with an aqueous phase to create a suspension. The solvent dissolves in 
the aqueous phase leaving a precipitate of polymer droplets of the order of 10 to 
100 µm in diameter. Ethyl acetate was used rather than dichloromethane (DCM) due 
to its lower toxicity (MSDS data in Appendix A). The solubility of ethyl acetate is 
8.4 g in 100 g water at 20°C(Altshuller and Everson, 1953). The amount of ethyl 
acetate in the dope added to the aqueous phase was below this solubility threshold. 
This means that the solvent has the opportunity to dissolve extensively into the 
aqueous phase. PLGA was added to ethyl acetate at 10% by weight. This was mixed 
on a rolling bed until it had completely dissolved forming a viscous polymer 
solution, or dope, for device manufacture. For batches to which drugs were added, 
40 % weight of polymer was mixed with the dope at this stage. 
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Batch PLGA Polymer in dope (%) Cisplatin in dope (%) 
M1, M3, M4, M7 50:50 9.5-9.7 3.2-4.9 
M8, M14, M17, M20, 
M21, M25, M26, M27 
65:35 9.6-9.7 3.2-3.9 
M18 65:35 13.3 4.7 
M19 65:35 16.9 5.9 
M16, M22 65:35 9.6-9.7 - 
 
Table 4: Batches of PLGA microspheres manufactured and ranges of polymer and 
cisplatin concentrations in the dope. 
Polymer and cisplatin in dope calculated as percentage of total mass including polymer, 
solvent and drug. 
 
Table 4 summarizes the conditions of manufacture of PLGA 65:35 and 50:50 
microspheres. The recipe used was derived from methods reported elsewhere(Watts 
et al., 1990). Additional batch details are noted in Appendix K. 
 
 
 
Figure 23: Manufacture of PLGA microspheres.  
(a) Dope added to PVA solution. (b) Mixture homogenised for 13 minutes at 9500 rpm. 
(c) Suspension stirred for 4 hours at 500 rpm. (d) Suspension centrifuged at 500 g for 
3 minutes, the supernatant decanted and the pellet of microspheres resuspended in distilled 
water. (e) Suspension filtered and the cake air dried for 12 hours. 
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Figure 23 summarises the method used to manufacture PLGA microspheres. An 
aliquot of dope (6 g) was taken from the stock using a syringe and added to 150 ml 
of 0.2 % poly(vinyl alcohol) (PVA) aqueous solution at 5°C. To create the emulsion 
the mixture was mechanically homogenised at 9500 rpm for 13 min in a baffled 
conical flask. Flasks with baffles were used to improve mixing throughout the 
volume. The suspension was poured into a beaker to be stirred with a magnetic bead 
at 500 rpm for 3-5 h to allow for solvent evaporation and microsphere hardening. 
The suspension was centrifuged at 500 g for 3 min and the supernatant discarded. 
This process was repeated four times until the dope had been used up and combined 
into a single batch for processing. 
 
To remove surfactant, residual solvent and undersized microspheres the 
microspheres were washed with distilled water. For this, the suspension was 
centrifuged at 150 g for three minutes and the supernatant discarded. The 
microspheres were then resuspended in distilled water. This was repeated twice. The 
pellet was resuspended and filtered using Whatman M100 glass filter paper (pore 
size 1.47 µm). The filter cake was air dried overnight in a stream of air. Due to the 
low toxicity of ethyl acetate (Appendix A) it was not quantitatively confirmed that 
the solvent was completely removed by this washing protocol. The solidification of 
the microspheres as the solvent is removed increases the glass transition temperature 
of the polymer (section 1.5.4.3), thereby increasing the diffusivity of the solvent in 
the polymer at the temperature of manufacture. Therefore, the more the solvent is 
extracted, the lower the rate of further extraction. Varying amounts of residual 
solvent in different batches may result in a source of between batch variation both in 
the amount of drug initially present in the microspheres and in the diffusivity of the 
drug being released by the formulation. Due to the high boiling point of ethyl acetate 
(77°C) air drying may not completely remove the solvent. Freeze-drying samples 
with residual solvent in the centre may produce large voids on complete drying 
(section 3.3.1).  
 
The dry microspheres were separated by physical sieving in a stack of sieves with 
mesh sizes 106, 90, 53 and 38 µm. Particles above 90 µm were discarded. Particles 
below 90 µm were either recombined or maintained as two fractions of particles 
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below 38 µm and particles between 38 and 90 µm. Microspheres were stored in a 
refrigerator at 5°C.  
2.1.3 Manufacture of Solid Fibres 
Preliminary studies found that PLGA 75:25 microspheres appeared to encapsulate 
less cisplatin than PLGA 50:50 with PLGA 65:35 encapsulating the most by the 
microsphere method described above. Therefore, most fibres were manufactured 
using PLGA 65:35. PLGA 65:35 was dissolved in N-methyl-2-pyrrolidone (NMP) 
(18 % by weight). Cisplatin (50 % by weight of PLGA) was added immediately (F2, 
F4) or after the PLGA had completely dissolved (F3). 
 
Batch PLGA Polymer in dope (%) Cisplatin in dope (%) 
F1 75:25 16.4 1.8 
F2-F4, F7 65:35 16.2-16.4 8.1-8.4 
F6 65:35 16.0 9.8◊ 
F5 65:35 16.3 - 
 
Table 5: Batches of PLGA fibres manufactured and polymer and cisplatin 
concentrations in the dope.  
Polymer and cisplatin in dope calculated as percentage of total mass including polymer, 
solvent and drug. ◊ Carboplatin was used instead of cisplatin for F6 fibres. 
 
Table 5 shows the concentrations of the polymer dope used for manufacturing solid 
fibres.  
 
 
Figure 24: Polymer dissolved in syringe for spinning. 
This method reduced waste as it could be spun directly without an additional transfer step. A 
cardboard support allowed the dope to be mixed using a rolling bed. 
 
To reduce waste during transfer of polymer dope the PLGA was dissolved in NMP 
in a sealed syringe and mixed on a rolling bed. The syringe was rolled in a support as 
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shown in Figure 24 so that no modification of the syringe was necessary. 
Immediately before spinning the fused plastic cap can be removed with a scalpel, the 
air expelled and the syringe connected to the spinneret with tubing. 
 
 
Figure 25: Schematic of solid fibre spinning process.  
Dope is extruded through a needle at 60 ml h
-1
 into a water bath before being collected by a 
motorised spool into a second hardening bath. 
 
Figure 25 shows the manufacture of PLGA solid fibres. The dope was driven from 
the syringe at 60 ml h-1 using a syringe pump and extruded through a needle into a 
water bath. Rollers ensure that the fibre does not float during the phase inversion 
process. The fibres were collected at 14 rpm into a second water bath. Fibres are 
soaked in the water bath to allow the NMP to completely dissolve into the water, 
ensuring that there is no solvent remaining in the finished fibre. This could otherwise 
be toxic or cause degradation of the fibre. Fibres were then dried. The concentration 
of residual NMP was not quantitatively determined following this washing protocol. 
The solidification of the fibres as the solvent is removed increases the glass 
transition temperature of the polymer, thereby increasing the diffusivity of the 
solvent in the polymer at the temperature of manufacture. Therefore, as more solvent 
is extracted, the rate of further extraction decreases. Varying amounts of residual 
solvent in different batches may result in a source of between batch variation both in 
the amount of drug initially present in the fibres and in the diffusivity of the drug 
being released by the formulation. Freeze-drying samples with residual solvent in the 
centre caused large voids to form on complete drying (section 3.3.2). 
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Cisplatin is water soluble (section 1.4.1). Since excessive soaking would completely 
remove the drug, during the manufacture of F1 fibres different drying methods were 
trialled. A third of the fibre (F1-F) was soaked for one hour and then freeze-dried 
using a Heto PowerDry LL3000. A third of the fibre (F1-A) was soaked for one hour 
and then air dried at 30°C. The remaining fibre was soaked overnight (F1) and then 
freeze dried.  
 
The fibres were wrapped around cardboard supports to increase the rate of solvent 
removal and to prevent the fibre becoming fused together during drying. 
Determining the drug loading showed that the majority of cisplatin had been lost 
from F1 fibres while cisplatin remained in F1-F and F1-A fibres. Subsequent fibres 
were soaked for one hour and then freeze dried overnight to retain cisplatin while 
removing solvent. Detailed batch notes are given in Appendix K. 
2.1.4 Manufacture of Hollow Fibres 
Hollow fibres were manufactured as for solid fibres except that the dope was 
extruded through a spinneret (Perera and Tai, 2006) at 200 ml min-1 with distilled 
water flow through a central bore cavity.  
 
 
 
 
 
 99 
 
 
Figure 26: Hollow fibre spinneret. 
(a) Exploded schematic of the spinneret (Perera and Tai, 2006). (b) Fibre is directly extruded 
into water with water pumped through the central needle to create the hollow core.  
 
Sample F8 was a blank containing only made solely from PLGA and n-methyl-2-
pyrrolidone (NMP). Figure 26 shows the spinneret used for manufacturing hollow 
fibres. Polymer is extruded from the spinneret with distilled water flowing through 
the central bore. The central bore creates support for the nascent fibre allowing an air 
gap to be incorporated between the spinneret and the bath. This reduces the chance 
of blockage during spinning. 
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Figure 27: Schematic of hollow fibre spinning process.  
Dope is extruded through the spinneret at 200 ml h
-1
 with water pumped into the fibre bore at 
180 ml h
-1
 into a water bath before being collected by a motorised spool into a second 
hardening bath. 
 
Due to their larger size and more fragile structure the hollow fibres were spun into a 
deep water bath to give them enough time to begin to harden before the fibres are 
passed through the spools (Figure 27) and then collected via a second bath into a 
final water bath for soaking. Due to their larger surface area to volume ratio 
compared to solid fibres, hollow fibres were able to be handled sooner after 
collection into the hardening bath. This allowed fibres with higher drug loadings to 
be produced. Although the residual NMP in the fibres was not quantified, the less 
porous structure of the matrix following freeze-drying (section 3.3.3) suggests that 
the fibre contained less solvent than solid fibres. This is because molten polymer 
inside a solid polymer shell occupies a smaller volume, meaning that voids will form 
when the solvent is completely removed. 
 
Batch PLGA Polymer in dope (%) Cisplatin in dope (%) 
F9, F10 65:35 16.3 8.2 
F8 65:35 16.3 - 
 
Table 6: Batches of PLGA hollow fibres manufactured polymer and cisplatin 
concentrations in the dope. 
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Table 6 shows the concentrations of the polymer dope used for manufacturing 
hollow fibres. Batch measurements are noted in Appendix K. 
2.2 Device Analysis Methods 
2.2.1 Laser Scattering Analysis of Microspheres 
Microsphere particle size distributions were measured using a Malvern Mastersizer 
with a 100 mm lens (for particles of 0.5-180 µm). Particle size was calculated using 
the Mie scattering model. The microspheres were dispersed in cyclohexane with 
1 mg ml-1 lecithin as a stabiliser. Distribution was scanned at least four times for 
each sample. 
2.2.2 Physical Characterisation of Fibres 
Diameter of fibres was measured fibres using a digital micrometer (n = 16). 
Approximately 50 cm of each fibre was weighed and the volume determined by 
displacement of water in a measuring cylinder. 
2.2.3 Scanning Electron Microscopy 
A sample of microspheres (M4) were sieved (between sieves with mesh size 90 and 
38 µm) and separated into large (38 to 90 µm) and small (<38 µm) fractions. 
Microspheres were freeze dried and mounted on specimen plates with carbon tabs. 
Samples were sputter coated with gold. Imaging was carried out on a JEOL JSM 
6310 electron microscope at 5 keV accelerating voltage. 
 
A sample of microspheres was sieved (between pans with mesh size 90 and 53 µm) 
to isolate a fraction of large (53 to 90 µm) particles. The microspheres were mixed 
with a suspension of Staphylococcus epidermidis (~1×104 cfu ml-1) and incubated at 
room temperature for five minutes. The sample was then centrifuged at 100 g for 
1 min to sediment the microspheres only. The supernatant was aspirated and 
discarded. The microspheres from the pellet were fixed with 2 % glutaraldehyde in 
0.1 M sodium cacodylate buffer followed by 1 % osmium tetroxide. The sample was 
then freeze dried using a tissue drier, mounted on specimen plates with carbon tabs, 
and sputter coated with gold. Imaging was carried out on a JEOL JSM 6310 electron 
microscope at 10 keV accelerating voltage. 
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Samples of fibres (F3, F4, F10) were oven dried overnight at 30°C and cut into small 
sections, then pressed onto carbon tabs on specimen plates. Samples were carbon 
coated prior to imaging. SEM and backscattering images of fibres were taken using a 
JEOL 6480LV scanning electron microscope. Backscattering maps were performed 
on a JEOL JSM 6310 electron microscope at 15 or 20 keV accelerating voltage. 
Areas of high electron reflectivity by backscattering imaging were validated as 
cisplatin by spot X-ray analysis. No additional preparation was required for X-ray 
analysis as X-rays emitted by the excited samples were directly captured in situ 
using the JEOL JXA8600 Superprobe electron probe microanalyser attachment of 
the electron microscope. 
2.2.4 Digital Image Analysis 
Photographs of hollow fibres were taken using a digital camera. Hollow fibre wall 
thicknesses were estimated by taking measurements at twelve positions around the 
circumference using ImageJ (Abramoff et al., 2004). Fibres were cut with a scalpel 
using a gentle sawing motion to minimise disruption to the profile of the cross-
section.  
 
 
 
Figure 28: Photograph of hollow fibres. 
Digital photograph scale was calibrated using ImageJ and twelve measurements of wall 
thickness were taken for each fibre at ten cross-sections. Diameter of each fibre was 
measured at six points at each of ten cross-sections. Bar is 1 mm. 
 
The images where calibrated using a ruler (Figure 28). Although this method may 
have limited precision it is sufficient for comparisons between fibres and gives a 
good estimation of the variability of the thickness of the fibres. 
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Release of cisplatin from fibres was examined by digital image analysis of SEM and 
backscattered images. Samples of F3, F4 and F10 fibres were soaked in distilled 
water at 30°C for 1, 5 or 21 hours and oven dried at 30°C overnight. Unsoaked fibre 
samples were also placed in the oven to control for the effect of temperature. SEM 
and backscattered images were taken of cross-sections of fibre samples (n = 4). 
Images were analysed using ImageJ. 
 
Images were calibrated using the embedded scale bar. Area of fibre cross-section 
was measured by manually selecting the outline of the fibre in the scanning electron 
micrograph.  
 
 
 
Figure 29: Estimate of cisplatin area from backscattered electron image. 
(a) Backscattered electron image of F3 fibre. (b) Threshold mask. Bar is 100µm. 
 
The area of cisplatin was estimated by setting the threshold of the backscattered 
image to just before random speckles appeared in the threshold mask (Figure 29b). 
As setting the threshold is subjective quantitative data must be treated with caution. 
The area of the mask is related to the amount of drug present in the fibre. The 
measured area cannot be directly compared to quantity of drug remaining in the 
fibre. This area may be used to observe the qualitative pattern of cisplatin dissolution 
from the fibre by comparing fibres soaked for different lengths of time. 
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2.3 Atomic Absorption Spectroscopy 
2.3.1 Materials 
Platinum standard for concentration calibration and bovine serum albumin fraction V 
(BSA) for the protein binding studies were purchased from Sigma-Aldrich (UK). 
Analytical grade ethanol, 37 % hydrochloric acid (HCl) and 70 % nitric acid (HNO3) 
and Amicon Bioseparations Cetrifree micropartition ultrafiltration filters (Fisher 
Scientific, UK) were from Fisher Scientific (UK). Acetylene was from BOC (UK). 
2.3.2 Calibration 
Cisplatin release from delivery devices was quantified using a Perkin Elmer Model 
3110 for atomic absorption spectroscopy (AAS) at 265.9 nm. 
 
Figure 30: Typical calibration curve for analysis of cisplatin from PLGA devices.  
Equation of the quadratic fit is y = -0.41x
2
 +1.19x -0.00. 
 
To compensate for fluctuations in the fuel and oxidant pressure the instrument was 
manually calibrated using a working curve. The dilution series consisted of twelve 
platinum standards in HCl 2.0 M from 1.000 mg ml-1 to 0.001 mg ml-1. The method 
was validated by dissolving powdered cisplatin in water for comparison with the 
standard.  
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Where sample concentrations were low enough that the Beer-Lambert law was 
obeyed a linear fit was used for the calibration. At higher concentrations a quadratic 
equation was needed (Figure 30). The third parameter was excluded when not 
significant. Standards were run throughout data collection to confirm that there was 
no change in response of the instrument. In cases where a significant change in 
response was noted a new calibration curve was generated for subsequent samples. 
Absorbance was measured using a 2.0 s integration time and an aspiration rate of 
3.0 ml min-1. 
 
To compensate for the density dependent differences in 2.0 M HCl and water 
matrices the appropriate diluent was use depending on the matrix of the samples 
being analysed. 
 
))(NH(PtClion Concentrat
))(NH(PtClM
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232
232r
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⋅
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The amount of cisplatin present was calculated from the mass ratio of the molecular 
mass (Mr) of platinum in cisplatin (Equation 39). For example, an aliquot of 
0.50 mg ml-1 platinum standard solution should have the same absorbance as 
0.75 mg ml-1 cisplatin solution. 
 
To confirm that cisplatin detection was not affected by the presence of a PLGA 
digest matrix cisplatin was added to samples of PLGA 75:25 F1 fibre and then 
digested using aqua regia. Nominal cisplatin concentration was plotted against the 
concentration determined by AAS. 
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Figure 31: Validation of acid digestion for cisplatin quantification using AAS. 
Correlation between amount of cisplatin added to PLGA 72:25 F1 fibres as a series of spikes 
and the amount of cisplatin calculated from atomic absorption spectroscopy measurements 
(n = 3). Equation of linear fit is y = 1.02 x – 0.00. 
 
Figure 31 shows the comparison of the amount of cisplatin added to samples of F1 
PLGA 75:25 fibres to the amount of cisplatin measured. There is a close correlation 
(r2 = 0.98) of these values with a relationship of 1.0 (p = 4.4 × 10-9) which validates 
this method for cisplatin analysis. 
2.3.3 Cisplatin Loading 
Drug loading was calculated by digesting 21.6±0.7 mg F2 and F3 fibre pieces at 
105°C with 1.0 ml aqua regia (three parts concentrated HCl to one part HNO3) until 
near dryness twice. Once dry the samples were redissolved in 1.0 ml HCl 2 M. 
Samples with the blank were spiked with cisplatin before digestion to check for loss 
of platinum. Material appeared to be retained in the crucibles so the digestion was 
repeated and a second set of samples was collected in 1.0 ml HCl 2M. 
2.3.4 Release of Cisplatin from Microspheres 
Cisplatin release profiles were determined for microspheres in distilled water (Table 
7) at 37°C. At each sampling time point the microspheres were sedimented by 
centrifugation, the release medium was decanted and the microspheres were 
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resuspended in fresh water. This strategy maintained the release environment at close 
to sink conditions. The concentration in each sample was measured using atomic 
absorption spectroscopy (AAS). Plotting the amount released into each sample gave 
a cumulative release profile of the formulation. 
 
# Sample Mass (mg) Volume (ml) 
2 M3 200 20 
3 M3, M4 100 15 
4 M7, M8 150 15 
5 M14, M16 100 20 
6 M7, M13, M17 100 15 
7 M17, M18, M19, M20, M21, M22 100 10 
 
Table 7: Nominal mass of microspheres and volume of water used as release 
medium. 
 
The samples were stored at room temperature for analysis by atomic absorption 
spectroscopy (AAS). Absorbance values for platinum were converted into cisplatin 
release profiles as described above. Amount of cisplatin released by each sample was 
normalised to facilitate comparisons. Two and three compartment empirical, Higuchi 
and spherical Fickian models were fitted to cumulative release curves by non-linear 
least squares regression using the statistics package R (R Development Core Team, 
2007).  
2.3.5 Release of Cisplatin from Solid Fibres 
Cisplatin release profiles were determined for 5 mg portions of solid fibre in 1 ml 
distilled water at 37°C. At each time point the release medium was collected and 
replaced with fresh water. Absorbance values for platinum were converted into 
release profiles as described above. Two and three compartment empirical, Higuchi 
and cylindrical Fickian models were fitted to cumulative release curves by non-linear 
least squares regression using the statistics package R. 
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2.3.6 Release of Cisplatin from Hollow Fibres 
Cisplatin release profiles were determined as above for 5 mg portions of hollow fibre 
in 1 ml distilled water at 37°C. At each time point the release medium was collected 
and replaced with fresh water. Absorbance values for platinum were converted into 
release profiles as described above. Two and three compartment empirical, Higuchi 
and hollow cylinder Fickian models were fitted to cumulative release curves by non-
linear least squares regression using the statistics package R. 
2.3.7 Cisplatin Binding to Albumin 
Cisplatin becomes inactivated in vivo by binding of aquated cisplatin to nucleophiles 
such as glutathione, DNA and proteins. Albumin is a well characterised model 
protein that can be used as a representative cisplatin binding target. Albumin can be 
removed from solution by ultrafiltration or cold ethanol precipitation allowing the 
concentration of unbound cisplatin to be determined. Characterising the profile of 
concurrent cisplatin release from a polymer depot and binding to protein will 
improve understanding of the pharmacokinetics of drug release and test the 
usefulness of the mathematical models described above (section 1.6.3). 
 
Typically serum albumin concentration is approximately 44 mg ml-1 and a 
therapeutic dose of cisplatin needs to attain a serum concentration of the order of 
10 µg ml-1. To validate that cisplatin could be accurately detected under these 
conditions known amounts of cisplatin were incubated with bovine serum albumin 
(BSA) solution, digested and measured using AAS.  
 
For cisplatin standards cisplatin powder was dissolved in distilled water. Each 
sample was heated to 105°C on a hot plate in a crucible to concentrate the sample. 
To destroy the protein the sample was then further heated with 1.0 ml aqua regia 
(0.25 ml 70 % HNO3 and 0.75 ml 37 % HCl) until most liquid had evaporated. This 
was repeated and the almost dry crucible was allowed to cool before the addition of 
2.0 ml 2.0 M HCl for AAS. 
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Figure 32: Cisplatin concentration measured by AAS after digestion of protein 
against concentration of cisplatin in samples. 
Nominal concentration calculated from mass of cisplatin added (n = 3). Solid line shows 
linear model of these data and dashed lines show the 95 % confidence interval. 
 
Figure 32 shows that the concentration of cisplatin measured by chemical digestion 
of protein and analysis by AAS are close to the expected values based on the amount 
of cisplatin powder added to the samples. Although the value of the intercept was not 
significant the gradient, 1.2±0.04, was significant (p = 3×10-11) by linear regression. 
This suggests that there is a small positive systematic error in this experiment. This 
analysis does not incorporate errors in weighing the cisplatin powder. These could be 
high (~20 %) due to static charging which can occur when weighing small quantities 
of powders. During manufacture of drug depots amounts weighed were large enough 
that static would not be significant. Acid digestion enabled the determination of total 
cisplatin concentration in the presence of biological molecules. Although it is useful 
to be able to determine total cisplatin concentration, only unbound cisplatin is able to 
cause tumour killing. It is necessary to develop a method to determine the 
concentration of the unbound fraction.  
 
Therefore a protocol was developed to determine protein binding kinetic parameters 
for cisplatin solution. The principle is to use cold ethanol precipitation (Ma et al., 
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1996) to remove the protein bound fraction from solution. This involves mixing a 
sample of the release medium with two volumes of cold ethanol, incubating at -20°C 
and then centrifuging. The supernatant was acid digested to remove residual protein 
that would interfere with the AAS analysis. Once the cisplatin solution was mixed 
with the BSA solution aliquots were removed at sequential time points and the 
protein removed by ethanol precipitation. The concentration of unbound cisplatin 
was determined with time. A preliminary experiment with 0.02 and 0.04 mg ml-1 
cisplatin demonstrated the proof of this concept. 
 
 
 
Figure 33: Unbound cisplatin concentration measured by AAS against time. 
Solutions of 0.02 mg ml
-1
 (□) or 0.04 mg ml
-1
 (∆) (n=2) added to BSA solution. Lines shown 
are fitted to the data assuming a single binding constant for both series. 
 
Figure 33 shows the decrease of unbound cisplatin concentration caused by binding 
to BSA. The absorbance values measured were low meaning that the experiment was 
at the limit of detection and therefore numerical values must be treated with caution. 
There was a clear reduction in cisplatin concentration over four hours. Assuming that 
the binding constant was the same for both datasets the binding constant, kb, was of 
the order of 1×10-4 s-1 calculated using the Solver function of Excel. Following this 
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preliminary experiment a complete experiment was carried out validating the use of 
ethanol precipitation as an alternative to ultrafiltration.  
 
To compare whether protein precipitation is equivalent to ultrafiltration the two 
methods were directly compared. Samples (8 ml) were prepared containing 
0.10 mg ml-1 cisplatin with and without 0.44 mg ml-1 BSA. At each of five time 
points an aliquot was withdrawn and the unbound cisplatin was collected using 
either ultrafiltration or ethanol precipitation (n = 4) to remove the protein. For 
ultrafiltration, 0.70 ml of sample were withdrawn, placed in Amicon Bioseparations 
Cetrifree micropartition ultrafiltration filters and centrifuged at 4000 g for 10 min 
and stored at -20°C until analysis. For ethanol precipitation, 0.67 ml of sample were 
pipetted into 1.33 ml cold ethanol, mixed and stored for 2 h at -20°C before 
centrifugation at 20 000 g for 30 min. The methods of protein extraction were found 
to be equivalent (section 3.5.1). 
2.3.8 Binding of Cisplatin Released from PLGA Depots to Albumin 
2.3.8.1 Release from Microspheres 
Samples of microspheres (M21, M25, M26, and M27) were suspended in distilled 
water (118 mg in 8 ml). Samples were well mixed and 0.56 ml of each was quickly 
added to six of twenty-four Eppendorf tubes. Distilled water or 100 mg ml-1 BSA 
(0.44 ml) was added to each sample and incubated at room temperature. At each time 
point the tubes were spun at 500 g for 3 min to pellet the microspheres and then 
0.67ml of release medium was withdrawn and added to 1.33 ml cold (-20°C) 
ethanol. The remaining release medium was aspirated and discarded. Fresh release 
medium (1.0 ml water or 0.44 mg ml-1 BSA) was added to the microsphere samples. 
The samples for each time point were spun at 20 000 g for 10 min and stored at 
-20°C for analysis. These samples were subsequently evaporated in ceramic 
crucibles (discarding the protein pellet) and digested with aqua regia at 105°C until 
near dryness twice. Once dry the samples were dissolved in 1.0 ml HCl, 2 M. 
2.3.8.2 Release from Solid Fibres 
Fibres (F1, F2, and F3) were cut into 5.0±0.17 mg pieces. Release medium (1 ml 
distilled water or 0.44 mg ml-1 BSA at 37°C) was added to each sample (n = 6) and 
incubated at 37°C. At each of ten time points 0.67 ml of release medium was 
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withdrawn and added to 1.33 ml cold (-20°C) ethanol. The remaining release 
medium was aspirated and discarded. Fresh release medium (1 ml) was added to the 
fibre samples. The samples for each time point were spun at 20 000 g for 10 min and 
stored at -20°C for analysis. These samples were subsequently evaporated in ceramic 
crucibles (discarding the protein pellet) and digested with aqua regia at 105°C until 
near dryness twice. Once dry the samples were redissolved in 1.0 ml 2.0 M HCl. 
2.3.8.3 Release from Hollow Fibres 
Fibres (F10) were cut into pieces weighing 5.6±1.0 mg. Release medium (1 ml 
distilled water or 0.44 mg ml-1 BSA at 37°C) was added to each sample (n = 8) and 
incubated at 37°C. At each of eight time points 0.67 ml of release medium was 
withdrawn and added to 1.33 ml cold (-20°C) ethanol. The remaining release 
medium was aspirated and discarded. Fresh release medium (1 ml) was added to the 
fibre samples. The samples for each time point were spun at 20 000 g for 10 min and 
stored at -20°C for analysis. These samples were subsequently evaporated in ceramic 
crucibles (discarding the protein pellet) and digested with aqua regia at 105°C until 
near dryness twice. Once dry the samples were redissolved in 1.0 ml 2.0 M HCl. 
2.4 Determination of Peritoneal pH 
Samples of ascites were obtained with informed consent from a stage IIIc ovarian 
cancer patient. Peritoneal fluid was taken from the abdominal drain catheter and pH 
was measured immediately using a pH meter. The pH meter was calibrated using 
standards. 
2.5 Bacterial Attachment to Drug Delivery Devices 
2.5.1 Materials 
Staphylococcus epidermidis strain ATCC35984 was purchased from LGC 
Promochem (Teddington, UK), revived and then stored under liquid nitrogen for 
later use. Solid potassium phosphate (KH2PO3 and K2HPO3) was obtained from 
Fisher Scientific, UK and dissolved in distilled water to 1.0 M. Phosphate buffered 
saline (PBS) 0.1 M, pH 7.4 was made from 5 ml 1.0 M KH2PO3, 20 ml 1.0 M 
K2HPO3 and 225 ml distilled water and sterilized in a Rodwell Scientific Instruments 
Series 56 autoclave at 121°C (2.1 bar), for 15 minutes. Peptone, Tryptone soya broth 
 113 
(TSB) and tryptone soya agar (TSA) were obtained from Sigma Aldrich, UK and 
were also sterilised in an autoclave. 
2.5.2 Bacterial Attachment to Microspheres 
As bacterial attachment to implanted devices is a fact, the degree of attraction 
between PLGA 50:50 microspheres and S. epidermidis was investigated. S. 
epidermidis ATCC 35984 was grown overnight in tryptone soya broth (TSB) at 
37°C without agitation to approximately 107 cfu ml-1. The culture was centrifuged at 
1000 g for 10 min, the nutrient media removed and the pellet of cells resuspended in 
the same volume of PBS. The culture was diluted 1:10 four times. To determine the 
concentration of the culture for each repetition of the experiment, test plates were 
made, plating 100 µl of 10-4 and 10-5 dilutions. 
 
A 1 ml aliquot was added to each container with or without microspheres. The 
samples were incubated for one hour at room temperature with a density of bacteria 
of 103 cfu ml-1. The microspheres were separated from the culture by centrifuging 
the mixture at 100 g; this sedimented the microspheres but not the free bacteria. The 
supernatant was aspirated and discarded. To reduce numbers of cells remaining in 
the liquid surrounding the microspheres but not attached, 1 ml PBS was added, 
mixed, centrifuged at 100 g and aspirated. To determine the number of cells loosely 
associated with the microspheres, samples were incubated with sterile PBS for one 
minute. Tubes were centrifuged at 100 g and 100 µl was spread plated onto TSA. 
This experiment was carried out four times. 
2.5.3 Freeze Drying to Kill Bacteria Attached to Microspheres 
Blank and cisplatin-containing microspheres (M22 and M20, 1.3 g) were freeze 
dried in Sterilin containers by pouring liquid nitrogen onto the samples and freeze-
dryed with a Heto PowerDry LL3000. The microspheres were then suspended in 
sterile distilled water (13 ml). 
 
S. epidermidis ATCC 35984 was grown overnight in tryptone soya broth (TSB) at 
37°C and agitated at 60 rpm to approximately 108 cfu ml-1. The culture was 
centrifuged at 1000 g for 10 min, the nutrient media removed and the pellet of cells 
resuspended in the same volume of peptone. This culture was diluted 1:10 three 
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times. A 1 ml aliquot of dilute culture was added to each container of microspheres. 
The samples were incubated overnight at room temperature with a density of bacteria 
of 2×104 cfu ml-1.  
 
Samples were spun at 1000 g for 10 minutes and the supernatant discarded. Half of 
the pellets were freeze dried at -59°C, half stored at room temperature. Pellets were 
resuspended in peptone and plated on tryptone soya agar (TSA). 
2.5.4 Bacterial Attachment to Fibres 
Samples of fibre (F5, 50 cm and 100 cm) were added to Sterilin containers and 
sanitised by shaking with 5 ml ethanol (70 %) for one minute and then rinsed with 
5 ml PBS for one minute. In addition containers without fibre were treated in the 
same way as a negative control to quantify the amount of bacteria transferred by the 
container alone. PBS (9 ml) was added to each of these containers.  
 
S. epidermidis ATCC 35984 was grown to approximately 108 cfu ml-1 in tryptone 
soya broth (TSB) as above. The culture was centrifuged at 1000 g for 10 min, the 
nutrient media removed and the pellet of cells resuspended in the same volume of 
PBS pH 7.4. This culture was diluted 1:10 three times. A 1 ml aliquot was added to 
each container. The samples were incubated at room temperature for 15 minutes with 
a density of bacteria of 3.4×103 cfu ml-1. 
 
For each sample two independent series of six two-fold dilutions were made in a 
96-well plate. From each dilution series 10 µl was spotted onto a TSA plate and 
incubated overnight and the colonies counted and the data were analysed using R. 
 
The experiment was repeated with F1 fibres. Samples of F1 fibre (50 cm, 100 cm, 
150 cm) were added to Sterilin containers and sanitised by shaking with 5 ml ethanol 
(70 %) for one minute and then rinsed with 5 ml PBS for one minute. In addition 
containers without fibre were treated in the same way as a negative control to 
quantify the amount of bacteria transferred by the container alone. Sterile PBS (9 ml) 
was added to each of these containers.  
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S. epidermidis ATCC 35984 was grown to approximately 107 cfu ml-1 in tryptone 
soya broth (TSB) as above. The culture was centrifuged at 1000 g for 10 minutes, the 
nutrient media removed and the pellet of cells resuspended in the same volume of 
PBS pH 7.4. This culture was diluted 1:10 three times. A 1 ml aliquot was added to 
each container. The samples were incubated at room temperature for 45-105 minutes 
with a density of bacteria of 1.5×103 cfu ml-1, plated and analysed as above. 
2.5.5 Ethanol to Kill Bacteria Attached to Fibres 
Samples of fibre (F5, 50 cm) were added to Sterilin containers and sanitised by 
shaking with 5 ml 70 % ethanol (Fisher Scientific, UK) for one minute, then rinsed 
with 5 ml PBS for one minute. PBS (9 ml) was added to each of these containers.  
 
S. epidermidis ATCC 35984 was grown overnight in tryptone soya broth (TSB) at 
37°C and agitated at 60 rpm to approximately 108 cfu ml-1. The culture was 
centrifuged at 1000 g for 10 minutes, the nutrient media removed and the pellet of 
cells resuspended in the same volume of PBS. This culture was diluted 1:10 three 
times. A 1 ml aliquot was added to each container. The samples were incubated at 
room temperature for 15 minutes with a density of bacteria of 1.2×104 cfu ml-1. The 
diluted culture was decanted and 5 ml 70 % ethanol was added to the samples for 30 
or 60 seconds or not at all. The ethanol was decanted and sterile 5 ml PBS was added 
to each container for 5 minutes. 
 
For each sample two independent series of six two-fold dilutions were made in a 
96-well plate. Spread plating is resource and labour intensive. To increase the 
number of measurements for each sample, serial dilutions were made in 96-well 
plates and spot plated. From each dilution series 10 µl was spotted onto a TSA plate 
and incubated overnight and the colonies counted. 
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3 Results and Discussion 
3.1 Laser Scattering Analysis of Microspheres 
PLGA 50:50 and 65:35 microspheres were manufactured by oil in water emulsion. 
This process produces microspheres with a wide particle size distribution. In addition 
the non-spherical particles are produced at the interfaces between the bulk solution 
and with the foam at the surface of the fluid and between the bulk solution and the 
walls of the vessel. The oversized particles are not desirable in the formulation as 
their haphazard structures may result in unpredictable release characteristics. In 
addition, non-spherical particles may skew the particle size distribution during laser 
scattering analysis due to their variable profile in the path of the laser beam. 
Therefore, all microspheres were sieved to below 90 µm using a mesh sieve prior to 
analysis.  
 
Samples were dispersed in cyclohexane and kept in suspension in the analysis cell 
using a magnetic flea. Static and surface charging effects can cause microspheres to 
aggregate. Aggregates would be measured as larger particles, skewing the measured 
size distributions. To reduce aggregation the particles were ultrasonicated 
immediately prior to analysis. In addition, 1 % lecithin was added to the 
cyclohexane. This surfactant is intended to reduce between-particle interactions. 
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Label Lactide:glycolide 10th  Percentile 
(µm) 
Median 
Diameter (µm) 
90th Percentile 
(µm) 
M1 50:50 13 53 127 
M7 50:50 6 32 72 
M8 65:35 7 35 75 
M17 65:35 6 29 74 
M18 65:35 10 39 75 
M19 65:35 17 66 118 
M20 65:35 10 42 98 
M21 65:35 5 59 73 
M22 65:35 4 25 54 
 
Table 8: Tenth, fiftieth and ninetieth percentiles of microsphere particle diameter as 
determined by laser scattering analysis. 
 
The median diameter of cisplatin microspheres made by homogenisation of 
PLGA/ethyl acetate in PVA solution was 25-66 µm (Table 8). By laser scattering 
particle size analysis the logarithm of the volume distribution plotted against the 
particle diameter showed different particle size distributions even between 
microspheres made under the same conditions (M17, M20, M21). 
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Figure 34: Particle size distribution of PLGA 65:35 cisplatin microspheres (M17-M21) 
determined by laser scattering. 
Density distribution, Q3×log(2×R), against particle diameter, 2×R, shows that for these 
samples, most particles are 20-100 µm in diameter. 
 
Figure 34 shows the particle size distribution of cisplatin microspheres. The 
differences in particle size distributions could be due to the profile of the oil in water 
emulsion during manufacture. Alternatively, similar starting particle size distribution 
formulations could be filtered to different extents due to differences in the sieving 
end point. Extent of static charging could alter the behaviour of the microspheres 
during sieving. Surface charging could also affect aggregation in cyclohexane 
suspension, despite the precautions taken. As expected sieving does not provide a 
clear particle size cut off. Whether this is a challenge for formulation depends on to 
what extent particle size effects drug release profiles (sections 3.4.2 and 3.4.3). 
3.2 Physical Characterisation of Fibres 
The diameter of sixteen pieces of each fibre was measured using a digital 
micrometer. Approximately 50 cm of each fibre was weighed and the volume 
determined by displacement of water in a measuring cylinder. 
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Sample Diameter (mm) Density (mg cm
-3
) 
F1 0.44±0.06 210 
F2 0.48±0.03 290 
F3 0.48±0.05 270 
F4 0.52±0.11 290 
F5 0.59±0.02 240 
F6 0.97±0.16 270 
F7 0.65±0.05 220 
F8 1.10±0.38 510 
F9 1.27±0.08 280 
F10 1.49±0.15 360 
 
Table 9: Diameter and estimated density of PLGA fibres. 
Diameters given as mean ± standard deviation. 
 
Table 9 show the diameters and densities (sample calculations in Appendix J) of 
fibres. The lower density of the solid fibres (F1-F7) may be due to the larger pores 
(Figure 37) than present in the hollow fibres (F8-F10) (Figure 44). The differences in 
morphology could be caused by a higher concentration of residual NMP in solid 
fibres following soaking due to the lower surface area to volume ratio compared to 
hollow fibres (section 3.3). The carboplatin containing fibre, F6, was extruded 
through a larger orifice than other fibres due to the higher dope viscosity. The hollow 
fibres, F8 to F10, were extruded through a spinneret. The outer diameter of F9 fibres 
was calculated as 0.144±0.017 cm and of F10 fibres as 0.154±0.032 cm by image 
analysis of digital photographs. Analysis of covariance determined that the 
micrometer values were 0.012±0.005 cm lower than the image analysis values for 
these fibres (p = 0.03). This difference could be due to a slight crushing of the fibre 
during measurement. 
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3.3 Electron Microscopy Imaging 
3.3.1 Microspheres 
Microspheres were filtered using a stack of mesh filters of mesh sizes 106, 90, 58, 
and 38 µm. Particles greater than 90 µm were discarded. Particles less than and 
greater than 38 µm were imaged separately. Scanning electron microscopy images 
were taken of microspheres stuck to carbon tags. 
 
 
 
Figure 35: SEM image showing PLGA 65:35 microspheres. 
Microspheres (M4) filtered to 38-90 µm and <38 µm. Bar is 100 µm. 
 
The 38-90 µm fraction contained particles smaller than 38 µm. These particles are 
retained in the upper filters by electrostatic interactions with each other or larger 
particles. It was observed that larger fractions of microspheres tended to be less 
spherical. Non-spherical particles can be seen in Figure 35. Particle size distributions 
could not reliably be calculated from images because overlapping particles are not 
readily detected by imaging software. Small microspheres appeared to be more 
spherical and less misshapen than large microspheres. Some large microspheres had 
fractured to reveal their internal structure. 
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Figure 36: SEM image showing fractured PLGA 75:25 and 65:35 microspheres. 
Microspheres which had fractured during freeze drying were observed in some images. Bar 
is 10 µm. 
 
Figure 36 shows microspheres which had fractured, revealing their internal structure. 
This may have been caused by freeze drying, although it is also possible that shear 
forces during sieving were responsible. Fractured microspheres were composed of 
solid matrices with small internal pores. Although some pores were connected the 
majority were discrete. Some microspheres appeared to have engulfed other 
microspheres with shell-like pores surrounding some regions of a microsphere. This 
type of structure reflects the properties of the suspension from which the 
microspheres were formed. These cavities may have been formed during freeze-
drying of microspheres with molten centres produced by the reduction in the rate of 
diffusion of the solvent following outer skin formation. The low porosity of these 
microspheres suggests that diffusion of drug will be slow as there are few aqueous 
channels to allow faster movement. 
3.3.2 Fibres 
Scanning electron microscopy and back scattering electron microscopy was 
performed on solid fibres. While SEM detects secondary electrons which are emitted 
from the carbon coating of the sample, back scattering detects electrons which are 
reflected directly back from the electron beam by the sample if it meets an electron 
opaque material such as platinum atoms.  
 
 122 
 
 
Figure 37: SEM images showing PLGA 65:35 solid fibres (F2, F3 and F5). 
Bar is 100 µm. 
 
Figure 37 shows a cross-section of F2, F3 and F5 fibres. The fibre had a smooth 
solid surface and a porous internal structure.  
The increased porosity may caused by the higher concentration of residual NMP in 
the solid fibre during freeze-drying. The higher solvent concentration is caused by 
the longer diffusion path for solvent molecules between the centre of the fibre and 
the aqueous phase in solid fibres compared to hollow fibres. The excess solvent 
means that the polymer in the centre of the fibre has a lower glass transition 
temperature and is fluid. When the solvent it removed by freeze-drying the volume 
of the polymer is reduced, and as it aggregates voids are formed. An alternative 
theory is that the high porosity of the fibres is caused by the rapid entry of water into 
the stream of polymer dope during spinning. As the NMP dissolves into the water 
the polymer aggregates into a solid matrix leaving channels in the fibre. However, 
the water may not be able to freely enter into these small (~10 µm) channels given 
the relative hydrophobicity of high molecular mass PLGA. The low density of solid 
fibres (Table 9) compared to solid fibres could possibly be due to the larger pores 
present (Figure 37) compared to hollow fibres (Figure 44).  
 
Once these channels become water filled they may be expected to increase the 
overall rate of diffusion of drug from the fibres since small molecules diffuse faster 
in water than in glassy matrices. However, the rate at which these pores become 
water-filled may be relatively slow due to the high contact angle of water with 
PLGA. 
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Figure 38: SEM and electron back scattering images of the same region of PLGA 
65:35 cisplatin solid fibre (F2). 
Images of fibre show co-localisation of crystalline structures and electron dense regions 
corresponding to cisplatin crystals. Bar is 50 µm. 
 
Figure 38 shows SEM and back scattered images of the same region of F2 fibre. 
Structures which are electron opaque show as white on the back scattered image 
while electron transparent material is grey. As the small atoms (hydrogen, carbon) 
which comprise PLGA are known to be poorly electron reflective and the only 
expected large atoms are platinum and chlorine it is likely that white regions 
correspond to cisplatin crystals. 
 
 
 
Figure 39: SEM and electron back scattering images of the same region of PLGA 
65:35 cisplatin solid fibre (F3). 
Images of fibre show co-localisation of crystalline structures and electron dense regions 
corresponding to cisplatin crystals. Bar is 50 µm. 
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Figure 39 shows needle shaped crystal structures in the pores of the F3 matrix which 
are revealed to be cisplatin crystals by back scattering imaging. Image analysis 
suggests that mean and median particles are around an order of magnitude larger in 
F3 fibres. 
 
 
 
Figure 40: SEM and electron back scattering images of the same region of blank 
PLGA 65:35 solid fibre (F5).  
Images of fibre show no crystal structures and no electron dense regions. Bar is 50 µm. 
 
Figure 40 shows the SEM and back scattering image of F5 fibres. The absence of 
notable bright regions in the back scattering image is expected as F5 are blank.  
 
Regions of F2, F3 and F5 fibres which appeared brightest under backscattering were 
analysed by X-ray microanalysis. The electron beam was focussed on the fibre and 
the X-rays generated by atoms which had been excited by the electrons were 
collected. The wavelength of the X-rays generated will be determined by electron 
transition energies in the excited atoms. As these transitions are distinctive, atoms 
can be identified based on their fingerprint on the X-ray spectrum.  
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Figure 41: X-ray microanalysis of PLGA 65:35 solid fibres.  
Two batches of fibres, (a) F3 and (b) F2, contained cisplatin. Peaks correspond to platinum 
and chlorine. One batch was a drug-free control, (c) F5, and shows no major peaks 
indicating that sample contains no elements heavier than sodium. 
 
Figure 41 shows X-ray microanalysis plots for F2, F3 and F5 fibres. The hump of 
background radiation is braking-radiation (or Bremsstrahlung) emitted as the 
electrons slow down as they interact with the sample. The peak at the origin is 
caused by the beryllium window. The window screens low energy X-rays from low 
atomic weight atoms lower than sodium (Gedcke, 1972). Peaks from the polymer, 
such as carbon signals, are not detected. The detector units, counts per second, is not 
an absolute value as it depends on many factors and in addition is not consistent 
across the energy axis.  
 
These plots show peaks corresponding to the strongest wavelengths of platinum 
(Mα/Mβ at 2.1 keV and Lα at 9.4 keV) and chlorine (Kα at 2.6 keV) in F2 and F3 
fibres but not F5 fibres. This makes it very likely that a platinum salt is present. 
Small peaks which could correspond to trace amounts of copper and calcium were 
detected for F2 fibres. This contamination could have occurred at any of several 
stages during manufacture or analysis. They are not a significant contaminant of the 
polymer as they are not present in F5 fibres. 
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Figure 42: SEM image of PLGA 65:35 cisplatin solid fibre (F2) and associated X-ray 
maps. 
X-ray maps recorded at wavelengths corresponding to platinum Mβ and Lα bands and 
chlorine Kα band. Bar is 100 µm. 
 
To confirm that the platinum and chlorine were co-localised in the fibre X-ray maps 
were collected for F2 and F3 fibres. Figure 42 shows an SEM of F2 PLGA 65:35 
cisplatin fibre and associated X-ray microanalysis maps. From the co-localisation of 
peaks at wavelengths corresponding to platinum Mβ and Lα bands and chlorine Kα 
bands it can be inferred that cisplatin is the major electron reflecting species in the 
fibre. These images show a single large cisplatin crystal with smaller particles 
dispersed throughout the fibre. 
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Figure 43: SEM image of PLGA 65:35 cisplatin solid fibre (F3) and associated X-ray 
maps. 
X-ray maps recorded at wavelengths corresponding to platinum Mβ and Lα bands and 
chlorine Kα band. Bar is 100 µm. 
 
Figure 43 shows an SEM of F3 PLGA 65:35 cisplatin fibre and associated X-ray 
microanalysis maps. As for F2 fibres the platinum and chlorine bands overlap but 
appear as a number of large crystals rather than smaller finely dispersed crystals. 
 
Cisplatin particles appear in fibres as crystals, generally associated with pores rather 
than finely dispersed in the polymer matrix. Cisplatin was added to the dope early 
for F2 fibres and late for F3 fibres. Cisplatin in F2 fibres is more finely dispersed 
than for F3 fibres where individual crystals can be seen. It is possible that crystals of 
cisplatin had time to disaggregate in the F2 dope and become well dispersed during 
the extended mixing period. 
 
Large crystalline aggregates of cisplatin dispersed in the matrix with direct contact 
between water and the drug avoided suggests that the system may act like a reservoir 
device. This is not satisfactorily modelled using the Higuchi equation (section 1.6.4), 
since the drug will dissolve into the matrix as it is removed, maintaining the drug 
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concentration at the maximum solubility of the drug in the matrix. Very finely 
dispersed crystals where the cisplatin is dissolved in the matrix will behave as 
described by Higuchi kinetics, eluting from an inert support. Differences between the 
release profiles of F2 and F3 fibres could be predicted from these X-ray maps. 
 
SEM was also used to examine cisplatin containing PLGA 65:35 hollow fibres 
(F10). 
 
 
Figure 44: SEM images of PLGA 65:35 fibre (F10) and close up of section of wall. 
Bar is 100 µm and 10 µm. 
  
Figure 44 shows a cross-section through the wall of a PLGA 65:35 hollow fibre. The 
matrix structure is similar to that observed for solid fibres (Figure 37) but different 
from microspheres (Figure 36). This suggests that there may be differences during 
matrix solidification during suspension solidification and phase inversion processes. 
Due to the short diffusion path length between the centre of microspheres and the 
aqueous phase, the matrix is not excessively porous. Conversely, water soluble 
organic solvents such as NMP rapidly partition out of the stream of dope. As the 
polymer loses its solvent and water begins to enter the fibre, voids are left in the 
structure, creating finger-like pores. These pores will create a faster alternative 
pathway for cisplatin release compared to the more dense structure of microspheres. 
This may be an advantage for fibres since their larger physical size may otherwise 
hinder drug release too much. 
 
The effect of soaking F3, F4 and F10 fibres was studied following 1, 5 and 21 hours 
in distilled water. The aim was to determine whether drug dissolved throughout the 
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fibre matrix or from the edge in as assumed using the Higuchi model. The presence 
of finger-like pores suggests that drug will not be released from the outside in as 
water is able to more rapidly penetrate deep into the fibre. 
 
 
 
Figure 45: SEM images of PLGA 65:35 fibres after soaking in distilled water.  
SEM images of F3 (a, d, g), F4 (b, e, h) and F10 (c, f, i) fibres before soaking (a, b, c), and 
after soaking for 5 h (d, e, f) and 21 h (g, h, i). Bar is 100 µm. 
 
SEM images showed that fibres decreased in size after only a few hours in an 
aqueous environment (Figure 45). In addition the fibres appeared to become less 
symmetric. The backscattered images showed a trend of decreasing cisplatin. There 
was no clear pattern of cisplatin being removed from the edge of the fibre first with 
the advance of the solvent front predicted by the Higuchi model (section 1.6.4). This 
is due to the porous nature of the fibres.  
 
For each data series, the area of the fibre and area of cisplatin were plotted against 
time. A linear model was fitted to these data. Plotting the area of the fibre against 
time showed that after soaking for 21 hours the fibres had shrunk. Solid F3 fibres 
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had decreased in area by a third and hollow F10 fibres were half the area. The 
gradient for F4 fibres cannot be interpreted individually as it was not strongly 
significant (p = 0.099). The area of cross-section and the area of drug both decreased 
so there was no significant change in the ratio of cisplatin area to fibre area. 
 
To determine whether the decrease in fibre size and decrease in cisplatin area was 
significant for these structures the data were normalised and combined. Each data 
point was divided by the intercept (the mean initial area) of its linear model to give 
relative area. The mean initial area from the model was used rather than the mean at 
before soaking because each sample is an independent sample, not the same sample 
measured repeatedly.  
 
Figure 46: Decrease of normalised area of cross-section and area of cisplatin of 
PLGA 65:35 fibres. 
Batches of PLGA 65:35 fibres, F3 (o), F4 (×) and F10 (∆), were soaked for up to 21 hours, 
dried and imaged by SEM and backscattered electron imaging. Area of fibre and cisplatin for 
each sample was measured using R. Mean area used to normalise data was intercept of 
individual batch plots. Solid line is least squares best fit of combined data, dashed line is 
95 % confidence interval of the model and dotted line is 95 % prediction interval. 
 
Figure 46 shows the change in relative fibre and cisplatin area with time. There 
appears to be a large variability in the relative area of the fibres. This is because 
cross-sectional area varies with the radius squared. Analysing the aggregated data for 
all fibres predicted a decrease in cross-section area of -1.8±0.4 % h-1 (p = 1×10-4). 
This suggests that there would be changes in device morphology within a few hours 
of implantation. Assuming that the PLGA in the fibres degrades at a rate of 
 131 
approximately 5×10-7 s-1 (see section 1.5.4.2) after 21 h, 4 % of the ester bonds will 
have hydrolysed. This is insufficient to explain the decrease of fibre cross-section of 
37 %.  
 
Analysing the combined cisplatin area data gave an estimated release gradient of 
-2.0±0.5 % h-1 (p = 2×10-4). Assuming that this linear gradient is an initial rate 
estimate of the exponential release model (equation 6) the rate constant can be 
calculated. 
 
( ) tkeMk
dt
dX
212
2
21
−⋅∞−=  
(40) 
 
Equation 40, the differential of the two compartment model, can be solved for the 
boundary condition t = 0 and dX2/dt = -2.0±0.5 % h-1. This is the equivalent of a 
release constant of 6×10-6 s-1. This calculation suggests that 34 % of the cisplatin has 
been released after 21 h. The estimate is approximately half the rate calculated from 
release curves (see section 3.4.4). It is possible that this discrepancy could be 
removed by analysing image intensity. Areas of dispersed drug in the matrix 
included in the image mask could not be distinguished from an equivalent area of 
solid crystal. Difficulties and expense involved with calibrating image intensity 
against drug loading do not make this a practical alternative to directly measuring 
drug release. 
 
The average ratio of area of cisplatin to area of cross-section estimated as the 
intercept of the linear models is 29 %. This is close to the drug loading estimated for 
fibres. If the area of drug released corresponds to a decrease in the area of cross-
section of the fibre then 17 % of the decrease is accounted for by the loss of 
cisplatin. This is insufficient to completely explain the 37 % decrease of area. A 
possible explanation for the larger than expected decrease in fibre area is that as the 
cisplatin is released the fibre contracts as the cisplatin crystals no longer support the 
structure. The reduction in the area of cross section of the fibres may be explained by 
the fibre becoming more hydrophilic as it begins to degrade. This may allow water to 
enter the finger-like pores and then crush some of them due to the attractive surface 
tension force between water on the pore walls. 
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These data show that the process of cisplatin release from a PLGA matrix does not 
occur by diffusion from a static matrix but rather a continual evolution in the size 
and porosity of the matrix with time. 
3.4 Drug Release from Delivery Devices 
3.4.1 Analysis of Published data of Release of Cisplatin from PLGA 
Microspheres  
Although many formulations of cisplatin microspheres have been produced (section 
1.5.4.5) very little kinetic analysis has been performed on the release profiles by the 
authors themselves. The release profiles of cisplatin microspheres produced by other 
authors were estimated from graphs in their papers. Due to the limited amount of 
data available only the two compartment model (equation 5) was fitted to the data 
(apart from Huo, 2005). 
 
Figure 47: Published release profiles of cisplatin microspheres. 
Data transformed to show release from 100 mg microspheres. Data from Ike, 1992 (o), 
Fujiyama, 2002 (□), Huo, 2005 (■), Araki, 1999 (×), Tamura, 2002 (▲) and Matsumoto, 2005 
(∆). Lines show two compartment model, apart from Huo, 2005 which is three compartment 
model. 
 
Figure 47 shows the release profiles of six formulations of cisplatin microspheres 
from the literature. Data were extracted from digital images in published papers 
using ImageJ (Abramoff et al., 2004). The two compartment model was fitted to 
these data using R. Data were published as percentage of total release. To allow 
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comparison between formulations the data were multiplied by the nominal drug 
loading claimed by the respective authors. 
 
Author Release 
constant (s
-1
) 
Estimated release 
(%) 
Nominal microsphere 
drug loading (%) 
Ike, 1992 2.6E-05 95 4 
Araki, 1999 1.6E-06 120 9 
Fujiyama, 2002 2.7E-06 94 3 
Tamura, 2002 7.9E-07 121 5 
Huo, 2005 1.1E-04† 60 17 
Matsumoto, 2005 1.7E-06 80 10 
 
Table 10: Estimated percentage of cisplatin released and first order rate constant for 
six published polyester microsphere formulations calculated using a two 
compartment model
†
.  
Data were extracted from digital images using ImageJ. Two compartment model was fitted 
to data using R. 
†
 Huo, 2005 data was a better fit to a three compartment model. 
 
Table 10 shows the estimated first order rate of drug release for six published PLGA 
microsphere formulations (section 1.5.4.5). Data from Huo, et al., 2005 fit a three 
compartment model better than a two compartment model when the models were 
compared using ANOVA (p = 7×10-4) and AIC. Based on the three compartment 
model 72 % of the nominal cisplatin loading was released with a burst release 
constant of 1.5 × 10 -4 s-1 and slow release constant of 1.5 × 10 -6 s-1. The claimed 
drug loading of microspheres by Huo, et al., 2005 was 17 %. However, based on the 
release profile reported, less than 72 % was released over the reported timescale. 
This suggests that the effective drug loading was 12 %. The difference could be due 
to an overestimation of the drug loading during sample analysis or due to 
inactivation of cisplatin by binding to the matrix (see effect of microsphere aging in 
section 3.4.3). The release profile of cisplatin from microspheres by Huo, et al., 2005 
is not appropriate for sustained release as the majority of the drug in the depot is 
released within a few hours. Cisplatin microspheres in the literature have a drug 
loading of 3-12 %. 
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The groups who have previously reported the characteristics of cisplatin 
microspheres have used low molecular mass polyester (Table 3) of ~20 kDa. For this 
work high molecular mass PLGA (~100 kDa) was used (section 2.1.1). This was to 
attempt to reduce the rate of cisplatin release (section 1.5.4.2). In addition, spinning 
fibres requires a viscous dope. Higher molecular mass polymer has a higher 
viscosity. To ensure suitable spinning characteristics high molecular mass PLGA 
was used for spinning fibres. To allow comparisons to be made between 
formulations, microspheres were also manufactured using high molecular mass 
PLGA. 
 
The release of cisplatin from the BSA containing microspheres of Araki, et al., 1999 
was measured as total platinum. Since protein bound and unbound cisplatin was not 
determined separately, the amount of unbound drug is not recorded. The slower 
release is likely due to the release of BSA-cisplatin adduct which was able to form 
during formulation manufacture. Diffusivity of a species through a matrix is 
determined partly by its size. The large size of BSA (66 kDa) is responsible for the 
apparent slow release of BSA-cisplatin compared to unbound cisplatin. The tumour 
killing of these BSA containing microspheres was lower than cisplatin solution, 
suggesting that the hypothesis that unbound cisplatin is the major agent of tumour 
killing (section 1.4.3) is correct. Therefore, although the microspheres of Araki, et 
al., 1999 appear to have the most favourable release profile, the efficacy of the 
formulation as a successful chemotherapeutic is questionable.  
 
The microspheres with the most favourable characteristics reported for continuous 
release of cisplatin to date are those of Tamura, et al., 2002 and Matsumoto, et al., 
2005 with drug loadings of 6-8 % and release constants of 0.8-2×10-6 s-1. 
3.4.2 Cisplatin Release from PLGA 50:50 Microspheres 
PLGA 50:50 microspheres were manufactured by oil in water emulsion (section 
2.1.2). PLGA 50:50 was dissolved in ethyl acetate and dispersed in dilute PVA 
solution using a mechanical homogeniser. The microspheres were allowed to harden 
for four hours. The mixture was centrifuged and waste continuous phase-solvent 
solution was decanted and discarded. The microspheres were washed by 
resuspension in distilled water followed by centrifugation and removal of the 
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supernatant. This was repeated three times. The particles were then filtered and dried 
in a stream of air. The microspheres were then filtered using a sieve with a 90 µm 
mesh and the oversized portion discarded. The drug release profile of independent 
batches of PLGA 50:50 (M3 and M7) was determined in two experiments for known 
masses of microspheres in distilled water by AAS (sections 2.3.4). Rate of diffusion 
is proportional to the concentration gradient (section 1.6.5). Therefore, the rate 
constant will decrease if cisplatin accumulates in solution. The release medium was 
kept at sink conditions by completely refreshing the release medium at each time 
point. Sink conditions ensured that the release rate was not affected by an increase in 
drug concentration in the release medium. 
 
Figure 48: Cisplatin release from PLGA 50:50 microspheres. 
Cumulative release from equivalent of 100 mg large (38-90 µm) (■, ▲) and small (0-38 µm) 
(□, ∆) PLGA 50:50 M3 (■, □, dashed lines) and M7 (▲, ∆, solid lines) microspheres into 
distilled water over nine days (n = 3). Lines show Higuchi model. 
 
Figure 48 shows release of cisplatin from two batches of PLGA 50:50 microspheres 
which had been separated by mesh sieves to below 38 µm and between 38 and 
90 µm. Twice as much cisplatin was released from small M7 microspheres than from 
the large fraction. Four times more cisplatin was released from small M3 
microspheres after sixteen days than large microspheres. A mixture of large and 
small M3 microspheres had an intermediate profile (not shown). 
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The two batches of PLGA 50:50 microspheres showed similar release characteristics 
with the major difference being in the drug loading of the small microspheres. The 
lower drug loading of M7 microspheres is probably due to additional leaching of 
cisplatin from the microspheres during washing. The washing step is likely to be the 
major source of between-batch variation and should be carefully controlled. 
 
The two compartment and Higuchi models could be fitted to each of the release 
profiles for large and small microspheres (Appendix L). There were insufficient data 
to fit three compartment and Fickian models. 
 
Akaike’s Information Criterion (AIC) (Akaike, 1974) allows comparison of 
mathematical models of data by comparing residual error with the number of 
parameters used (section 1.6.6). The AIC of both two compartment and Higuchi 
models were similar for these data which suggests that neither is better at explaining 
the data. The models can be used for different purposes. The two compartment 
model provides a release constant that can be used to compare release kinetics over 
long time scales. The Higuchi model can be used to estimate the diffusivity from 
equation 13, which may offer greater mechanistic insight. 
 
The Higuchi constant, k, was 1.1±0.04×10-3 mg s-0.5 for large microspheres. The 
surface area of the sample can be estimated as 130 cm2 (Appendix I) based on an 
approximate mean radius of 30 µm and a density of 780 mg cm-3. Diffusivity of 
cisplatin from the microspheres can be estimated from the experimental values using 
equation 13. The solubility of cisplatin, Cs, is 2 mg cm
-3 (section 1.4.1). The 
concentration of cisplatin in the sample (M(∞)/V) was 1.2 % of the 100 mg sample or 
0.012 mg mg-1. This calculation predicts a diffusivity of 1×10-12 cm2 s-1 which is 
within the range expected for a small molecule diffusing in a glassy matrix. 
 
For small microspheres the Higuchi constant was 3.4±0.13×10-3 mg s-0.5. Using 
10 µm as the approximate mean radius of the microspheres, the surface area of the 
sample was estimated as 380 cm2. The concentration of cisplatin in the sample was 
4.9 % of the 100 mg sample or 0.049 mg mg-1. This calculation predicts a diffusivity 
of 5×10-13 cm2 s-1. Given the uncertainty present in the estimate reliable 
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determination of differences between these fractions cannot be rigorously claimed.  
Additional uncertainty was generated by using a rough approximation of the surface 
area. A more precise calculation could have been performed based on a particle size 
distribution. However, dynamic light scattering measurements were not performed 
for these samples due to the limited amount of sample available. 
 
The two compartment model release rate constant, k21, for large particles was 
2.5±0.44×10-6 s-1 and for small microspheres was 1.4±0.43×10-6 s-1. The difference 
in release constants corresponds to the difference seen in the diffusivities of cisplatin 
in large and small microspheres. Cisplatin loading was four times higher in small 
particles suggesting that loading is strongly dependent on particle size. This is an 
unfavourable characteristic of the method of oil in water microsphere production as 
larger (38-90 µm) microspheres would be preferred in a therapeutic formulation 
(section 1.5.4.6). In addition, variability in the particle size distribution has been 
shown for these formulations (section 3.1).  
 
The rate of release of the PLGA 50:50 microspheres reported here was slower than 
release from the PLA microspheres of Ike, et al., 1992. The release profiles of PLGA 
50:50 microspheres were similar to those achieved by the PLGA 75:35 microspheres 
of Fujiyama, et al., 2002 and the PLA microspheres of Tamura, et al., 2005 (section 
3.4.1). The current recipe is an improvement over those reported formulations as the 
release profile is equivalent but the microspheres were manufactured using ethyl 
acetate rather than DMF or DCM, which are more toxic solvents (Appendix A). 
3.4.3 Cisplatin Release from PLGA 65:35 Microspheres 
PLGA 65:35 microspheres were manufactured by oil in water emulsion (section 
2.1.2). PLGA 65:35 was dissolved in ethyl acetate and dispersed in dilute PVA 
solution using a mechanical homogeniser. The microspheres were allowed to harden 
for four hours. The mixture was centrifuged and waste continuous phase-solvent 
solution was decanted and discarded. The microspheres were washed by 
resuspending them in distilled water followed by centrifugation and removal of the 
supernatant. This was repeated three times. The particles were then filtered and dried 
in a stream of air. The microspheres were then filtered using a sieve with a 90 µm 
mesh and the oversized portion discarded. The drug release profile was determined 
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in four experiments for known masses of microspheres in distilled water by AAS 
(sections 2.3.4 and 2.3.8.1). 
 
The level of batch variation in the production of PLGA 65:35 microspheres was 
determined by nonlinear mixed effects modelling. Four batches (M14, M17, M20, 
M21) were made under the same conditions from polymer dope made with 10 % 
PLGA to ethyl acetate. Two batches were made with 14 % (M18) and 18 % (M19) 
PLGA to ethyl acetate instead. The integrity of the baseline was confirmed for each 
experiment with blank (M13, M16) or phenolphthalein (M22) microspheres.  
 
Figure 49: Cisplatin release from PLGA 65:35 microspheres. 
Cumulative cisplatin release from 100 mg of six batches of PLGA 65:35 microspheres into 
distilled water over twenty days. Batches made with 14 % (M18) and 18 % (M19) polymer 
did not appear to have different release profiles from those made with 10 % (M17, M20, 
M21) polymer (n = 3). Data for M14 (n = 2) and M17 (n=3) were included. Dashed line 
shows two compartment model average for all batches. Solid line shows two compartment 
model for each batch (parameters in Table 11). 
 
Figure 49 shows release of cisplatin from six independently manufactured batches of 
microspheres. The release profiles of all batches were similar. The two compartment 
model was fitted to the grouped data. 
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Batch Release constant k21 (s
-1
) Drug loading M2(∞) (mg) 
M19 4.0E-06 12.1 
M17 1.6E-05 11.2 
M18 4.3E-06 12.6 
M21 3.2E-06 10.8 
M20 3.0E-06 10.9 
M14 6.5E-06 9.5 
 
Table 11: Parameters for cisplatin release for six batches of PLGA 65:35 
microspheres calculated using a two compartment model. 
Two compartment model was fitted to combined microsphere data (Figure 49) using R. 
 
Table 11 shows the parameters for the two compartment model for each batch of 
PLGA 65:35 microspheres. There is some between batch variation of the release 
constant for PLGA 65:35 microspheres but the drug loading was reproducible. There 
appeared to be no correlation between the median particle size (Table 8) and the 
release rate constant (Table 11) for these batches. Non-linear mixed effects 
modelling of the two compartment model calculated that M2(∞) = 11.3±0.63 mg and 
k21 = 5.27±3.23×10
-6 s-1 (mean ± standard deviation) for the combined data.
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Figure 50: Four mathematical models were fitted to microsphere release data. 
Two compartment (solid line), three compartment (dotted line), spherical Fickian (dashed 
line) and Higuchi (grey line) models were fitted to release data for PLGA 65:35 
microspheres. Higuchi model was fitted only to data of the first 200 h of release. Data points 
of combined data with standard errors shown. 
 
Figure 50 shows the four mathematical models (section 1.6) to which the data for the 
release of cisplatin from PLGA 65:35 microspheres were fitted. The spherical 
Fickian and three compartment models were found to have more explaining power as 
determined using Akaike’s Information Criterion (AIC) compared to the two 
compartment model (Appendix L). The Fickian and three compartment models 
predicted similarly shaped release profiles. Although the two compartment model 
offers an acceptable description of the data it underestimates the amount of drug 
initially released (<48 h). As a large proportion of the drug (~50 %) is released 
during the first 48 h the suitability of using the two compartment to describe drug 
release from microspheres is called into question. The systematic error is of a similar 
order to the magnitude to the variance of the release profiles. This means that the 
systematic error may be small enough to ignore for some applications where only an 
approximation is needed, given the robustness of a single exponential. 
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It is not appropriate to use the Higuchi model with the complete dataset as this model 
assumes that the depot is infinitely deep (section 1.6.4). The data corresponding to 
only the first 200 h of release were fitted to the Higuchi model. The AIC cannot be 
used to compare the Higuchi model with the other models since the AIC assumes 
that the models have the same error structure (section 1.6.6). Although the 
comparison cannot be statistically rigorous, comparing the diffusivity as calculated 
by the Higuchi model with the spherical Fickian model is still of interest. 
 
The Higuchi constant, k, was 1.34±0.00×10-2 mg s-0.5. The surface area of the sample 
can be estimated as 130 cm2 (Appendix I) based on an approximate mean radius of 
20 µm and a density of 780 mg cm-3. Diffusivity of cisplatin in the microspheres can 
be estimated from the fitted value of k using equation 13. The solubility of cisplatin 
in water, Cs, is 2 mg cm
-3. The concentration of cisplatin in the sample is 11.3 % of 
the 100 mg sample or 0.113 mg mg-1 (Appendix I). This calculation estimates that 
the diffusivity of cisplatin in the microspheres is 1.3×10-10 cm2 s-1 which is within 
the range expected for a small molecule diffusing in a glassy matrix.  
 
The rate of cisplatin release is determined by the effective diffusivity of cisplatin in 
the formulation, D, and the particle radius, R according to the solution of Fick’s 
second law for spheres (section 1.6.5.1). The Fickian model has been extended  as 
the sum of the release profile as a function of the experimentally determined particle 
size distribution (Ritger and Peppas, 1987). However, this would require the 
calculation of the drug loading for each fraction of the particle size distribution as 
well as an accurate assessment of the distribution itself. More complicated 
interpretations of this model are computationally more demanding without offering 
major improvements in the accuracy of the estimate. To maintain the robustness of 
the calculation, R can also be more simply interpreted as the median particle size. By 
non-linear least squares regression for the first 120 terms in the Taylor series D/R2 
was calculated to be 1.02±0.13×10-5 s-1. The median radius of the six microsphere 
batches used in these experiments was estimated to be 20 µm. Using this 
approximation, the diffusivity was calculated as 4.1×10-11 cm2 s-1. This value is an 
order of magnitude lower than that predicted by Higuchi kinetics. This value may be 
a more accurate prediction as it takes the morphology of the microspheres and the 
finite nature of the drug depot into account. 
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The rate of drug release from the microsphere samples was estimated from the 
release data by dividing the amount of drug released since the previous sampling by 
the time elapsed since the previous sampling. The rate equation for the two 
compartment model was plotted by combing rate equation 4 with concentration 
equation 6. This can be used to define the rate in terms of the starting amount of 
drug, M2(∞), the release constant, k21, and the amount of time elapsed since 
implantation, t (equation 41). 
 
( ) ( )tkMk
dt
dX
2121 exp2
1
−∞=  (41) 
 
The rate equation for the three compartment model was plotted by combing rate 
equation 67 with the appropriate analogues to concentration equation 6, giving 
equation 42.  
 
( ) ( ) ( ) ( )tkMktkMk
dt
dX
41413131 exp4exp3
1
−∞+−∞=  (42) 
 
These two and three compartment rate models were used to analyse the rate data. 
Analysing the rate data rather than the release profiles has the advantage that the 
large changes in rate during the early release will have proportionally less error than 
the smaller changes later towards the end of release. Since the fit will be dominated 
by the higher concentration, more accurate data, rate estimates should be improved.  
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Figure 51: Rate of release of cisplatin from PLGA 65:35 microspheres. 
Release rates were calculated by dividing the amount of cisplatin released from 100 mg 
microspheres since the previous sampling by the time elapsed since the previous sampling. 
Solid line shows two compartment model rate equation. 
 
Figure 51 shows the cisplatin release rate against time for PLGA 65:35 
microspheres. The release rate is initially high but quickly drops to close to zero 
during the first two days of release. The two compartment model estimated total 
cisplatin released as M2(∞) = 12.0±0.2 mg (parameter ± standard error). The model 
was skewed   by the very high initial release rate with k21 = 2.7±0.08×10
-4 s-1 which 
is two orders of magnitude faster than when calculated using the release profile. The 
two compartment model describes the initial rate of release well but does not include 
the additional information about the slower release component. This supports the 
earlier observation that the three compartment model was a better fit than the two 
compartment model in that it distinguished between early and late release rates. The 
three compartment model did not converge on a solution. A larger dataset may be 
required to achieve convergence for this more complicated model. The sensitivity of 
the three compartment model suggests that it is not robust enough to be routinely 
used for analysing release profiles. 
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The release characteristics of additional samples of microspheres were determined 
both in water and in albumin solution (section 2.3.8.1). One batch of microspheres 
had been stored for five months at 5°C (<90 µm, M21). Three batches were freshly 
manufactured and sieved to between 38 and90 µm (M25, M26, and M27). The 
cisplatin concentration resulting from release from these four samples in the 
presence of protein was determined and the results are reported in section 3.6.2. 
 
Figure 52: Release of cisplatin from large (38-90 µm) PLGA 65:35 microspheres. 
Cumulative release of cisplatin from 100 mg of three independent batches of PLGA 65:35 
microspheres (M25, M26 and M27) (n = 6). Microspheres had been sieved to between 38 
and 90 µm. Dashed line shows two compartment model average for three batches. Solid line 
shows two compartment model for each batch (parameters in Table 12). 
 
Figure 52 shows release of cisplatin from three independently manufactured batches 
of large microspheres. Although the drug loadings were lower than for samples 
which included smaller microspheres, the release profiles were of a similar form 
with negligible cisplatin being released after 200 h. Sample M26 released less 
cisplatin than the other two samples. This could be due to an inadvertently prolonged 
wash step or a different ambient temperature on the day of manufacture, causing 
decreased drug retention. An alternative source of error for these samples is the 
proportion of fine particles below 38 µm retained in the larger fraction during 
filtering.  
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Batch Release constant k21 (s
-1
) Drug loading M2(∞) (mg) 
M25 4.6E-05 5.5 
M26 2.6E-05 3.9 
M27 4.8E-05 5.0 
 
Table 12: Parameters for cisplatin release for three batches of PLGA 65:35 
microspheres calculated using a two compartment model. 
Two compartment model was fitted to combined 100 mg of large microsphere (M25, M26 
and M27) data (Figure 52) using R. 
 
Table 12 shows the parameters of the two compartment model for PLGA 65:35 
microspheres M25-M27 which had been filtered to between 38 and 90 µm. Using 
non-linear mixed effects modelling to fit the data to the two compartment model it 
was calculated that the drug loading, M2(∞) = 4.78±0.65 mg and the first order 
release constant, k21 = 4.04±0.87×10
-5 s-1 (mean ± standard deviation) for the 
combined data. This is less than half the drug loading of the equivalent mass of 
microspheres taken from a sample comprised of particles of the complete particle 
size distribution (<90 µm) (Table 11). This supports the observation in section 3.4.2 
that large microspheres (39-90 µm) have a higher drug loading than small (<38 µm) 
microspheres.  
 
The data were also fitted to the spherical Fickian and three compartment models. The 
Fick’s second law model was calculated using the first 120 terms of the Taylor series 
(parameters of the Fickian, two and three compartment models are shown in 
Appendix L). The Higuchi model was not applicable since the data was collected 
until complete release. As was observed for the samples M14-M21, the three 
compartment model described the data better than the two compartment model (the 
AIC was lower). The spherical Fickian model described a similar profile. The 
Fickian model was used to calculate the diffusivity assuming a mean particle radius 
of 30 µm. Diffusivity was 1.3×10-11 cm2 s-1 for M25 and M27 and 7.1×10-11 cm2 s-1 
for M26 microspheres. The diffusivity of cisplatin in these large microspheres (38-
90 µm) is within an order of magnitude of the diffusivity of cisplatin calculated from 
the combined microsphere data with the complete particle size distribution (<90 µm). 
Given the approximations used for calculating the radius of the particles differences 
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between these samples can not be conclusively determined. Although the rate 
constants are different between large and small microspheres, for both types of 
sample the Fickian and three compartment models were a better fit. This suggests 
that although the two compartment model may give a useful approximation of the 
release profile, it does not give an accurate mechanistic description. The assumption 
that cisplatin is released from microspheres at a constant rate with only the amount 
of remaining drug in the depot determining how much drug is released is not 
accurate.  
 
The release profiles of cisplatin from a batch of microspheres when freshly made 
(section 2.3.4) and after five months cold storage (section 2.3.8.1) were compared. 
 
Figure 53: Effect of ageing on microspheres. 
Release was determined for M21 microspheres when they were freshly made (o) and after 
five months (x). Less cisplatin was released after ageing and release was quicker.  
 
Figure 53 shows the effect of storing PLGA 65:35 microspheres at 5°C for five 
months. Approximately 10 mg cisplatin was released from 100 mg fresh 
microspheres over 200 h. Five months later, the same batch only released 6 mg from 
100 mg microspheres over 50 h. The loss of cisplatin is probably due to reaction of 
cisplatin with the PLGA matrix. This is a disadvantage of slow release cisplatin 
formulations as it suggests that the shelf-life of the formulation is only a few months. 
Strategies to increase the length of time for which cisplatin slow release devices can 
be stored could include freeze-drying and storage at -20°C. Alternatively, a desiccant 
 147 
could be used to keep the formulation dry to slow the rate of polymer hydrolysis and 
cisplatin decomposition and binding. 
 
PLGA 65:35 cisplatin microspheres formulations show similar release characteristics 
to the best microspheres manufactured elsewhere (section 3.4.1). The drug loading is 
high at 11 %, similar to Huo, et al., 2005 but the release constant is two and a half 
orders of magnitude lower. The release constant of these formulations is around 
5×10-6 s-1 which represents a similar control of release to formulations reported by 
Tamura, et al., 2002 and Matsumoto, et al., 2005 but with superior drug loading. 
3.4.4 Cisplatin Release from Solid Fibres 
Solid fibres were spun from a dope solution of PLGA 65:35 dissolved in NMP and 
were formed by phase inversion of the dissolved polymer into a solid fibre (section 
2.1.3). The fibre must harden in water as the residual solvent must be allowed to 
fully diffuse out of the fibre and dissolve in the water bath. PLGA fibres are 
traditionally hardened overnight for solvent removal from the fibre (Ellis and 
Chaudhuri, 2006). As cisplatin also dissolves in water a prolonged hardening step 
will lower the drug concentration. For microsphere manufacture the drug loading is 
limited by cisplatin dissolving into the continuous phase during emulsion, hardening 
and washing. The fibre can be handled from approximately 30 minutes following 
spinning. This observation has been exploited in this work to allow the drug loading 
to be increased. To prevent excess cisplatin being lost from the fibres, once the fibres 
were strong enough to be handled they were wrapped around cardboard supports. 
These coils of fibre were then freeze dried to remove water and remaining solvent. 
This method produced solid fibres with drug loadings higher than those previously 
seen for microspheres. 
 
Solid fibres are larger structures that are easier to handle than microspheres. Their 
higher weight reduces handling difficulties which can be experienced due to static 
charging. Experimentally, fibres have the advantage that no depot material is lost as 
may occur when decanting release medium containing microspheres. In the event of 
a patient suffering an allergic reaction or other serious toxicity to the drug, a fibre 
can more easily be completely removed than microspheres. In addition, the 
mechanical properties of fibres could be used to provide physical support as a woven 
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patch or coiled stent. Fibres can also be more readily manufactured by a continuous 
process. Solid fibre manufacture could be a continuous method for manufacturing 
implantable pellets.  
 
Label Drug Loading (%) Diameter (mm) 
F1 0 0.44±0.06 
F2 11 0.48±0.03 
F3 24 0.48±0.05 
F4 15 0.52±0.11 
F5 0 0.59±0.02 
 
Table 13: Drug loading estimated from release profile and diameter measured using 
a digital micrometer of cisplatin PLGA 65:35 fibres. 
Diameter given as mean ± standard deviation (n = 12). 
 
Table 13 shows the drug loading and diameter of PLGA 65:35 solid fibres. The drug 
loading is estimated from the cylindrical Fickian model. The drug loading of F2 and 
F3 fibres was measured as 10 % and 9 % by acid digestion of the fibre (section 
2.3.3). The fibres were digested using aqua regia and the cisplatin was dissolved in 
HCl for analysis. The discrepancy for F3 fibres was probably caused by incomplete 
dissolution of the cisplatin in HCl. This is because 21 mg F3 fibre contained 5 mg 
cisplatin. As the loading was not expected to be so high, 1 ml HCl was used to 
dissolve this sample. As the solubility of cisplatin in water is 2 mg ml-1 the drug 
loading was underestimated more than two-fold. The cylindrical Fickian model 
appears to produce good estimates of the drug loading. 
 149 
 
Figure 54: Release of cisplatin from PLGA 65:35 solid fibres. 
Cumulative release of cisplatin from equivalent of 100 mg of three independent batches of 
PLGA 65:35 solid fibres (F2, F3, and F4). Dashed line shows two compartment model 
average for three batches. Solid line shows two compartment model for each batch 
(parameters in Table 14). 
 
Figure 55 shows release of cisplatin from three independently manufactured batches 
of solid fibres. The two compartment model was fitted to the grouped data. The 
release profiles of all batches were quite different. One batch of fibres (F3) had a 
higher drug loading than the other batches but more variation in the release profile. 
Images of the cross-section of F3 fibres show heterogeneous distribution of large 
cisplatin crystals in the matrix (Figure 39). The variation observed in the release 
profile is probably caused by this poor dispersion of drug. This batch was 
manufactured from a dope to which cisplatin was added after the polymer had 
dissolved. For the other batches (F2, F4) the cisplatin was added at the same time as 
the polymer meaning that the drug had more time to become well dispersed. 
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Batch Release constant k21 (s
-1
) Drug loading M2(∞) (mg) 
F3 7.4E-06 21 
F2 4.2E-06 9.9 
F4 3.0E-06 15 
 
Table 14: Parameters for cisplatin release for three batches of PLGA 65:35 solid 
fibres calculated using a two compartment model. 
Two compartment model was fitted to combined fibre data (Figure 54) using R. 
 
Table 14 shows the parameters for the two compartment model for each batch of 
PLGA 65:35 solid fibres. There is significant batch variation of the release profiles. 
Non-linear mixed effects modelling of the two compartment model calculated that 
M2(∞) = 15±5 mg and k21 = 5±0.2×10
-6 s-1 (mean ± standard deviation) for the 
combined data. One batch (F3) had a higher drug loading and a rate constant that 
was twice as high as for the other batches. As each batch has different release 
characteristics they should be analysed separately (parameters in Appendix M). 
 
F2 fibre was cut into 5 mg fragments and release into 1 ml distilled water was 
determined using AAS (section 2.3.5). To maintain sink conditions the release 
medium was decanted for analysis and 1 ml fresh water was added.  
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Figure 55: Release of cisplatin from PLGA 65:35 (F2) solid fibres. 
Cumulative cisplatin release from 5 mg of PLGA 65:35 F2 fibres into distilled water over ten 
days (n = 9). Solid line shows Higuchi model. Dashed line shows three compartment model. 
 
Figure 55 shows release of cisplatin from F2 fibres over ten days. Data from two 
independent experiments was combined to increase the analysis reliability. As the 
release profile has not levelled off during the experiment, the spherical Fickian 
model did not converge towards significant parameters. The Higuchi model 
produced the significant parameter, k, as 5.8±0.1×10-4 mg s-0.5 (p < 2×10-16). The 
diffusivity can be estimated using equation 13 assuming that each sample of fibre 
has a surface area of approximately 1.4 cm2 (Appendix J). Based on a drug loading 
of 9.9 % and a density of 290 mg cm-3 the diffusivity, D, is estimated as 
1.5×10-9 cm2 s-1 which is within the range expected for a small molecule diffusing in 
a glassy matrix. This value is two orders of magnitude higher than the diffusivity 
calculated using Higuchi kinetics for microspheres. This difference could be caused 
by open pores in the fibre allowing faster diffusion than would be possible in a solid 
membrane. The drug loading is higher than for microspheres produced in this work 
and elsewhere. Parameters calculated are given in Appendix M. 
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The release profile of F3 fibres was determined in the same way. The only difference 
in manufacture between F2 and F3 fibres was that cisplatin was added to the dope 
after the polymer had fully dissolved rather than concurrently with the polymer. 
 
Figure 56: Release of cisplatin from PLGA 65:35 (F3) solid fibres. 
Cumulative cisplatin release from 5 mg of PLGA 65:35 F3 fibres into distilled water over ten 
days (n = 9). Solid line shows cylindrical Fickian model. Dashed line shows two 
compartment model. 
 
Figure 56 shows the release profile of F3 fibres. The fibres appear to contain more 
cisplatin than F2 fibres. One sample showed much greater release than others. This 
may have been due to a single large crystal being entrapped within the fibre and in 
addition to smaller, well dispersed crystals. The single replicate with the widely 
different profile may influence the analysis. However, with only nine replicates, it is 
not rigorous to exclude the series as an outlier as it may reflect the true properties of 
the fibre. The non-homogeneity in this sample suggests that adding cisplatin to the 
spinning dope after the polymer has dissolved produces poor fibres. If a drug depot 
contains an uncertain amount of cisplatin then the dose of drug cannot be controlled. 
A high dose could be extremely toxic for a patient. A low dose could be ineffective 
at controlling the disease. Since the therapeutic margin is small for cisplatin a depot 
which cannot be rigorously controlled is not appropriate for clinical use. 
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The parameters of the analysis using the four models are given in Appendix M. The 
two compartment empirical model calculated the drug loading to be 22 %. Not all of 
the parameters of the three compartment model were significant. The Higuchi model 
was a worse fit than the two compartment empirical model. The Higuchi model 
calculates the diffusivity to be 4×10-9 cm2 s-1 using equation 13 from k = 
1.5×10-3 mg s-0.5, surface area of 1.5 cm2, drug loading of 22 % and density of 
270 mg cm-3. This suggests that cisplatin travels almost four times faster in F2 fibres 
than F3 fibres. This difference may be an artefact of the pattern of the data 
influencing the model. Alternatively, it may be due to differences in the matrix 
structure. Release appears complete by around 100 h for F3 fibres. The qualitative 
observation that release is still occurring from F2 fibres after 200 h suggests that the 
Higuchi model has correctly identified real differences between these fibres. Not 
only are F3 fibres highly variable, they also have faster drug release, which is 
undesirable for continuous delivery devices. 
 
The cylindrical Fickian model had the lowest AIC for this sample. By non-linear 
least squares regression for the first 120 terms in the Taylor series of the cylindrical 
model, D was calculated to be 3.4±1.0×10-10 cm2 s-1 assuming that the fibre had a 
constant diameter of 0.024 cm. This is an order of magnitude slower than the value 
calculated using the Higuchi model. The Fickian model is derived from a more 
complete physical model. Since the Fickian model is valid for the entire release 
profile it is likely that the estimate of diffusivity derived in this way is closer to the 
true value. 
 
The release profile of F4 fibres was determined in the same way. F4 fibres were 
manufactured in the same way as F2 fibres with the cisplatin and polymer dispersed 
in NMP at the same time. 
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Figure 57: Release of cisplatin from PLGA 65:35 (F4) solid fibres. 
Cumulative cisplatin release from 5 mg of PLGA 65:35 F4 fibres into distilled water over ten 
days (n = 6). Solid line shows Higuchi model. Dashed line shows two compartment model. 
 
Figure 57 shows the release profile of F4 fibres. The fibres appear to have similar 
cisplatin loadings to F2 fibres. One replicate had a lower release rate, possibly with 
lower drug content. Although low drug content is safer than high content, this is still 
not a desirable property of the solid fibre. Variability in the drug loading could be 
caused by settling of suspended cisplatin during spinning.  
 
The more linear profile of one replicate and the lack of a clear plateau meant that the 
empirical models were not good fits to the data. The Higuchi model was a better fit 
to the data than the empirical models. The two compartment empirical model 
predicted a drug loading of 15 %. By the Higuchi model (equation 13) the diffusivity 
is predicted to be 2×10-9 cm2 s-1 using k = 7.6×10-4 mg s-0.5, surface area of 1.4 cm2, 
drug loading of 15 % and density of 290 mg cm-3. The cylindrical Fickian model did 
not converge for this dataset so no significant parameters were generated. 
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Batch Diffusivity (Higuchi) (cm
2
 s
-1
) Diffusivity (Fickian) (cm
2
 s
-1
) 
F2 2×10-9 *** 9×10-9 
F3 4×10-9 *** 3×10-10 *** 
F4 2×10-9 *** 1×10-12 
 
Table 15: Diffusivity of cisplatin in PLGA 65:35 solid fibres calculated by Higuchi 
and Fickian models.  
Model parameters, where significant at p < 0.001, are marked ***. 
 
Table 15 shows the diffusivity of cisplatin as calculated by the Higuchi and 
cylindrical Fickian models. There is considerable variability in the diffusivity 
calculated by both models, with almost three orders of magnitude difference in the 
values calculated for F4 fibres. For this batch the Fickian model was a poor fit for 
the data and the parameters were not significant. This suggests that the non-
significant parameters can be ignored. There was an order of magnitude difference 
between the significant parameters for release from F3 fibres. These fibres had the 
greatest within batch variation in the release profile. Therefore the diffusivity 
probably lies in the range indicated by these values. 
 
This analysis suggests that for release profiles the simpler and more robust Higuchi 
model is more likely to achieve a likely estimate for the diffusivity. The diffusivity 
of cisplatin in PLGA 65:35 should be constant as long as the matrix is homogenous 
and has the same microscopic structure. However, images of the cross-section of 
these fibres (Figure 37) show that the microscopic structure of solid fibres is 
heterogeneous and may vary between (and within) batches. To be considered as a 
successful drug delivery formulation, the variability between and within batches 
must be reduced. 
 
These results show that spinning solid fibres is a promising method for producing 
PLGA matrices with higher cisplatin loading than microspheres. A drug loading of 
up to 15 % for F4 fibres is an improvement over polyester microspheres produced 
here and elsewhere. The advantage of a high drug loading is that less excipient is 
implanted in the patient. Cisplatin should be added to the dope at the same time as 
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the PLGA rather than subsequently. Cisplatin is released from fibres manufactured in 
this way in a diffusion controlled manner for a period of ten days.  
3.4.5 Cisplatin Release from Hollow Fibres 
Hollow fibres were manufactured using a spinneret to create fibres with a hollow 
central bore. Fibres were spun from a dope solution of PLGA 65:35 dissolved in 
NMP and were formed by phase inversion of the dissolved polymer into a solid fibre 
(section 2.1.4). The fibre must harden in water as the residual solvent must be 
allowed to fully diffuse out of the fibre and dissolve in the water bath. PLGA fibres 
are traditionally hardened overnight for solvent removal from the fibre (Ellis and 
Chaudhuri, 2006). As cisplatin also dissolves in water a prolonged hardening step 
will reduce the drug loading. The fibre can be handled from approximately 30 
minutes following spinning. This observation has been exploited in this work to 
allow the cisplatin loading of hollow fibres to be increased above that previously 
observed for polyester microspheres. To prevent excess cisplatin being lost, once the 
fibres were strong enough to be handled, they were wrapped around cardboard 
supports. These coils of fibre were then freeze dried to remove water and remaining 
solvent. This method produced solid fibres with drug loadings higher than those 
previously seen for microspheres. 
 
Batch Drug Loading (%) Outer Diameter (mm) Wall Thickness (mm) 
F9 21-22 1.44±0.17 0.32±0.09 
F10 27-28 1.54±0.32 0.30±0.12 
 
Table 16: Drug loading and size of PLGA 65:35 hollow fibres. 
Outer diameter (n = 60) and wall thickness (n = 120) of hollow fibres (mean ± standard 
deviation) calculated from photographs of cross-sections using ImageJ. 
 
Table 16 summarizes the properties of F9 and F10 fibres. The fibre dimensions were 
determined from images of cross sections (see section 2.2.4). The release profile of 
F9 and F10 fibres was determined as for solid fibres. 
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Figure 58: Release of cisplatin from PLGA 65:35 hollow fibres. 
Cumulative release of cisplatin from equivalent of 100 mg of two independent batches of 
PLGA 65:35 hollow fibres (F9 and F10). Dashed line shows two compartment model 
average for two batches. Solid line shows two compartment model for each batch 
(parameters in Table 17). 
 
Figure 58 shows release of cisplatin from two independently manufactured batches 
of hollow fibres. The release profiles of both batches were similar with high drug 
loading of over 20 % with significant drug release over 200 h. F10 fibres had a 
higher drug loading than F9 fibres. The two compartment model was fitted to the 
grouped data. 
 
Batch Release constant k21 (s
-1
) Drug loading M2(∞) (mg) 
F9 5.0E-06 21 
F10 4.8E-06 27 
 
Table 17: Parameters for cisplatin release for both batches of PLGA 65:35 hollow 
fibres calculated using a two compartment model. 
Two compartment model was fitted to combined fibre data (Figure 58) using R. 
 
Table 17 shows the parameters for the two compartment model for each batch of 
PLGA 65:35 hollow fibres. There is significant batch variation of the release 
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profiles. Non-linear mixed effects modelling of the two compartment model 
calculated that M2(∞) = 23.9±3.1 mg and k21 = 4.9±0.12×10
-6 s-1 (mean ± standard 
deviation) for the combined data. The batches were also analysed separately 
(Appendix N). 
 
Figure 59: Release of cisplatin from PLGA 65:35 (F9) hollow fibres 
Cumulative cisplatin release from 5 mg of PLGA 65:35 F9 fibres into distilled water over nine 
days (n = 7) and 24 days (n=3). Solid line shows hollow cylindrical Fickian model. Dashed 
line shows two compartment model. 
 
Figure 59 shows the release profile of F9 fibres. The two compartment empirical 
model calculated the drug loading as 21 %. One of the parameters of the three 
compartment model was not significant. The Higuchi model was a less good fit to 
the data than the two compartment model. The diffusivity was 5×10-9 cm2 s-1 for F9 
fibres. This was calculated from the Higuchi model using equation 13, where k = 
1.7×10-3 mg s-0.5, surface area was 1.4 cm2, drug loading was 21 % and density was 
approximately 270 mg cm-3. 
 
The hollow cylinder Fickian model was the best fit to the F9 data out of the four 
models. By non-linear least squares regression for the first 120 terms in the Taylor 
series of the cylindrical model, D was calculated as 3.3±0.3×10-10 cm2 s-1. 
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Figure 60: Release of cisplatin from PLGA 65:35 (F10) solid fibres 
Cumulative cisplatin release from 5 mg of PLGA 65:35 F10 fibres into distilled water over 
sixteen days (n=10). Solid line shows hollow cylindrical Fickian model. Dashed line shows 
two compartment model. 
 
Figure 60 shows the release profile of F10 fibres. The two compartment empirical 
model predicted a drug loading of 27 %. Two of the parameters of the three 
compartment model were not significant because the initial release was not a major 
proportion of the release profile. The Higuchi model was a poor fit to this complete 
dataset. By the Higuchi model the diffusivity is predicted to be 4×10-9 cm2 s-1 by 
equation 13 using k = 1.5×10-3 mg s-0.5, an estimated surface area of 1.4 cm2, drug 
loading of 27 % and an estimated density of 270 mg cm-3. 
 
The cylindrical Fickian model had a similar AIC to the two compartment model. 
This suggests that both models have a similar explanatory power for the data. By 
non-linear least squares regression for the first 120 terms in the Taylor series of the 
cylindrical model D was calculated to be 2.3±0.3×10-10 cm2 s-1 assuming that the 
fibre had a constant diameter of 0.024 cm. 
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Batch Diffusivity (Higuchi) (cm
2
 s
-1
) Diffusivity (Fickian) (cm
2
 s
-1
) 
F9 5×10-9 *** 3×10-10 *** 
F10 4×10-9 *** 3×10-10 *** 
 
Table 18: Diffusivity of cisplatin in PLGA 65:35 hollow fibres calculated by Higuchi 
and Fickian models.  
Model parameters were significant at p < 0.001 where marked ***. 
 
Table 18 shows the diffusivity of cisplatin as calculated by the Higuchi and 
cylindrical Fickian models. Since the Fickian model has significantly improved 
explaining power over the Higuchi model for both batches it seems probable that the 
Fickian model offers a better description of this system. Therefore the diffusivity of 
cisplatin in PLGA 65:35 hollow fibres is 3×10-10 cm2 s-1. The release profiles of both 
batches appear to be reliable given the high drug loading achieved. 
 
The diffusivity of cisplatin in PLGA hollow fibres calculated using the Higuchi 
model (4×10-9 cm2 s-1) is similar to the diffusivity of cisplatin in PLGA solid fibres 
(2×10-9 cm2 s-1). This difference is similar to the difference in the rate constant for 
first order drug release. This suggests that properties of the matrix structure dominate 
the release rate rather than overall morphology of the depot. 
 
The diffusivity of cisplatin in PLGA microspheres is much lower (1×10-10 cm2 s-1) 
than for fibres. This suggests that the matrix structure is similar between solid and 
hollow fibres. This outcome is expected as both formulations are manufactured by 
phase inversion of a stream of polymer dope into water. The matrices of solid 
(Figure 37) and hollow (Figure 44) fibres appeared similar under SEM (section 
3.3.2) with finger-like pores orthogonal to the central axis of the fibre. Microspheres 
had a denser matrix that contained fewer, spherical pores (Figure 36). 
 
Two different independent batches of hollow fibres were manufactured. These 
batches had very similar properties and low within batch variation. The mean drug 
loading for these batches was 24 % which is substantially higher than for 
microspheres and solid fibres. Drug was released over five days. Hollow fibres 
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represent a great improvement in formulation over microspheres for sustained 
cisplatin delivery with a 42 % reduction in the amount of PLGA needed to be 
implanted for an equivalent dose. 
3.4.6 Effect of Ethanol Treatment on Cisplatin Release from Solid 
Fibres 
Ethanol can be used to reduce the microbiological burden of surfaces in clinical 
applications. Treating microspheres and fibres was found to reduce the density of S. 
epidermidis (section 3.7.4). Because of that, this study has addressed the effect of 
this treatment on PLGA fibres. Solid fibres (F9 and F10) were treated with 70 % 
ethanol for one minute and then the release profile was determined. 
 
Figure 61: Effect of ethanol treatment on cisplatin release from PLGA 65:35  hollow 
fibres (F9). 
Mean and standard error of cumulative cisplatin release from 5 mg of PLGA 65:35 F9 fibres 
into distilled water over sixteen days with (□) and without (○) ethanol treatment (n=10). Solid 
line shows cylindrical Fickian model for untreated fibre. Dashed line shows cylindrical 
Fickian model for ethanol treated fibre. 
 
Figure 61 shows the effect of treatment with 70 % ethanol for one minute on F9 
PLGA 65:35 hollow fibres. The diffusivity of cisplatin in F9 fibres is calculated by 
the cylindrical Fickian model to be 2.2±0.3×10-10 cm2 s-1 (95 % CI 1.7-
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2.8×10-10 cm2 s-1) before ethanol treatment and increased to 2.7±0.3×10-10 cm2 s-1 
(95 % CI 2.1-3.2×10-10 cm2 s-1) after treatment (Appendix N). 
 
Figure 62: Effect of ethanol treatment on cisplatin release from PLGA 65:35  hollow 
fibres (F10). 
Mean and standard error of cumulative cisplatin release from 5 mg of PLGA 65:35 F10 fibres 
into distilled water over sixteen days with (□) and without (○) ethanol treatment (n=10). Solid 
line shows cylindrical Fickian model for untreated fibre. Dashed line shows cylindrical 
Fickian model for ethanol treated fibre. 
 
Figure 62 shows the effect of treatment with 70 % ethanol for one minute on F10 
PLGA 65:35 fibres. The diffusivity of cisplatin in F10 fibres is calculated by the 
cylindrical Fickian model to be 2.3±0.3×10-10 cm2 s-1 (95 % CI 1.7-2.9×10-10 cm2 s-1) 
before ethanol treatment and doubled to 4.4±0.3×10-10 cm2 s-1 (95 % CI 
3.8-5.1×10-10 cm2 s-1) after treatment. 
 
For both F9 and F10 fibres the diffusivity of the fibres increased. Damage of PLGA 
structures by ethanol has been reported elsewhere (Shearer et al., 2006). The effect 
of treatment is likely to be real as it could be expected that ethanol causes disruption 
of the structure of the fibre and increased wetting of the polymer surface.  
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3.4.7 Carboplatin Release from Solid Fibres 
Carboplatin is a cisplatin analogue with reduced toxicity, reduced efficacy at 
equivalent doses and negligible irreversible protein binding in the plasma (section 
1.5.1). Carboplatin is more soluble in water than cisplatin and so harder to 
encapsulate in polyesters at high doses than cisplatin. To compare the formulation 
properties of carboplatin with cisplatin, PLGA 65:35 solid fibres were manufactured 
by phase inversion spinning (section 2.1.3). So that an equivalent amount of 
platinum was present in cisplatin and carboplatin containing fibres, the mass of 
carboplatin added to the polymer dope was higher than the equivalent mass of 
cisplatin. Carboplatin containing dope was too viscous to spin through the spinning 
needle. Carboplatin containing solid fibre (F6) was made by extrusion through a 
5 ml pipette tip instead. Therefore, no morphological analysis was performed on 
carboplatin containing fibres. The major differences in manufacture suggested that 
SEM observation would not be useful for comparisons with cisplatin containing 
fibres. Fibres were observed to have a rough surface, possibly caused by the 
presence of large crystals incorporated in the matrix. This suggests an irregularity of 
the drug distribution that may make this formulation unsuitable for drug delivery 
applications. 
 
Batch Drug Loading (%) Outer Diameter (mm) 
F6 3-5 0.97±0.16 
 
Table 19: Drug loading and diameter of carboplatin PLGA 65:35 solid fibre (F6). 
Diameter given as mean ± standard deviation (n = 12). 
 
The wider diameter of the fibre (Table 19) than other solid fibres (Table 13) means 
that the cylindrical Fickian model is less applicable as the surface area of the ends of 
5 mg fibres is a larger proportion of the total surface area.  
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Figure 63: Carboplatin release from PLGA 65:35 (F6) solid fibres. 
Cumulative carboplatin release from 5 mg of PLGA 65:35 F6 fibres into distilled water over 
ten days (n = 6). Solid line shows cylindrical Fickian model. Dashed line shows two 
compartment model. 
 
Carboplatin was completely released from F6 fibres within 48 hours, around four 
times faster than for cisplatin. This faster rate of release would be expected as 
carboplatin is around seven times more soluble than cisplatin. The rate of diffusion 
of carboplatin is not even higher due to its higher molecular mass compared to 
cisplatin. The diffusivity of carboplatin in PLGA 65:35 solid fibres was 
7.0±2.3×10-9 cm2 s-1 from fibre with a mean radius of 0.49 mm using non-linear least 
squares fitting to the cylindrical Fickian model (Appendix O). 
 
One replicate released twice as much drug as the others. This is likely due to the 
incorporation of a large carboplatin crystal in that part of the fibre. This is an 
undesirable property for a drug delivery device which must give a reproducible 
release profile to be safely used. Micronisation of the carboplatin before it is added 
to the spinning dope may improve homogeneity of drug dispersal. 
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3.4.8 Summary of Release Studies 
Ovarian cancer is one of the five most common causes of cancer death in women in 
the USA and UK. The tumour is generally well established in the peritoneum when 
diagnosed. Intraperitoneal therapy has been shown to improve survival for patients. 
Poly(lactide-co-glycolide) (PLGA) is a biodegradable polyester which has been 
proven safe for medical implantation. PLGA microspheres or fibres have been 
considered in this work as depots for delivering intraperitoneal cisplatin directly to 
the tumour site. PLGA 65:35 microspheres have been manufactured using the ethyl 
acetate that is a safer than solvents used for previously published formulations, such 
as DCM (Table 3). The microspheres produced by this improved method have higher 
cisplatin loadings than previously reported. Formulations with higher drug loading 
require less excipient. 
 
PLGA 65:35 solid fibres have been manufactured with a typical drug loading of 
15 % and an equivalent release constant to microspheres. PLGA 65:35 hollow fibres 
have been manufactured with a typical drug loading of 21 % and an equivalent 
release constant to microspheres. In addition, between batch and within batch 
variation of hollow fibres was relatively low compared to microspheres and solid 
fibres. Manufacturing fibres can be readily adapted to act as a continuous process, 
making scale up easier to achieve than for microspheres. Fibres could be sliced into 
pellets for intraperitoneal delivery of cisplatin. Carboplatin solid fibres were 
manufactured for comparison with cisplatin formulations. The longer residence time 
of carboplatin in an active form in blood plasma may reduce the advantage of 
regional delivery. The drug loading was lower for carboplatin (5 %) than for 
cisplatin solid fibres (15 %). Carboplatin was almost completely released within 
24 h. 
 
First order models such as the two compartment model are robust model and allow 
rapid comparison between formulations. The rate constants of the three formulations 
are similar (3-5×10-6 s-1). Due to differences in the PLGA matrix the diffusivity of 
cisplatin in microspheres is an order of magnitude slower than in solid or hollow 
fibres. An additional exponential (three compartment model) improved the 
description of the data for microsphere formulations but was not necessarily an 
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improvement for fibres. The Higuchi model is only appropriate to describe early 
release from drug depots but is robust and can converge on a solution even for poor 
datasets. The Fickian models offer a good mechanistic description of drug release 
and can generate a physical parameter, the diffusion coefficient, directly. The 
disadvantage of this model is that is may not achieve convergence for poor or 
incomplete datasets. The diffusivity was determined for fast releasing F3 fibres but 
did not have sufficient information to resolve clear parameters for the more slowly 
releasing F2 and F4 solid fibres.  
 
The Higuchi model systematically overestimated the diffusivity compared to the 
Fickian models. This is expected since increasing the range to which the model is 
fitted decreases the gradient of the model. This increases the value of k in equation 
12. Since the Higuchi constant, k, is proportional to D  fitting the Higuchi model to 
more than the initial release will increase the calculated diffusivity. 
 
All models are approximations to reality, so considering several is the best way to 
inform interpretation of diffusion data.  
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3.5 Peritoneal pH 
Release of cisplatin from PLGA depot devices was determined in water. This 
ensured that the release conditions or cisplatin detection were not disrupted by 
complex background matrices. Although PLGA degradation is pH sensitive (section 
1.5.4.2) the change of pH of water was not detectable during release experiments. In 
addition, cisplatin was released from PLGA depots before major changes in the 
molecular mass could have occurred. For treating cancer patients, the PLGA devices 
would be implanted in the peritoneum. Significant physiological changes can occur 
at tumour sites. If the pH of the peritoneum is greatly altered during ovarian cancer 
the rate of drug release could be affected, reducing the efficacy or increasing the 
toxicity of the treatment. To determine whether the peritoneum deviates from 
physiological pH during ovarian cancer, the pH of samples of peritoneal fluid was 
determined for a stage III patient.  
 
Peritoneal fluid was taken from the abdominal drain catheter and pH was measured 
immediately using a pH meter. The pH of the fluid was measured five times over 
five days. The pH was 7.4±0.1 (mean ± standard deviation). This is in agreement 
with the normal range of 7.4-8.1 for peritoneal pH (Noh, 2003). This suggests that 
rate of PLGA hydrolysis should not vary due to pH dependent effects. Therefore the 
rate of drug release should not be altered in the peritoneum by pH effects as it should 
remain close to neutral. Peritoneal fluid is a complex mixture of cells, small 
molecules, proteins and salts in solution. To determine the effect of the presence of 
nucleophilic groups, drug release was determined in the presence of a model protein 
solution (section 3.6). 
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3.6 Protein Binding of Cisplatin 
3.6.1 Removal of Cisplatin from Solution by Albumin 
Cisplatin exerts its therapeutic action by covalent attack of DNA (section 1.4.3). If 
cisplatin is sequestered by binding to nucleophiles in the serum or cell it is no longer 
available to cause tumour killing. Cisplatin binds to biological molecules with very 
high affinity. Unlike most drugs, unbound and protein bound cisplatin are not in 
equilibrium. Cisplatin becomes permanently bound nucleophiles. A well studied 
model protein is albumin. Albumin is present at ~40 mg ml-1 in serum. It is unlikely 
that albumin bound cisplatin retains therapeutic efficacy. Albumin contains a 
nucleophilic cysteine residue which is attacked by cisplatin (Espósito and Najjar, 
2002). Cisplatin that is released from a biodegradable depot and passes into a cell 
will be sequestered by nucleophiles such as glutathione. As removal of cisplatin by 
pathways other than renal clearance is significant, the effect of permanent binding is 
important for fully understanding cisplatin therapy. Albumin was used as a model to 
demonstrate the effect of concurrent drug release and removal from solution. To 
detect the concentration of cisplatin remaining in solution at each time point the 
albumin was removed by cold ethanol precipitation of the protein (section 2.3.7).  
 
A potential pitfall of this approach is that co-precipitation is indistinguishable from 
irreversible binding using this method. Adding ethanol to water reduces the 
solubility of cisplatin in the water. The solubility of cisplatin in 20 % ethanol in 
water solution is 1 mg ml-1(Peleg-Shulman et al., 2001). However, for these 
experiments, 1 mg cisplatin is being released into 1 ml over several days with the 
release medium being repeatedly refreshed. The cisplatin concentration should be 
sufficiently low that free cisplatin is not precipitated during addition of the sample to 
ethanol. To confirm that cisplatin was not precipitating due to the change in 
solubility caused by the ethanol, the release profiles of F2 and F3 solid fibres were 
determined by release of cisplatin into water (section 2.3.5) and into water followed 
by ethanol precipitation, evaporation, chemical digestion and resuspended in 2 M 
HCl (section 2.3.8.2). The release profiles of the fibres (Figure 55 and Figure 56) 
show the combined datasets from two experiments where different sampling time 
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points were used. Despite the differences in experimental methods, both sets of data 
follow the same release pattern. This implies that no cisplatin had been removed by 
precipitation at the ethanol precipitation step when no BSA is present. To verify 
covalent cisplatin-protein binding, second method may be used. Appropriate 
techniques would be electrophoresis of the protein before and after binding, analysis 
of free thiols in the protein sample, or UV analysis to detect changes in the UV 
spectrum due to cisplatin binding. 
 
Preliminary experiments showed that detection of low concentrations of cisplatin 
was possible in the presence of protein. The binding of cisplatin in solution to 
protein was compared by ultrafiltration and ethanol precipitation. Due to the 
heteroscedasticity of the dataset linear regression was performed using quasi-Poisson 
family linear model simplification. By linear regression from the saturated model 
(filtration method, time and the interaction) filtration method was found not to be a 
significant parameter (p = 0.45) using the F test.  
 
Figure 64: The concentration of unbound cisplatin in solution in the presence of 
BSA.  
Protein removed by ultrafiltration (o) or protein precipitation (x) (n = 4). Solid line shows 
exponential of linear model of logarithm of data and dashed lines are 95 % confidence 
intervals. 
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The removal of unbound cisplatin from solution can be modelled as an exponential 
decay of the form; 
 
( ) ( ) ( )tkCtC b−⋅= exp0  (43) 
 
where C(t) is the concentration at time t, where C(0) is the starting concentration and 
kb is the binding constant. 
 
The binding constant for the combined dataset is 6.1±0.92×10-5 s-1. This rate may be 
slightly underestimated if the concentration of binding sites on the BSA has fallen 
significantly during the course of the experiment. The rate of aquation determined 
elsewhere is 8×10-5 s-1 (Knox et al., 1986, Wenclawiak and Wollmann, 1996). The 
rate of aquation determines the maximum rate of observed protein binding so these 
values do not contradict each other. 
3.6.2 Cisplatin Release from Microspheres and Binding to Albumin 
In solution cisplatin binds to BSA. This reaction is effectively irreversible at 
biologically relevant concentrations. The concentration of unbound cisplatin in 
solution is predicted to be described by a two or three compartment model of protein 
binding (section 1.6.3). The rate of drug release will initially be high causing the 
concentration of drug in solution to rise. As the concentration of unbound cisplatin 
increases, the rate of protein binding will increase. The concentration of unbound 
cisplatin then decreases as both rates fall.  
 
The concentration of unbound cisplatin was determined as above in the presence of a 
depot suspension of PLGA 65:35 microspheres (section 2.3.8.1). Drug concentration 
was measured by complete replacement of the release medium. The difference 
caused by the removal of cisplatin in the release medium should not affect measured 
results. The system is dynamic. Cisplatin is initially released at a faster rate than 
protein binding. This means that the concentration of unbound cisplatin will return to 
almost the same concentration as if the solution had not been removed. Therefore, 
instantaneous samplings should be equivalent whether or not the solution is replaced 
at each time point. In addition, this method avoids the possibility that the rate of 
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cisplatin-protein binding decreases as the number of nucleophilic sites on the BSA 
molecules falls. 
 
Figure 65: Unbound cisplatin concentration in BSA solution during cisplatin release 
from PLGA 65:35 microspheres. 
Cisplatin concentration resulting from release from 8.3 mg PLGA 65:35 microspheres M21 
(o), M25 (x), M26 (□) and M27 (∆) and removal from solution by binding to BSA and cold 
ethanol precipitation (n=6). 
 
Figure 65 shows the concentration of cisplatin in 1 ml BSA solution in the presence 
of 8.3 mg PLGA 65:35 microspheres. The concentration initially appears to fall but 
is higher than expected after 24 hours than would be predicted by a protein binding 
constant of 6×10-5 s-1 (section 3.6.1). Attempting to fit the two compartment protein 
binding model produced large errors for the final three time points (line of fit not 
shown). 
 
The unexpectedly high values at 24 hours could be due to an unconsidered 
experimental variable such as transfer of microspheres into the digested portion of 
the sample. This is possible because the microspheres had to be removed from 
suspension by centrifugation which does not pellet all microspheres. Alternatively 
the longer sampling time between the third and fourth sample could mean that the 
rate of protein binding changed as the number of unoccupied binding sites reduced. 
This unusual profile makes definitive predictions for microspheres difficult. 
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Nevertheless, it is possible to see that the presence of BSA decreased the 
concentration of unbound cisplatin. 
 
Subsequent experiments were carried out with fibres rather than microspheres that 
cannot be accidentally transferred into the sample for analysis. In addition, samples 
were taken at intermediate time points to provide more time points for the profile. 
3.6.3 Cisplatin Release from Solid Fibres and Binding to Albumin 
The irreversible binding of cisplatin to BSA during drug release from solid fibres 
was determined as above (section 2.3.8.2). The concentration of unbound cisplatin in 
solution is predicted to be described by a two or three compartment model of protein 
binding (section 1.6.3). 
 
The release profile of PLGA 65:35 F2 (Figure 55) and F3 (Figure 56) solid fibres 
was determined in water (section 3.4.4). Concurrently the concentration of unbound 
cisplatin as it was released from fibres and bound to BSA was determined in BSA 
solution. Bound cisplatin was removed by cold ethanol precipitation of protein as for 
microspheres. The concentration of unbound cisplatin was determined as above in 
the presence of a depot suspension of PLGA 65:35 microspheres. Drug concentration 
was measured by completely replacing the release medium. Drug is initially released 
at a faster rate than protein binding. This means that the concentration of unbound 
cisplatin will return to almost the same concentration as if the solution had not been 
removed. Therefore, instantaneous samplings should be equivalent whether or not 
the solution is replaced at each time point. In addition, this method avoids the 
possibility that the rate of cisplatin-protein binding decreases as the number of 
nucleophilic sites on the BSA molecules falls. 
 
Assuming that the three compartment model (section 1.6.3) is appropriate for 
describing the release and binding profiles, the amount of protein bound can be 
calculated using equation 44. 
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The variance associated with the release profile was larger than the values for the 
cisplatin concentration due to the large difference in scale between the 
measurements. To demonstrate the difference between the proportion of drug 
released and the proportion of drug which had become bound, the three compartment 
model was applied to the normalized data to produce a mean profile of proportional 
cisplatin release in the presence of water only. The concentration profile in the 
presence of albumin was then normalized by dividing by the mean maximum 
cisplatin release from the paired experimental samples in water. The data were then 
subtracted from the mean proportional release profile and fitted to the three 
compartment model, using the values for M3(∞), M4(∞), k31, and k41 from the mean 
proportional release profile (Figure 66). Using this model, kb was calculated as 
2×10-4 s-1. The errors associated with this estimate cannot be calculated since the 
release profile has been coerced to fit by using the model as the background. 
However, individual datasets cannot any more rigorously be used since a different 
sample from the same batch was necessarily used for each repeat in the experiment. 
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Figure 66: Proportion of cisplatin released from F2 fibres and proportion that has 
become protein bound. 
Mean proportional cisplatin release was calculated by normalizing the release data and 
applying the three compartment model. The proportion of bound cisplatin was calculated by 
subtracting the normalized cisplatin concentration in the presence of cisplatin from the mean 
proportional release. The release constant, kb was calculated as 2×10
-4
 s
-1
 using the three 
compartment model (equation 44). Data points have been omitted for clarity. 
 
Since analysis of the relative amount of bound cisplatin was statistically unsound 
due to the high degree of processing needed for the data, the two (equation 8) and 
three (equation 9) compartment models were used directly for component of drug in 
solution. Although both the two and three compartment models were significant for 
F2 fibres, the three compartment model incorporating protein clearance did not 
converge to significant parameters for F3 fibres. However, the two compartment 
model was significant (Table 20 and Table 21). 
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Figure 67: Unbound cisplatin concentration in BSA solution during cisplatin release 
from PLGA 65:35 solid fibres. 
Cisplatin concentration resulting from release from 5 mg Fibres F2 (o), F3 (x), and removal 
from solution by binding to BSA (n=9). Solid line is predicted value using two compartment 
model with parameters shown in Table 20 and Table 21. 
 
Figure 67 shows the concentration of cisplatin as it is released from F2 and F3 fibres 
(compared to Figure 55 and Figure 56) and concurrently removed from solution by 
binding to protein.  
 
 F2 in water F2 in protein solution 
 Mean St. Error Mean St. Error 
M2(∞) (mg) 4.93E-01*** 2.00E-02 1.25E+00*** 2.91E-01 
k21 (s
-1) 4.25E-06*** 4.30E-07 6.98E-06*** 8.71E-07 
kb (s
-1) -  4.09E-04*** 7.90E-05 
 
Table 20: Release parameters for release of cisplatin from PLGA 65:35 fibres (F2).  
Parameters calculated by non-linear least squares regression using empirical two 
compartment model with and without protein binding term fitted to protein concentration in 
the absence or presence of BSA respectively. Parameters are marked *** as they are 
significant at p < 0.001. 
 176 
 
 F3 in water F3 in protein solution 
 Mean St. Error Mean St. Error 
M2(∞) (mg) 1.08E+00*** 5.57E-02 1.82E+00*** 4.66E-01 
k21 (s
-1) 7.45E-06*** 1.16E-06 8.90E-06*** 1.22E-06 
kb (s
-1) -  4.06E-04*** 8.64E-05 
 
Table 21: Release parameters for release of cisplatin from PLGA 65:35 fibres (F3).  
Parameters calculated by non-linear least squares regression using empirical two 
compartment model with and without protein binding term fitted to protein concentration in 
the absence or presence of BSA respectively. Parameters are marked *** as they are 
significant at p < 0.001. 
 
This method appears to produce robust results for release of cisplatin from PLGA 
fibres. For F2 and F3 fibres binding constants were similar using the two 
compartment model. In addition the release constants were calculated to be similar 
whether protein was present or not. The total cisplatin present in each formulation 
was overestimated in the presence of protein although this is not surprising as the 
release constants, k21, were somewhat overestimated. The rate constant for protein 
binding, kb, is calculated 4.1±0.9×10
-4 s-1 by this method, higher than, 
6.1±0.9×10-5 s-1, the value measured from protein binding of unbound cisplatin 
(section 3.6.1). This difference may be caused by the additional removal of cisplatin 
at each time point. It is also possible that the some component of the fibre increased 
the rate of protein binding. Alternatively, depot formation may increase the rate of 
aquation of cisplatin on its release.  
 
The two compartment model successfully offers a reasonable approximation of the 
unbound cisplatin concentration when cisplatin is released from solid fibres in the 
presence of protein. 
3.6.4 Cisplatin Release from Hollow Fibres and Binding to Albumin 
The release profile of PLGA 65:35 F10 hollow fibres was determined in water 
(Figure 60) and in BSA solution as above (section 2.3.8.3). The two compartment 
model incorporating irreversible protein binding was used to analyse the 
concentration-time profile (section 1.6.3).  
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Figure 68: Unbound cisplatin concentration in BSA solution during cisplatin release 
from PLGA 65:35 hollow fibres. 
Cisplatin concentration resulting from release from 5 mg F10 fibres and removal from 
solution by binding to BSA (n=9). Solid line is predicted value using two compartment model 
with parameters shown in Table 21. 
 
Figure 68 shows the concentration of cisplatin as it is released from F10 fibres and 
concurrently removed from solution by binding to protein. As for solid fibres, the 
protein binding model was a better fit to this dataset than the data from 
microspheres. Drug concentration initially rises high, before dropping off as the rate 
of drug release from fibres falls. 
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 F10 in water F10 in protein solution 
 Mean St. Error Mean St. Error 
M2(∞) (mg) 1.35E+00*** 2.66E-02 2.99E+00** 9.88E-01 
k21 (s
-1) 6.99E-06*** 5.44E-07 8.60E-06*** 1.70E-06 
kb (s
-1) -  6.91E-04*** 1.78E-04 
 
Table 22: Release parameters for release of cisplatin from PLGA 65:35 fibres.  
Parameters calculated by non-linear least squares regression using empirical two 
compartment model with and without protein binding term fitted to protein concentration in 
the absence or presence of BSA respectively. Parameters are marked *** as they are 
significant at p < 0.001. 
 
Table 22 shows the parameters of the two compartment model in the presence and 
absence of BSA. Ethanol precipitation appears to produce robust results for release 
of cisplatin from PLGA fibres. The binding constant calculated is similar to that 
calculated based on release from solid fibres (see section 3.6.3). In addition the 
release constant, k21, was calculated to be similar whether protein was present or not. 
As for solid fibres the total cisplatin present was overestimated in the presence of 
protein. The two compartment model successfully predicted the release profile of 
cisplatin released from fibres in the presence of protein and the results are consistent 
with in vivo values for cisplatin binding to protein. 
3.6.5 Summary of Protein Binding Studies 
Rate constant of protein binding of unbound cisplatin in solution, kb, was 6×10
-5 s-1. 
The two compartment protein binding model for cisplatin release described the data 
for irreversible binding to protein following release from PLGA 65:35 solid (kb = 
4×10-4 s-1) and hollow fibres (kb = 7×10
-4 s-1). The model slightly overestimated the 
binding constant. This is because of additional removal of cisplatin during sampling 
that was not accounted for in the model. The method is useful as it does give relevant 
approximations. This method was not suitable for analysing microspheres due to 
transfer of microspheres in suspension which effected the measured drug 
concentrations. To the author’s knowledge, this work has demonstrated for the first 
time that cold ethanol precipitation is a suitable method for determining rate 
parameters for irreversible protein binding of a drug. 
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3.7 Bacterial Attachment 
3.7.1 Bacterial Attachment to Microspheres 
Bacteria bind to all surfaces (section 1.7.2) but the affinity of binding is difficult to 
quantify. Attachment of Staphylococcus epidermidis to PLGA microspheres was 
observed under SEM (section 2.2.3). Microspheres were sieved before mixing with 
the bacterial culture so that only microspheres between 53 and 90 µm were present. 
 
 
 
Figure 69: SEM images showing attachment of S. epidermidis to PLGA 75:25 
microsphere. 
Bar is 10 µm. 
 
S. epidermidis were shown to bind to PLGA microspheres (Figure 69). Because the 
sample had been sieved using a 53 µm sieve, no bacterial sized microspheres were 
present. This was confirmed using a bacteria free control (not shown). Therefore, the 
numerous particles of 0.8 µm diameter can be identified as bacterial cells. In the first 
stages of bacterial attachment, the cells form weak interactions with the 
microspheres. These images show that the interactions are strong enough to allow 
attachment to microspheres within a few minutes. It would be interesting to be able 
to quantify rate of bacterial attachment. Since binding studies would be difficult, 
slow and expensive using SEM, viable cell count culture techniques were developed 
to attempt to assess rates of attachment of S. epidermidis to microspheres. 
 
To quantify initial bacterial attachment S. epidermidis were briefly incubated in PBS 
with microspheres (section 2.5.2). The microspheres were separated from the culture 
by centrifuging the mixture at 100 g. Relatively slow centrifugation preferentially 
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sedimented the microspheres but not bacteria which had not become attached. The 
contaminated microspheres were then incubated with sterile PBS for one minute. As 
the initial attachment to microspheres is weak, the faster cells become attached in the 
first incubation, the more cells are available to become unattached during the second 
incubation. The microspheres were then removed by centrifuging the mixture at 
100 g. The supernatant was diluted and spread plated on TSA.  
 
Differences between the initial culture concentration and high variance of cell counts 
hindered analysis. The data were combined and analysed for trends using generalised 
linear models fitted using the R statistics package. A quasi-Poisson distribution was 
chosen for the error structure for this count data because negative counts were not 
possible (as would be allowed assuming a normal distribution). When a Poisson 
distribution was used for the error structure some outliers had too much influence on 
the model (leverage). A quasi-Poisson distribution has the same shape as the Poisson 
distribution but does not require that the mean equals the variance.  
 
AIC cannot be used to compare quasi-Poisson models. Quasi-Poisson models allow 
the error structure to vary. This means that the likelihood function is not comparable 
between models (see section 1.6.6). Instead, significant parameters of the combined 
dataset for the four experiments were determined by model simplification using χ2 
ANOVA. Interactions between parameters could not be calculated due to insufficient 
sample sizes. For example, for some samples the microspheres were transferred to a 
fresh Eppendorf before plating. To determine whether this factor is significant a χ2 
test is performed comparing the model with and without transfer. Removing the 
parameter increases the overall deviance of the data from the model but adds one 
degree of freedom. The probability that this change is not significant is quite high 
(p = 0.10) and so the parameter is not retained. Attempting to remove the parameter 
for mass of microspheres produces a large increase in deviance while gaining one 
degree of freedom.  The probability that this change is not significant is low 
(p = 4.5×10-5) and so the parameter for mass was retained. 
 
washfmasseinitdccount ⋅+⋅+⋅+=  (45) 
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Remaining significant coefficients (equation 45) used to describe count, the cell 
count (cfu ml-1) were d affecting init, the initial culture concentration (cfu ml-1), e 
(mg-1) affecting mass, the mass of microspheres added (mg) and f affecting wash, a 
categorical parameter for whether one or two wash steps were used. The intercept, c, 
is equivalent to the mean count at the origin. 
 
Coefficient Parameter Estimate St. Error Pr(>|t|) 
c (Intercept) 7.85E+00 2.23E-01 < 2E-16*** 
d init 1.13E-03 1.81E-04 8.14E-09*** 
e mass 2.56E-02 6.49E-03 1.41E-04*** 
f wash -2.14E+00 2.14E-01 < 2E-16*** 
 
Table 23: Parameters of minimal generalised linear model of attachment of S. 
epidermidis to PLGA 50:50 microspheres.  
Model assumed a quasi-Poisson distribution with coefficient of dispersion = 236. 
 
The parameters of the model (Table 23) correlate with the designs of the experiment. 
As the link function is the logarithm, these parameters are interpreted by plotting the 
exponential of the predicted count. There was a range of initial culture 
concentrations from 6×102 to 2×103 cfu ml-1. It is therefore expected that increasing 
the concentration of bacteria increased the cell counts. One experiment was 
performed with only one wash step. The additional wash decreased the cell counts as 
expected. The combined data showed that increasing the amount of microspheres 
present with the culture increased the number of bacteria transferred.  
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Figure 70: Increasing the mass of microspheres elevates the cell count remaining in 
tubes after washing.  
Plotted values show data and model for init = 2025, wash = two (□, solid line), init = 820, 
wash = two (o, dashed line) and init = 592, wash = one (∆, dotted line). 
 
Figure 70 shows the most simplified model describing this dataset. For one of the 
experiments cell counts were very low and so have not been included in this semi-
logarithmic plot but were not excluded from the statistical analysis. It should be 
noted that although these trends are significant, the variability in the system is very 
high. For example, doubling the mass of microspheres used from 10 mg to 20 mg 
with an initial culture of 1000 cfu ml-1 and two wash steps will on average cause a 
30 % increase in cell count from 141 cfu ml-1 to 183 cfu ml-1. Unfortunately, the 
95 % confidence interval of these predicted values are 23.5-801 cfu ml-1 and 26.8-
1180 cfu ml-1 respectively. 
 
The highly variable nature of biological systems creates challenges for analysing 
interactions with interfaces of interest. To successfully make predictions about 
interactions of bacteria with microspheres, which themselves show variance in their 
properties a method must be robust, be able to be performed many times rapidly to 
generate sufficient data for significant analyses and have as few uncontrolled 
independent variables as possible.  
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3.7.2 Bacterial Removal from Microspheres 
Freeze drying may produce broad spectrum killing of contaminants of microspheres. 
Freeze drying will not sterilise microspheres since ice crystals will not form to kill 
the cells. To determine to what level freeze drying reduced bacterial burden samples 
of blank (M22) and cisplatin containing (M20) microspheres were incubated with S. 
epidermidis. The microspheres were then centrifuged at 100 g and the supernatant 
was aspirated and discarded. The pellet of microspheres was either incubated at 
room temperature or freeze dried. The pellets were then resuspended in PBS and 
incubated at room temperature to allow weakly attached microspheres to become 
detached. The microspheres were pelleted at 100 g and the supernatant plated to 
assess level of cell killing (section 2.5.3).  
 
Figure 71: Freeze drying reduced cell count for blank PLGA 65:35 microspheres 
following coating with S. epidermidis.  
Bold line shows median count (n = 9). Box shows interquartile range. Whiskers show the 
range of the data. 
 
Three quarters of the bacteria were killed by freeze drying blank PLGA 65:35 
microspheres. Freeze drying significantly reduced burden of bacteria on PLGA 
microspheres (Figure 71). No S. epidermidis grew on plates after being incubated 
with cisplatin microspheres.  
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3.7.3 Bacterial Attachment to PLGA Fibre 
Bacterial attachment to PLGA 65:35 blank fibres (F5) was investigated. Samples of 
fibre (50 cm and 100 cm) were incubated with a dilute culture of S. epidermidis. It 
was expected that cells would form weak interactions with the fibre and become 
removed from the culture. Sample with more fibre in was expected to remove more 
cells due to having twice the area for attachment. The culture was then spot plated as 
a two-fold dilution series (section 2.5.4). The experiment was repeated with F1 
fibres. 
 
 
 
Figure 72: Increasing the amount of PLGA 65:35 solid fibre added to a S. epidermidis 
culture reduced the number of cells remaining in the culture. 
Plates of eight spots of 10 µl S. epidermidis culture which had been incubated with (a) 0, (b) 
50 or (c) 100 cm PLGA 65:35 F5 fibre for 15 minutes plated as six two-fold dilutions. 
 
Figure 12 shows typical spot plates for 10 µl S. epidermidis culture which had been 
incubated with (a) 0, (b) 50 or (c) 100 cm PLGA 65:35 fibre for 15 minutes plated as 
six two-fold dilutions. A Poisson distribution can be assumed for count data because 
the normal linear model is not appropriate. A generalised linear model estimates 
count data values using a logarithmic link function. This avoids negative count 
predictions and more accurately represents the variance at low counts. 
 
massedilddcount ⋅+⋅=  (46) 
 
A saturated generalised linear model was fitted to the data for all dilutions and 
simplified as justified by χ2 ANOVA. Just two parameters (equation 45) were 
required to describe count, the cell count (cfu ml-1) adequately. Parameters were dd 
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affecting dil, the dilution factor (no units), and e (mg-1) affecting mass. The 
experiment number and the type of fibre were not required for the model. Finally the 
intercept was also removed as it was not significant (p = 0.12). 
 
Coefficient Parameter Estimate St. Error t value Pr(>|t|) 
dd dil 7.7E-02 1.1E-03 73 < 2E-16*** 
e mass -1.2E-02 7.2E-04 -17 < 2E-16*** 
 
Table 24: Parameters of minimal generalised linear model of attachment of S. 
epidermidis to PLGA 65:35 solid fibres.  
Model assumed a Poisson distribution. 
 
The parameters of the model (Table 23) correlate with the designs of the experiment. 
As the link function is the logarithm, these parameters are interpreted by plotting the 
exponential of the predicted count. 
 
Figure 73: Increasing the amount of PLGA 65:35 fibre present in culture with S. 
epidermidis decreased the cell count in the bathing solution.  
Samples of PLGA 65:35 solid fibre, F5 (□) and F1 (o), were added to dilute bacterial 
cultures. Data shown for most concentrated plating only. Solid line shows generalised linear 
model fitted to binding data for two batches of PLGA 65:35 solid fibre. Mass and dilution 
were significant parameters. Dashed lines show 95 % confidence intervals. 
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Figure 73 shows the cell counts from the most concentrated spots as the amount of 
fibre added to each sample of culture varied. The effect of mass of fibre was 
significant. However, the high degree of variation in the data means that quantitative 
predictions about the binding rate cannot be made. 
3.7.4 Ethanol to kill Bacteria attached to PLGA Fibre 
Samples of fibre were sanitised with ethanol and rinsed with PBS. A dilute culture of 
S. epidermidis was incubated with the fibres to allow some cells to become attached 
and then decanted. Half of the samples were incubated at room temperature and half 
were sanitized with ethanol. The ethanol was decanted and the fibres were rinsed 
with PBS to remove residual ethanol. The fibres were then incubated with PBS to 
allow release of weakly attached cells. This incubation medium was then spot plated 
(section 2.5.5).  
 
Cells survived on the fibres which had not been treated with ethanol. Assuming that 
this count data had a Poisson distribution the cell count after incubation with F5 fibre 
was 1.24±0.16×104 cfu ml-1. There was no cell growth on plates which had been 
plated with cultures derived from fibres been treated with ethanol. This implies that 
cell killing was effective or that no cells which had attached to the fibre were 
released into the plated buffer after 5 minutes. When these samples of fibre were 
incubated overnight with 25 ml TSB no colonies grew in the 60 second ethanol 
treated sample but turbid cultures >107 cfu ml-1 grew in the samples without 
treatment or a short 30 second treatment. A 60 second ethanol treatment had killed 
all cells associated with the sample as the culture remained clear. It is unlikely that 
cells had survived the ethanol treatment and not grown under nutrient conditions. 
Although cells had not been detected by plating following the 30 second treatment, 
some had survived attached to the fibre. Cells from untreated fibre grew to form a 
dense, opaque culture. 
 
A single sample does not confirm that every S. epidermidis cell will be killed by 60 
seconds ethanol or that other species will be as sensitive. However, it does imply that 
60 seconds of treatment will dramatically reduce the microbial burden of the fibres 
and should be implemented as standard. The effect on the release profile of the fibre 
must be taken into account (see section 3.4.6). 
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4 Conclusion 
4.1 Study Findings 
Ovarian cancer is one of the five most common causes of cancer death in women in 
the USA and UK. The tumour is generally well established in the peritoneum when 
diagnosed. Current opinion in the medical and scientific literature is that prolonged 
delivery of cisplatin may offer reduced toxicity compared to IV delivery of a single 
bolus. Prolonged release can also be achieved by sustained release from a drug depot 
Sustained release of cisplatin from implantable microspheres or fibres offers the 
reduced toxicity of prolonged delivery. In addition, the risks associated with resident 
catheters and costs of extended hospitalization are avoided. Intraperitoneal therapy 
has been shown to improve survival for patients. Poly(lactide-co-glycolide) (PLGA) 
is a biodegradable polyester which has been proven safe for medical implantation. 
 
Aim (1) of this work was to develop microsphere depot formulations with improved 
drug release profiles compared to previous work. PLGA 65:35 microspheres have 
been manufactured using the ethyl acetate that is a safer solvent than other solvents 
used by others, such as DCM. The microspheres produced by this improved method 
have higher cisplatin loadings than previously reported. Formulations with higher 
drug loading require less excipient. 
 
Aim (2) of this work was to develop and investigate novel cisplatin containing solid 
and hollow fibres as alternative structures for depot devices. PLGA 65:35 solid 
fibres have been manufactured with a typical drug loading of 15 % and an equivalent 
release constant to microspheres. PLGA 65:35 hollow fibres have been 
manufactured with a typical drug loading of 21 % and an equivalent release constant 
to microspheres. In addition, between batch and within batch variation of hollow 
fibres was relatively low compared to microspheres and solid fibres. Manufacturing 
fibres can be readily adapted to act as a continuous process, making scale up easier 
to achieve than for microspheres. Fibres could be sliced into pellets for 
intraperitoneal delivery of cisplatin. 
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Aim (3) of this work was to examine the drug release profiles of the formulations 
produced using mathematical models to allow rational comparison of the devices. 
Determination of release kinetics was achieved using non-linear least squares to fit 
the semi-empirical and Fickian models to the datasets. First order models such as the 
two compartment model is a robust model that allows rapid comparison between 
formulations. An additional exponential improved the description of the data for 
some formulations. The Higuchi model is only appropriate to describe early release 
from drug depots but is robust and can converge on a solution even for poor datasets.  
 
PLGA Depot 
Structure 
Rate Constant (s
-1
) Diffusivity 
(Higuchi) (cm
2
 s
-1
) 
Diffusivity 
(Fickian) (cm
2
 s
-1
) 
Microspheres 5×10-6 1×10-10 4×10-11 
Solid Fibres 3×10-6 2×10-9 - 
Hollow Fibres 5×10-6 5×10-9 3×10-10 
 
Table 25: Typical kinetic parameters of PLGA 65:35 microspheres, solid fibres, and 
hollow fibres. 
Rates and diffusivities of combined microsphere data (M14, M17, M18-M21), F4 solid fibres 
and F9 hollow fibres. 
 
The Higuchi model systematically overestimates the diffusivity compared to the 
Fickian model (Table 25). The Fickian models offer a good mechanistic description 
of drug release and can generate a physical parameter, the diffusion coefficient, 
directly. The disadvantage of this model is that it may not achieve convergence for 
poor or incomplete datasets. All models are approximations to reality, so considering 
several at once is the best way to inform interpretation of diffusion data. 
 
Cisplatin undergoes a ligand exchange in the presence of water, forming to a potent 
electrophile. This charged cisplatin species readily forms DNA-platinum adducts. 
These adducts are thought to be the major mechanism of toxicity to cancer cells. 
Charged cisplatin also binds other nucleophiles in cells. Cisplatin binding other 
cellular components reduces the amount of cisplatin available for DNA attack. 
Irreversible protein binding influences cisplatin pharmacokinetics compared to other 
drugs. 
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Aim (4) of this project was to investigate irreversible binding of cisplatin to non-
DNA targets, cisplatin binding to protein. The two compartment protein binding 
model for cisplatin release described the data for irreversible binding to protein 
following release from PLGA 65:35 solid (kb = 4×10
-4 s-1) and hollow fibres (kb = 
7×10-4 s-1). Rate constant of protein binding was slightly overestimated compared to 
decrease of concentration of unbound cisplatin in solution (kb = 6×10
-5 s-1). The 
method is useful as it does give relevant approximations. To the author’s knowledge, 
this work has demonstrated for the first time that cold ethanol precipitation is a 
suitable method for determining rate parameters for irreversible protein binding of a 
drug. 
 
All implanted surfaces are susceptible to bacterial attachment. Bacteria are able to 
survive on implants in a hostile environment-resistant slow growth mode.  
 
Aim (5) of this thesis was to investigate attachment of bacteria to PLGA depots. 
 
S. epidermidis is an important pathogen associated with long term implanted 
polymeric devices such as intravenous catheters. S. epidermidis was found to rapidly 
bind to PLGA fibres in vitro. Attached cell numbers can be reduced by freeze drying 
or by exposure to 70 % ethanol for 60 seconds. 
 
In conclusion, the novel high cisplatin loading PLGA 65:35 hollow fibres reported in 
this thesis represent a formulation of continuous release that may offer a therapeutic 
benefit to ovarian cancer patients as an additional component to current optimum 
therapy. 
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4.2 Future Work 
High cisplatin loading PLGA 65:35 hollow fibres may offer an improvement to 
intraperitoneal cisplatin therapy. Cisplatin becomes bound to polyesters when stored 
at 5°C. Optimization of storage conditions by examining freezing and a desiccated 
environment may improve the shelf life of cisplatin containing PLGA depots. 
 
High cisplatin loading PLGA 65:35 hollow fibres have a reduced soaking following 
spinning. To confirm that the NMP levels remaining in the fibre are low the fibres 
could be analysed using chromatographic methods. 
 
This work has shown that depot morphology plays a role in determining rate of drug 
release. Preliminary work to extend these studies showed that although carboplatin 
was released quickly from solid PLGA 65:35 fibres, release was slower from PLGA 
75:25 coated double layer hollow fibres. The method of manufacture followed was 
similar to that used in section 2.1.4, except that the spinneret had an inner and outer 
polymer channel as well as an aqueous phase central bore (Figure 74).  
 
 
 
Figure 74: Double layer hollow fibre spinneret. 
 
PLGA 65:35 dissolved in NMP with carboplatin (50 % of the weight of PLGA 
65:35) and PLGA 75:25 dissolved in NMP were spun (by Mr Thomas Richards) 
through the inner and outer bores of a double layer hollow fibre spinneret 
respectively with distilled water in the central bore. The release profile of this fibre 
was determined in water as for other depots analysed in this work  with acid 
digestion to allow detection of the carboplatin (section 2.3.5). 
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Figure 75: Release of carboplatin from PLGA 75:25 coated PLGA 65:35 double layer 
hollow fibres.  
Solid line shows two compartment release. Dashed lines are 95 % confidence intervals 
(n = 4). 
 
Figure 75 shows the release of carboplatin from 5 mg of PLGA 75:25 coated PLGA 
65:35 double layer hollow fibres. There was insufficient data to fit the three 
compartment model. The model estimated a drug loading of 0.30 mg carboplatin in 
5 mg fibre with a release constant of 3.7±0.58×10-6 s-1 (parameter ± standard error). 
This is an order of magnitude reduction in rate of release compared to carboplatin 
solid fibres which released drug at 2.8±0.82×10-5 s-1 (section 3.4.7). This additional 
degree of control is due to the PLGA 75:25 membrane coating the drug containing 
depot and restricting the rate of diffusion. Although the number of samples examined 
was low (n = 4), this preliminary experiment suggests that double layer hollow fibres 
have less variability in profiles of drug release than solid fibres. 
 
 As carboplatin is even more soluble than cisplatin the soak following spinning had 
to be minimised. The fibre was transferred to cylindrical supports after 40 minutes 
and freeze dried. This caused some sections of the hollow fibre to distend and swell 
as the pressure fell. This was due to air and water trapped in the lumen of the fibre 
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evaporating due to the low pressure and not being able to escape through the open 
ends of the fibre fast enough. Immersing the fibres in liquid nitrogen prior to freeze 
drying may prevent this. In addition, the fibres remained soft which suggests that 
NMP remained in the fibre. These difficulties should be possible to overcome 
offering the potential for improved drug release of more compounds with higher 
water solubility than cisplatin. 
 193 
 
References 
ABRAMOFF, M. D., MAGELHAES, P. J. & RAM, S. J. (2004) Image Processing 
with ImageJ. Biophotonics International, 11, 36-42. 
AKAIKE, H. (1974) A new look at the statistical model identification. IEEE 
Transactions on Automatic Control, 19, 716-23. 
ALBERTS, D. S., GREEN, S., HANNIGAN, E. V., O'TOOLE, R., STOCK-
NOVACK, D., ANDERSON, P., SURWIT, E. A., MALVLYA, V. K., 
NAHHAS, W. A. & JOLLES, C. J. (1992) Improved therapeutic index of 
carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: 
final report by the Southwest Oncology Group of a phase III randomized trial 
in stages III and IV ovarian cancer. J Clin Oncol, 10, 706-717. 
ALBERTS, D. S., LIU, P. Y., HANNIGAN, E. V., O'TOOLE, R., WILLIAMS, S. 
D., YOUNG, J. A., FRANKLIN, E. W., CLARKE-PEARSON, D. L., 
MALVIYA, V. K., DUBESHTER, B., ADELSON, M. D. & HOSKINS, W. 
J. (1996) Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide 
versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage 
III Ovarian Cancer. N Engl J Med, 335, 1950-1955. 
ALTSHULLER, A. P. & EVERSON, H. E. (1953) The Solubility of Ethyl Acetate 
in Water. J Am Chem Soc, 75, 1727. 
ANDERSON, J. M. & SHIVE, M. S. (1997) Biodegradation and biocompatibility of 
PLA and PLGA microspheres. Adv Drug Deliv Rev, 28, 5-24. 
ARAKI, H., TANI, T. & KODAMA, M. (1999) Antitumor Effect of Cisplatin 
Incorporated into Polylactic Acid Microcapsules. Artif Organs, 23, 161-168. 
ARMSTRONG, D. K., BUNDY, B., WENZEL, L., HUANG, H. Q., BAERGEN, R., 
LELE, S., COPELAND, L. J., WALKER, J. L., BURGER, R. A. & THE 
GYNECOLOGIC ONCOLOGY GROUP (2006) Intraperitoneal Cisplatin 
and Paclitaxel in Ovarian Cancer. N Engl J Med, 354, 34-43. 
ARTURSSON, P., BROWN, D., DIX, J., GODDARD, P. & PETRAK, K. (1990) 
Preparation of Sterically Stabilized Nanoparticles by Desolvation from Graft 
Copolymers. J Polym Sci A, 28, 2651-2663. 
AVGOUSTAKIS, K., BELETSI, A., PANAGI, Z., KLEPETSANIS, P., 
KARYDAS, A. G. & ITHAKISSIOS, D. S. (2002) PLGA-mPEG 
nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug 
release and in vivo drug residence in blood properties. J Control Release, 79, 
123-135. 
BACH, F. D., CARLIER, R. Y., ELIS, J. B., MOMPOINT, D. M., FEYDY, A., 
JUDET, O., BEAUFILS, P. & VALLÉE, C. (2002) Anterior Cruciate 
Ligament Reconstruction with Bioabsorbable Polyglycolic Acid Interference 
Screws: MR Imaging Follow-up. Radiology, 225, 541-550. 
BATES, D. M. & WATTS, D. G. (1981) A Relative Offset Orthogonality 
Convergence Criterion for Nonlinear Least Squares. Technometrics, 23, 179-
183. 
BENET, L. Z. (1985) Mean residence time in the body versus mean residence time 
in the central compartment. J Pharmacokinet Pharmacodyn, 13, 555-558. 
BENET, L. Z. & TURI, J. S. (1971) Use of the General Partial Fraction Theorems 
for Obtaining Inverse Laplace Transforms in Pharmacokinetic Analysis. J 
Pharm Sci, 60, 1593-94. 
 194 
BOURNE, D. W. A. & STRAUSS, S. (1995) Mathematical Modeling of 
Pharmacokinetic Data, CRC. 
BRAUNECKER, J., BABA, M., MILROY, G. E. & CAMERON, R. E. (2004) The 
effects of molecular weight and porosity on the degradation and drug release 
from polyglycolide. Int J Pharm, 282, 19-34. 
BROWN, M. R. W. & SMITH, A. W. (2003) Antimicrobial Agents and Biofilms. IN 
WILSON, M. & DEVINE, D. (Eds.) Medical Implications of Biofilms. 
Cambridge University Press. 
BRUNTON, L. L., LAZO, S. L. & PARKER, K. (2005) Goodman & Gilman's The 
Pharmacological Basis Of Therapeutics, McGraw-Hill. 
BURGER, K. N., STAFFHORST, R. W., VIJLDER, H. C. D., VELINOVA, M. J., 
BOMANS, P. H., FREDERIK, P. M. & KRUIJFF, B. D. (2002) 
Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat 
Med, 1, 81-84. 
BURGHARDT, E., GIRARDI, F., LAHOUSEN, M., TAMUSSINO, K. & 
STETTNER, H. (1991) Patterns of pelvic and paraaortic lymph node 
involvement in ovarian cancer. Gynecol Oncol, 40, 103-106. 
CARSLAW, H. S. & JAEGER, J. C. (1959) Conduction of Heat in Solids, Oxford, 
Oxford University Press. 
CHEN, J. T., HIRAI, Y., SHIMIZU, Y., HASUMI, K. & MASUBUCHI, K. (1990) 
New Cisplatin Schedule in Combination with Aclarubicin (ACR) with High 
Response Rate in Recurrent Gynecological Adenocarcinomas. Gynecol 
Oncol, 38, 1-5. 
CHEUNG, Y., CRADOCK, J., VISHNUVAJJALA, B. & FLORA, K. (1987) 
Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly 
used intravenous solutions. Am J Hosp Pharm, 44, 124-130. 
CLERICI, W. J., HENSLEY, K., DIMARTINO, D. L. & BUTTERFIELD, D. A. 
(1996) Direct detection of ototoxicant-induced reactive oxygen species 
generation in cochlear explants. Hear Res, 98, 116-124. 
CORI, C. F. & CORI, G. T. (1929) Glycogen Formation in the Liver from d- and l-
Lactic Acid. J Biol Chem, 81, 389-403. 
CRAMTON, S. E., ULRICH, M., GÖTZ, F. & DÖRING, G. (2001) Anaerobic 
Conditions Induce Expression of Polysaccharide Intercellular Adhesin in 
Staphylococcus aureus and Staphylococcus epidermidis. Infect Immun, 69, 
4079-4085. 
CRANK, J. (1975) The Mathematics of Diffusion, Bristol, Oxford University Press. 
CUTRIGHT, D. E., BEASLEY, J. D. & PEREZ, B. (1971) Histologic comparison of 
polylactic and polyglycolic acid sutures. Oral Surg Oral Med Oral Pathol, 
32, 165-173. 
DE JONG, S. J., ARIAS, E. R., RIJKERS, D. T. S., VAN NOSTRUM, C. F., 
KETTENES-VAN DEN BOSCH, J. J. & HENNINK, W. E. (2001) New 
insights into the hydrolytic degradation of poly(lactic acid): participation of 
the alcohol terminus. Polymer, 42, 2795-2802. 
DE KROON, A. I. P. M., STAFFHORST, R. W. H. M., DE KRUIJFF, B. & 
BURGER, K. N. J. (2005) Cisplatin Nanocapsules. Methods Enzymol, 391, 
118-125. 
DONLAN, R. M. (2001) Biofilms and Device-Associated Infections. Emerging 
Infectious Diseases, 7, 227-281. 
 195 
EASTMAN, A. (1986) Reevaluation of interaction of cis-
dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry, 25, 3912-
3915. 
EASTMAN, A. & SCHULTE, N. (1988) Enhanced DNA Repair as a Mechanism of 
Resistance to cis-Diamminedichloroplatinum(II). Biochemistry, 27, 4730-
4734. 
EINHORN, L. H. (2002) Curing metastatic testicular cancer PNAS, 99, 4592-95. 
EISENKOP, S. M., FRIEDMAN, R. L. & WANG, H.-J. (1997) Complete 
Cytoreductive Surgery Is Feasible and Maximizes Survival in Patients with 
Advanced Epithelial Ovarian Cancer: A Prospective Study. Gynecol Oncol, 
69, 103-108. 
ELLIS, M. J. & CHAUDHURI, J. B. (2006) Poly(lactic-co-glycolic acid) Hollow 
Fibre Membranes for use as a Tissue Engineering Scaffold. Biotechnol 
Bioeng, 96, 177-187. 
ERLICHMAN, C., SOLDIN, S. J., THIESSEN, J. J., STURGEON, J. F. G. & FINE, 
S. (1987) Disposition of total and free cisplatin on two consecutive treatment 
cycles in patients with ovarian cancer. Cancer Chemother Pharmacol, 19, 
75-79. 
ESPÓSITO, B. P. & NAJJAR, R. (2002) Interactions of antitumoral platinum-group 
metallodrugs with albumin. Coord Chem Rev, 232, 137-149. 
FABBRI, F., CARLONI, S., BRIGLIADORI, G., ZOLI, W., LAPALOMBELLA, R. 
& MARINI, M. (2006) Sequential events of apoptosis involving docetaxel, a 
microtubule-interfering agent: A cytometric study. BMC Cell Biol, 7. 
FOLEY, I., MARSH, P., WELLINGTON, E. M. H., SMITH, A. W. & BROWN, M. 
R. W. (1999) General stress response master regulator rpoS is expressed in 
human infection: a possible role in chronicity. J Antimicrob Chemother, 43, 
164-5. 
FRY, W. A., PHILLIPS, J. L. & MENCK, H. R. (2000) Ten-year survey of lung 
cancer treatment and survival in hospitals in the United States: A National 
Cancer Data Base Report. Cancer, 86, 1867-76. 
FU, J. C., HAGEMEIR, C. & MOYER, D. L. (1976) A Unified Mathematical Model 
for Diffusion from Drug-Polymer Composite Tablets. J Biomed Mater Res, 
10, 743-758. 
FU, S., KAVANAGH, J. J., HU, W. & JR., R. C. B. (2006) Clinical application of 
oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer, 16, 1717-1732. 
FUJIYAMA, J., NAKASEA, Y., OSAKIB, K., SAKAKURAA, C., YAMAGISHI , 
H. & HAGIWARA, A. (2003) Cisplatin incorporated in microspheres: 
development and fundamental studies for its clinical application. J Control 
Release, 89, 397-408. 
GADDUCCI, A., CARNINO, F., CHIARA, S., BRUNETTI, I., TANGANELLI, L., 
ROMANINI, A., BRUZZONE, M., CONTE, P. F. & GONO 
COLLABORATIVE CENTERS (2000) Intraperitoneal versus Intravenous 
Cisplatin in Combination with Intravenous Cyclophosphamide and 
Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian 
Cancer: A Randomized Trial of the Gruppo Oncologico Nord-Ovest Gynecol 
Oncol, 76, 157-162. 
GAO, W. G., PU, S. P., LIU, W. P., LIU, Z. D. & YANG, Y. K. (2003) [The 
aquation of oxaliplatin and the effect of acid] [Article in Chinese]. Yao Xue 
Xue Bao, 38, 223-226. 
 196 
GEDCKE, D. A. (1972) The Si(Li) X-ray Energy Analysis System: Operating 
Principles and Performance. X-Ray Spectrometry, 1, 129-141. 
GEORGOULIAS, V., PAPADAKIS, E., ALEXOPOULOS, A., TSIAFAKI, X., 
RAPTI, A., VESLEMES, M., PALAMIDAS, P. & VLACHONIKOLIS, I. 
(2001) Platinum-based and non-platinum-based chemotherapy in advanced 
non-small-cell lung cancer: a randomised multicentre trial. Lancet, 357, 
1478-84. 
GILDING, D. K. & REED, A. M. (1979) Biodegradable polymers for use in 
surgery—polyglycolic/poly(actic acid) homo- and copolymers: 1 Polymer, 
20, 1459-64. 
GLUECKAUF, E. & COATES, J. I. (1947) Theory of Chromatography. Part IV. 
The Influence of Incomplete Equilibrium on the Front Boundary of 
Chromatograms and on the Effectiveness of Separation. J. Chem. Soc., 1315–
1321. 
GOLUB, T. R., SLONIM, D. K., TAMAYO, P., HUARD, C., GAASENBEEK, M., 
MESIROV, J. P., COLLER, H., LOH, M. L., DOWNING, J. R., 
CALIGIURI, M. A., BLOOMFIELD, C. D. & LANDER, E. S. (1999) 
Molecular Classification of Cancer: Class Discovery and Class Prediction by 
Gene Expression Monitoring Science, 15, 531-537. 
GRAHAM, J. & FALK, S. (2005) ASWCS Chemotherapy Handbook Jan 2005 
Update: B2.8 Cisplatin. Avon, Somerset and Wiltshire NHS Cancer Services. 
GROSS, M., CRAMTON, S. E., GÖTZ, F. & PESCHEL, A. (2001) Key Role of 
Teichoic Acid Net Charge in Staphylococcus aureus Colonization of 
Artificial Surfaces Infection and Immunity, 69, 3423-26. 
HAGIWARA, A., TAKAHASHI, T., KOJINIA, O., YAMAGUCHI, T., SASABE, 
T., LEE, M., SAKAKURA, C., SHOUBAYASHI, S., LKADA, Y. & 
HYON, S.-H. (1993a) Pharmacologic Effects of Cisplatin Microspheres on 
Peritoneal Carcinomatosis in Rodents. Cancer, 71, 844-850. 
HAGIWARA, A., TAKAHASHI, T., SAWAI, K., SAKAKURA, C., TSUJIMOTO, 
H., OSAKI, K., SAKAKIBARA, T., OHYAMA, T., OHGAKI, M., 
MURANISHI, S., IKADA, Y. & HYON, S.-H. (1993b) Clinical trials with 
intraperitoneal cisplatin microspheres for malignant ascites--a pilot study. 
Anticancer Drug Des, 8, 463-470. 
HALL, M. D., AMJADI, S., ZHANG, M., BEALE, P. J. & HAMBLEY, T. W. 
(2004) The mechanism of action of platinum(IV) complexes in ovarian 
cancer cell lines. J Inorg Biochem, 98, 1614-24. 
HAYES, D., CVITKOVIC, E., GOLBEY, R., SCHEINER, E., HELSON, L. & 
KRAKOFF, I. (1977) High dose cis-platinum diammine dichloride. . Cancer, 
39, 1372. 
HEILMANN, C. (2003) Molecular Basis of Biofilm Formation by Staphylococcus 
epidermidis. IN WILSON, M. & DEVINE, D. (Eds.) Medical Implications of 
Biofilms. Cambridge University Press. 
HENGSTLER, J. G., HENGST, A., FUCHS, J., TANNER, B., POHL, J. & OESCH, 
F. (1997) Induction of DNA crosslinks and DNA strand lesions by 
cyclophosphamide after activation by cytochrome P450 2B1. Mutat Res, 373, 
215-223. 
HIGUCHI, T. (1961) Rate of Release of Medicaments from Ointment Bases 
Containing Drugs in Suspension. Journal of Pharmaceutical Sciences, 50, 
874-5. 
 197 
HOLSCHNEIDER, C. H. & BEREK, J. S. (2000) Ovarian Cancer: Epidemiology, 
Biology, and Prognostic Factors. Semin Surg Oncol, 19, 3-10. 
HOLY, C. E., CHENG, C., DAVIES, J. E. & SHOICHET, M. S. (2001) Optimizing 
the sterilization of PLGA scaffolds for use in tissue engineering 
Biomaterials, 22, 25-31. 
HORTOBAGYI, G. N., FRYE, D., BUZDAR, A. U., EWER, M. S., FRASCHINI, 
G., HUG, V., AMES, F., MONTAGUE, E., CARRASCO, C. H., MACKAY, 
B. & BENJAMIN, R. S. (1988) Decreased cardiac toxicity of doxorubicin 
administered by continuous intravenous infusion in combination 
chemotherapy for metastatic breast carcinoma. Cancer, 63, 37-45. 
HRECZUK-HIRST, D., CHICCO, D., GERMAN, L. & DUNCAN, R. (2001) 
Dextrins as potential carriers for drug targeting: tailored rates of dextrin 
degradation by introduction of pendant groups. Int J Pharm, 230, 57-66. 
HUO, D., DENG, S., LI, L. & JI, J. (2005) Studies on the poly(lactic-co-glycolic) 
acid microspheres of cisplatin for lung-targeting. Int J Pharm, 289, 63-67. 
ICH Q3C (R3) (2005) Impurities: Guideline For Residual Solvents. International 
Conference On Harmonisation Of Technical Requirements For Registration 
Of Pharmaceuticals For Human Use. 
IGA, K., HAMAGUCHI, N., IGARI, Y., OGAWA, Y., GOTOH, K., OOTSU, K., 
TOGUCHI, H. & SHIMAMOTO, T. (1991) Enhanced Antitumor Activity in 
Mice after Administration of Thermosensitive Liposome Encapsulating 
Cisplatin with Hyperthermia. J Pharmacol Exp Ther, 257, 1203-1207. 
IKE, O., SHIMIZU, Y., WADA, R., HYON, S.-H. & IKADA, Y. (1992) Controlled 
cisplatin delivery system using poly(d,l-lactic acid). Biomaterials, 13, 230-
234. 
ISHIDA, S., LEE, J., THIELE, D. J. & HERSKOWITZ, I. (2002) Uptake of the 
anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and 
mammals. PNAS, 99, 14298-14302. 
ISHIHARA, T., IZUMO, N., HIGAKI, M., SHIMADA, E., HAGI, T., MINE, L., 
OGAWA, Y. & MIZUSHIM, Y. (2005) Role of zinc in formulation of 
PLGA/PLA nanoparticles encapsulating betamethasone phosphate and its 
release profile. J Control Release, 105, 68-76. 
JAABACK, K. & JOHNSON, N. (2006) Intraperitoneal chemotherapy for the initial 
management of primary epithelial ovarian cancer. Cochrane Database of 
Systematic Reviews. 
JAMZAD, S., TUTUNJI, L. & FASSIHI, R. (2005) Analysis of macromolecular 
changes and drug release from hydrophilic matrix systems. Int J Pharm, 292, 
75-85. 
JANSSEN PHARMACEUTICAL PRODUCTS INC. (2006) Risperdal Consta® 
Package Insert. 
JEMAL, A., SIEGEL, R., WARD, E., MURRAY, T., XU, J. & THUN, M. J. (2007) 
Cancer Statistics, 2007. CA Cancer J Clin, 57, 43-66. 
JEONG, B., BAE, Y. H., LEE, D. S. & KIM, S. W. (1997) Biodegradable block 
copolymers as injectable drug-delivery systems. Nature, 388, 860-862. 
JONES, R. H. & VASEY, P. A. (2003) Part II: Testicular cancer—management of 
advanced disease. Lancet Oncol, 4, 738-747. 
KARTALOU, M. & ESSIGMANN, J. M. (2001) Mechanisms of resistance to 
cisplatin. Mutat Res, 478, 23-43. 
KAWASHIMA, Y., YAMAMOTO, H., TAKEUCHI, H., HINO, T. & NIWA, T. 
(1998) Properties of a peptide containing dl-lactide/glycolide copolymer 
 198 
nanospheres prepared by novel emulsion solvent diffusion methods Eur J 
Pharm Biopharm, 45, 41-48. 
KELLAND, L. (2007) The resurgence of platinum-based cancer chemotherapy. 
Nature Reviews Cancer, 7, 573-84. 
KEREN, I., KALDALU, N., SPOERING, A., WANG, Y. & LEWIS, K. (2004) 
Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett, 230, 13-
18. 
KIM, B.-S., NIKOLOVSKI, J., BONADIO, J., SMILEY, E. & MOONEY, D. J. 
(1999) Engineered Smooth Muscle Tissues: Regulating Cell Phenotype with 
the Scaffold. Exp Cell Res, 251, 318-328. 
KIM, H., SUH, H., AHN JO, S., WOO KIM, H., LEE, J. M., KIM, E. H., 
REINWALD, Y., PARK, S.-H., MIN, B.-H. & JO, I. (2005) In vivo bone 
formation by human marrow stromal cells in biodegradable scaffolds that 
release dexamethasone and ascorbate-2-phosphate. Biochem Biophys Res 
Commun, 332, 1053-60. 
KIRMANI, S., BRALY, P. S., MCCLAY, E. F., SALTZSTEIN, S. L., PLAXE, S. 
C., KIM, S., CATES, C. & HOWELL, S. B. (1995) A Comparison of 
Intravenous Versus Intraperitoneal Chemotherapy for the Initial Treatment of 
Ovarian Cancer. Obstet Gynecol Surv, 50, 115-117. 
KNOX, R. J., FRIEDLOS, F., LYDALL, D. A. & ROBERTS, J. J. (1986) 
Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-
diamminedichloroplatinum(II) and cis-diammine-(1,1-
cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their 
interaction with DNA. Cancer Res, 46, 1972-1979. 
KORST, A. E. C., VAN DER STERRE, M. L. T., GALL, H. E., FICHTINGER-
SCHEPMAN, A. M. J., VERMORKEN, J. B. & VAN DER VIJGH, W. J. F. 
(1998) Influence of Amifostine on the Pharmacokinetics of Cisplatin in 
Cancer Patients. Clin Cancer Res, 4, 331-336. 
KUMAGAI, S., SUGIYAMA, T., NISHIDA, T., USHIJIMA, K. & YAKUSHIJI, M. 
(1996) Improvement of intraperitoneal chemotherapy for rat ovarian cancer 
using cisplatin-containing microspheres. Jpn J Cancer Res, 87, 412-417. 
LA FONTAINE, S. & MERCER, J. F. B. (2007) Trafficking of the copper-ATPases, 
ATP7A and ATP7B: Role in copper homeostasis Arch Biochem Biophys, 
463, 149-167. 
LA MARCA, A. & VOLPE, A. (2007) The Anti-Mullerian hormone and ovarian 
cancer. Human Reproduction Update, 13, 265-73. 
LAKESHORE BIOMATERIALS DATASHEET Solubility Chart. Lakeshore 
Biomaterials. 
LEE, J., PEÑA, M. M. O., NOSE, Y. & THIELE, D. J. (2001) Biochemical 
Characterization of the Human Copper Transporter Ctr1. J Biol Chem, 277, 
4380-87. 
LEWIN, B. (2000) Genes VII, New York, Oxford University Press. 
LIDE, D. R. (2005) CRC Handbook of Chemistry and Physics, CRC Press, Taylor & 
Francis Group. 
LOS, G., MUTSAERS, P. H., LENGLET, W. J., BALDEW, G. S. & MCVIE, J. G. 
(1990) Platinum distribution in intraperitoneal tumors after intraperitoneal 
cisplatin treatment. Cancer Chemother Pharmacol, 25, 389-394. 
LOS, G., VERDEGAAL, E. M., MUTSAERS, P. H. & MCVIE, J. G. (1991) 
Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after 
intraperitoneal chemotherapy. Cancer Chemother Pharmacol, 28, 159-165. 
 199 
MA, J., STOTER, G., VERWEIJ, J. & SCHELLENS, J. H. M. (1996) Comparison 
of ethanol plasma-protein precipitation with plasma ultrafiltration and 
trichloroacetic acid protein precipitation for the measurment of unbound 
platinum concentrations. Cancer Chemother Pharmacol, 38, 391-94. 
MACHIDA, Y., ONISHI, H., KURITA, A., HATA, H., MORIKAWA, A. & 
MACHIDA, Y. (2000) Pharmacokinetics of prolonged-release CPT-11-
loaded microspheres in rats. J Control Release, 66, 159-175. 
MARKMAN, M., BUNDY, B. N., ALBERTS, D. S., FOWLER, J. M., CLARK-
PEARSON, D. L., CARSON, L. F., WADLER, S. & SICKEL, J. (2001) 
Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus 
Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and 
Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An 
Intergroup Study of the Gynecologic Oncology Group, Southwestern 
Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol, 
19, 1001-1007. 
MARKMAN, M., KENNEDY, A., WEBSTER, K., ELSON, P., PETERSON, G., 
KULP, B. & BELINSON, J. (1999) Clinical Features of Hypersensitivity 
Reactions to Carboplatin. J Clin Oncol, 17, 1141-1145. 
MATSUMOTO, A., MATSUKAWA, Y., SUZUKI, T. & YOSHINO, H. (2005) 
Drug release characteristics of multi-reservoir type microspheres with 
poly(dl-lactide-co-glycolide) and poly(dl-lactide). J Control Release, 106, 
172-180. 
MAYERSOHN, M. & GIBALDI, M. (1970) Mathematical methods in 
pharmacokinetics. I. Use of the Laplace transform for solving differential rate 
equations. Amer J Pharm Ed, 34, 608-614. 
MCGUIRE, W. P., HOSKINS, W. J., BRADY, M. F., KUCERA, P. R., 
PARTRIDGE, E. E., LOOK, K. Y., CLARKE-PEARSON, D. L. & 
DAVIDSON, M. (1996) Cyclophosphamide and Cisplatin Compared with 
Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian 
Cancer. N Engl J Med, 334, 1-6. 
MESSARITAKIA, A., BLACKB, S. J., VAN DER WALLEC, C. F. & RIGBY, S. 
P. (2005) NMR and confocal microscopy studies of the mechanisms of burst 
drug release from PLGA microspheres J Control Release, 108, 271-281. 
MIYAGI, Y., FUJIWARA, K., KIGAWA, J., ITAMOCHI, H., NAGAO, S., 
AOTANI, E., TERAKAWA, N. & KOHNO, I. (2005) Intraperitoneal 
carboplatin infusion may be a pharmacologically more reasonable route than 
intravenous administration as a systemic chemotherapy. A comparative 
pharmacokinetic analysis of platinum using a new mathematical model after 
intraperitoneal vs. intravenous infusion of carboplatin-A Sankai Gynecology 
Study Group (SGSG) study. Gynecol Oncol, 99, 591-596. 
MOMPARLER, R. L., KARON, M., SIEGEL, S. E. & AVILA, F. (1976) Effect of 
Adriamycin on DNA, RNA, and Protein Synthesis in Cell-free Systems and 
lntact Cells. Cancer Res, 36, 2891-95. 
MORTON, G. & THOMAS, G. (1996) Is there a place for whole abdominal 
radiotherapy in the management of ovarian cancer? Ann Acad Med 
Singapore, 25, 429-436. 
MUGGLI, D. S., BURKOTH, A. K. & ANSETH, K. S. (1999) Crosslinked 
polyanhydrides for use in orthopedic applications: Degradation behavior and 
mechanics. J Biomed Mater Res A, 46, 271-278. 
 200 
NAGAI, N. & OGATA, H. (1997) Quantitative relationship between 
pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: 
importance of area under the concentration-time curve (AUC) as the major 
toxicodynamic determinant in vivo. Cancer Chemother Pharmacol, 40, 11-
18. 
NEWMAN, M. S., COLBERN, G. T., WORKING, P. K., ENGBERS, C. & 
AMANTEA, M. A. (1999) Comparative pharmacokinetics, tissue 
distribution, and therapeutic effectiveness of cisplatin encapsulated in long-
circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer 
Chemother Pharmacol, 43, 1-7. 
NISHIYAMA, N., OKAZAKI, S., CABRAL, H., MIYAMOTO, M., KATO, Y., 
SUGIYAMA, Y., NISHIO, K., MATSUMURA, Y. & KATAOKA, K. 
(2003) Novel cisplatin-incorporated polymeric micelles can eradicate solid 
tumors in mice. Cancer Res, 63, 8977-8983. 
NIWA, T., TAKEUCHI, H., HINO, T., KUNOU, N. & KAWASHIMA, Y. (1993) 
Preparations of biodegradable nanospheres of water-soluble and insoluble 
drugs with  -lactide/glycolide copolymer by a novel spontaneous 
emulsification solvent diffusion method, and the drug release behavior J 
Control Release, 25, 89-98. 
NOH, S.-M. (2003) Measurement of Peritoneal Fluid pH in Patients with Non-
Serosal Invasive Gastric Cancer. Yonsei Med J, 44, 45-48. 
O’BRIEN, C. N. & GUIDRY, A. J. (1996) Formulation of Poly(DL-Lactide-Co-
Glycolide) Microspheres and Their Ingestion by Bovine Leukocytes. J Dairy 
Sci, 79, 1954-1959. 
OFFICE FOR NATIONAL STATISTICS (1995) Cancer survival trends in England 
and Wales, 1971-1995: deprivation and NHS Region (CDROM). 
OKADA, H. (1997) One- and three-month release injectable microspheres of the 
LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev, 28, 43-70. 
OMURA, G., BLESSING, J. A., EHRLICH, T. C. E., MILLER, A., YORDAN, E., 
CREASMAN, W. T. & HOMESLEY, H. D. (1986) A Randomized Trial of 
Cyclophosphamide and Doxorubicin With or Without Cisplatin in Advanced 
Ovarian Carcinoma: A Gynecologic Oncology Group Study. Cancer, 57, 
1725-30. 
PARKIN, D. M., BRAY, F., FERLAY, J. & PISANI, P. (2005) Global Cancer 
Statistics, 2002. CA Cancer J Clin, 55, 74-108. 
PELEG-SHULMAN, T., GIBSON, D., COHEN, R., ABRA, R. & BARENHOLZ, 
Y. (2001) Characterization of sterically stabilized cisplatin liposomes by 
nuclear magnetic resonance. Biochem Biophys Acta, 1510, 278-291. 
PERERA, S. P. & TAI, C. C. (2006) Hollow Fibres. UK. 
PETIT, T., VELTEN, M., D’HOMBRES, A., MARCHAL, C., MONTBARBON, 
X., MORNEX, F., QUETIN, P., GÉRARD, J.-P., ROMESTAING, P. & 
CARRIE, C. (2006) Long-term survival of 106 stage III ovarian cancer 
patients with minimal residual disease after second-look laparotomy and 
consolidation radiotherapy Gynecol Oncol, 104, 104-108. 
PLUNKETT, W., HUANG, P., XU, Y., HEINEMANN, V., GRUNEWALD, R. & 
GANDHI, V. (1995) Gemcitabine: metabolism, mechanisms of action, and 
self-potentiation. Semin Oncol, 22, 3-10. 
POLYZOS, A., TSAVARIS, N., KOSMAS, C., GIANNIKOS, L., KATSIKAS, M., 
KALAHANIS, N., KARATZAS, G., CHRISTODOULOU, K., 
GIANNAKOPOULOS, K., STAMATIADIS, D. & KATSILAMBROS, N. 
 201 
(1999) A Comparative Study of Intraperitoneal Carboplatin versus 
Intravenous Carboplatin with Intravenous Cyclophosphamide in Both Arms 
as Initial Chemotherapy for Stage III Ovarian Cancer. Oncology, 56, 291-
296. 
POPOVA, E. (2006) WebComputing Service Framework. Int. Journal Information 
Theories & Applications, 13, 246-254. 
PRIOR, S., GANDER, B., BLARER, N., MERKLE, H. P., SUBIRÁ, M. L., 
IRACHE, J. M. & GAMAZO, C. (2002) In vitro phagocytosis and 
monocyte-macrophage activation with poly(lactide) and poly(lactide-co-
glycolide) microspheres. Eur J Pharm Sci, 15, 197-207. 
QIN, J. & CHUNG, T.-S. (1999) Effect of dope flow rate on the morphology, 
separation performance, thermal and mechanical properties of ultrafiltration 
hollow fibre membranes. J Membr Sci, 157, 35-51. 
R DEVELOPMENT CORE TEAM (2007) R: A language and environment for 
statistical computing., R Foundation for Statistical Computing, Vienna, 
Austria. 
REEDIJK, J. (2003) New Clues for Platinum Antitumor Chemistry: Kinetically 
Controlled Metal Binding to DNA. PNAS, 100, 3611-3616. 
RICHARDS, M. J., EDWARDS, J. R., CULVER, D. H. & GAYNES, R. P. (2000) 
Nosocomial infections in combined medical-surgical intensive care units in 
the United States. Infect Control Hosp Epidemiol, 21, 510-515. 
RITGER, P. L. & PEPPAS, N. A. (1987) A simple equation for description of solute 
release I. Fickian and non-Fickian release from non-swellable devices in the 
form of slabs, spheres, cylinders or discs. J Control Release, 5, 23-36. 
ROSENBERG, B., VAN CAMP, L. & KRIGAS, T. (1965) Inhibition of Cell 
Division in Escherichia coli by Electrolysis Products from a Platinum 
Electrode. Nature, 205. 
SALTZMAN, W. M. & RADOMSKY, M. L. (1991) Drugs released from polymers: 
diffusion and elimination in brain tissue. . Chem. Eng. Sci. , 10, 2429-44. 
SAMIMI, G., VARKI, N. M., WILCZYNSKI, S., SAFAEI, R., ALBERTS, D. S. & 
HOWELL, S. B. (2003) Increase in Expression of the Copper Transporter 
ATP7A during Platinum Drug-Based Treatment Is Associated with Poor 
Survival in Ovarian Cancer Patients. Clin Cancer Res, 9, 5853-5859. 
SHANKARAN, V., IKEDA, H., BRUCE, A. T., WHITE, J. M., SWANSON, P. E., 
OLD, L. J. & SCHREIBER, R. D. (2001) IFN and lymphocytes prevent 
primary tumour development and shape tumour immunogenicity. Nature, 
410, 1107-11. 
SHEARER, H., ELLIS, M. J., PERERA, S. P. & CHAUDHURI, J. B. (2006) Effects 
of Common Sterilization Methods on the Structure and Properties of 
Poly(D,L Lactic-Co-Glycolic Acid) Scaffolds. Tissue Engineering, 12, 2717-
27. 
SIRCAR, S. & HUFTON, J. R. (2000) Why does the Linear Driving Force Model 
for Adsorption Kinetics Work? Adsorption, 6, 137-147. 
SMITH, A. W. (2005) Biofilms and antibiotic therapy: Is there a role for combating 
bacterial resistance by the use of novel drug delivery systems? Advanced 
Drug Delivery Reviews, 57, 1539-50. 
SORBE, B. (2003) Consolidation treatment of advanced (FIGO stage III) ovarian 
carcinoma in complete surgical remission after induction chemotherapy: A 
randomized, controlled, clinical trial comparing whole abdominal 
 202 
radiotherapy, chemotherapy, and no further treatment International Journal 
of Gynecological Cancer, 13, 278-286. 
SORENSON, C. M., BARRY, M.A.,EASTMAN, A. (1990) Analysis of events 
associated with cell cycle arrest at G2 phase and cell death induced by 
cisplatin. J Natl Cancer Inst, 82, 749-755. 
STEN-KNUDSEN, O. (2002) Biological Membranes: Theory of Transport, 
Potentials and Electric Impulses Cambridge University Press. 
SULLIVAN, J. B. J. & KRIEGER, G. R. (1992) Hazardous Materials Toxicology-
Clinical Principles of Environmental Health., Baltimore, MD, Williams and 
Wilkins. 
SWEETMAN, S. C. (2004) Martindale:The Complete Drug Reference, 
Pharmaceutical Press, London. 
SWENERTON, K., JEFFREY, J., STUART, G., ROY, M., KREPART, G., 
CARMICHAEL, J., DROUIN, P., STANIMIR, R., O'CONNELL, G., 
MACLEAN, G. & AL., E. (1992) Cisplatin-cyclophosphamide versus 
carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized 
phase III study of the National Cancer Institute of Canada Clinical Trials 
Group. J Clin Oncol, 10, 718-726. 
TABATA, Y. & IKADA, Y. (1988) Effect of the size and surface charge of polymer 
microspheres on their phagocytosis by macrophage. Biomaterials, 9, 356-
362. 
TAKAHARA, P. M., FREDERICK, C. A. & LIPPARD, S. J. (1996) Crystal 
Structure of the Anticancer Drug Cisplatin Bound to Duplex DNA. J Am 
Chem Soc, 118, 12309-12321. 
TAMAI, H., IGAKI, K., KYO, E., KOSUGA, K., KAWASHIMA, A., MATSUI, S., 
KOMORI, H., TSUJI, T., MOTOHARA, S. & UEHATA, H. (2000) Initial 
and 6-Month Results of Biodegradable Poly-l-Lactic Acid Coronary Stents in 
Humans. Circulation, 102, 399-404. 
TAMURA, T., IMAI, J., MATSUMOTO, A., TANIMOTO, M., SUZUKI, A., 
HORIKIRI, Y., SUZUKI, T., YOSHINO, H. & IKE, O. (2002) Organ 
distribution of cisplatin after intraperitoneal administration of cisplatin-
loaded microspheres. Eur J Pharm Biopharm, 54, 1-7. 
TAP PHARMACEUTICAL PRODUCTS INC. (2003) Lupron Depot® Package 
Insert. 
TOWNSEND, D. M., DENG, M., ZHANG, L., LAPUS, M. G. & HANIGAN, M. H. 
(2003) Metabolism of Cisplatin to a Nephrotoxin in Proximal Tubule Cells. J 
Am Soc Nephrol, 14, 1-10. 
TRACY, M. A., WARD, K. L., FIROUZABADIAN, L., WANG, Y., DONG, N., 
QIAN, R. & ZHANG, Y. (1999) Factors a!ecting the degradation rate of 
poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials, 
20, 1057-1062. 
TROPE, C., KAERN, J., HOGBERG, T., ABELER, V., HAGEN, B., 
KRISTENSEN, G., ONSRUD, M., PETTERSEN, E., ROSENBERG, P., 
SANDVEI, R., SUNDFOR, K. & VERGOTE, I. (2000) Randomized study 
on adjuvant chemotherapy in stage I high-risk ovarian 
cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol, 11, 
281-288. 
URIEN, S. & LOKIEC, F. (2004) Population pharmacokinetics of total and unbound 
plasma cisplatin in adult patients. Br J Clin Pharmacol, 57, 756-763. 
 203 
VON EIFF, C., JANSEN, B., KOHNEN, W. & BECKER, K. (2005) Infections 
Associated with Medical Devices: Pathogenesis, Management and 
Prophylaxis. Drugs, 65, 179-214. 
VON HOFF, D. D., SCHILSKY, R., REICHERT, C. M., REDDICK, R. L., 
ROZENCWEIG, M., YOUNG, R. C. & MUGGIA, F. M. (1979) Toxic 
effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep, 63, 
1527-1531. 
WALLACE, D. W., STAUDT-BICKEL, C. & KOROS, W. J. (2006) Efficient 
development of effective hollow fiber membranes for gas separations from 
novel polymers J Membr Sci, 278, 92-104. 
WANG, D., LI, K. & TEO, W. K. (1996) Polyethersulfone hollow fiber gas 
separation membranes prepared from NMP/alcohol solvent systems. J 
Membr Sci, 115, 85-108. 
WARME, W. J., ARCIERO, R. A., SAVOIE III, F. H., UHORCHAK, J. M. & 
WALTON, M. (1999) Nonabsorbable Versus Absorbable Suture Anchors for 
Open Bankart Repair Am J Sports Med, 27, 742-746. 
WARNER, D. F. & MIZRAHI, V. (2003) Mechanisms of Stationary-Phase 
Mutagenesis in Bacteria and their Relevance to Antibiotic Resistance. IN 
COATES, A. R. M. (Ed.) Dormancy and Low-Growth States in Microbial 
Disease. Cambridge University Press. 
WATTS, P. J., DAVIES, M. C. & MELIA, C. D. (1990) Microencapsulation using 
emulsification/solvent evaporation: an overview of techniques and 
applications. Crit Rev Ther Drug Carrier Syst, 7, 235-259. 
WEN, X. & TRESCO, P. A. (2006) Fabrication and characterization of permeable 
degradable poly(dl-lactide-co-glycolide) (PLGA) hollow fiber phase 
inversion membranes for use as nerve tract guidance channels Biomaterials, 
27, 3800-09. 
WENCLAWIAK, B. W. & WOLLMANN, M. (1996) Separation of platinum(II) 
anti-tumour drugs by micellar electrokinetic capillary chromatography J 
Chromatogr A, 724, 317-326. 
WILSON, R. H., LEHKY, T., THOMAS, R. R., QUINN, M. G., FLOETER, M. K. 
& GREM, J. L. (2002) Acute Oxaliplatin-Induced Peripheral Nerve 
Hyperexcitability. J Clin Oncol, 20, 1767-1774. 
WIRTH, T., ZENDER, L., SCHULTE, B., MUNDT, B., PLENTZ, R., RUDOLPH, 
K. L., MANNS, M., KUBICKA, S. & KÜHNEL, F. (2003) A Telomerase-
dependent Conditionally Replicating Adenovirus for Selective Treatment of 
Cancer. Cancer Res, 63, 3181-88. 
WITZIG, T. E., GORDON, L. I., CABANILLAS, F., CZUCZMAN, M. S., 
EMMANOUILIDES, C., JOYCE, R., POHLMAN, B. L., BARTLETT, N. 
L., WISEMAN, G. A., PADRE, N., GRILLO-LÓPEZ, A. J., MULTANI, P. 
& WHITE, C. A. (2002) Randomized Controlled Trial of Yttrium-90–
Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab 
Immunotherapy for Patients With Relapsed or Refractory Low-Grade, 
Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma J Clin Oncol, 
20, 2453-63. 
YEN, M.-S., JUANG, C.-M., LAI, C.-R., CHAO, G.-C., NG, H.-T. & YUAN, C.-C. 
(2001) Intraperitoneal cisplatin-based chemotherapy vs. intravenous 
cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial 
ovarian cancer Int J Gynecol Obstet, 72, 55-60. 
 204 
ZWEIZIG, S., ROMAN, L. D. & MUDERSPACH, L. I. (1994) Death from 
Anaphylaxis to Cisplatin: A Case Report. Gynecol Oncol, 53, 121-122. 
ZYLBERBERG, B., RAVINA, J., SALAT-BAROUX, J., DORMONT, D., LIPP, B. 
& GUILLET, J. (1986) [Polychemotherapy of ovarian cancer via combined 
intravenous and intraperitoneal routes. Technic and preliminary results]. J 
Gynecol Obstet Biol Reprod, 15, 671-6. 
 
 
 205 
Appendices 
Appendix A – Solvents of PLGA 
Appendix A Solvents of PLGA 
Name Ethyl acetate Dichloro-
methane 
Trichloro-
methane 
Propanone N,N-Dimethyl 
formamide 
Tetra-
hydrofuran 
Hexafluoro-
Isopropanol 
N-Methyl-2-
Pyrrolidone 
CAS (141-78-6) (75-09-2) (67-66-3) (67-64-1) (68-12-2) (109-99-9) (920-66-1) (872-50-4) 
Density (g cm-3) 0.9020 1.3320 1.4825 0.7825 0.944525 0.8825 1.4621 1.0225 
Solubility of PLGA 50:50  SS S S SS S SS S S 
Solubility in water S SS SS M M M M VS 
Boiling point (°C) 77 40 61 56 153 65 59 202 
Rat oral LD50 (mg kg
-1) 5600 1600 940 5800 2800 2200 1300 4000 
 
Table A1: Solvents of PLGA 50:50. 
Density of liquid at superscript temperature (°C) compared to the density of water at 4°C. Boiling points measured at 101.3kPa. S = soluble, SS = slightly 
soluble, VS = very soluble, M = miscible. Density (at temperature), solvent solubility in water and boiling point from Lide, 2005 (Lide, 2005). Solubility of PLGA 
50:50 in solvent from Lakeshore Biomaterials datasheet (Lakeshore Biomaterials datasheet). LD50 values from material safety data sheets (see Table A2 for 
MSDS online locations). 
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Chemical LD50 (mg kg
-1
) Source MSDS Online Location 
Ethyl acetate 5620 
5620 
Fisher 
Oxford 
https://fscimage.fishersci.com/msds/08750.htm 
http://physchem.ox.ac.uk/MSDS/ET/ethyl_acetate.html 
Dichloromethane 1600 
1600 
Fisher  
Oxford 
http://www.soest.hawaii.edu/krubin/MSDS/dichloromethane.html 
http://physchem.ox.ac.uk/MSDS/DI/dichloromethane.html 
Trichloromethane 695 
1194 
Fisher 
Oxford 
https://fscimage.fishersci.com/msds/93015.htm 
http://ptcl.chem.ox.ac.uk/MSDS/CH/chloroform.html 
Acetone 5800 
5800 
Fisher 
Oxford 
https://fscimage.fishersci.com/msds/00140.htm 
http://ptcl.chem.ox.ac.uk/MSDS/PR/propanone.html 
N,N-Dimethylformamide 2800 
2800 
Fisher 
Dupont 
https://fscimage.fishersci.com/msds/07860.htm 
http://msds.dupont.com/msds/pdfs/EN/PEN_09004a2f8061e698.pdf 
Tetrahyrdofuran 1650 
2816 
Fisher 
Oxford 
https://fscimage.fishersci.com/msds/23011.htm 
http://physchem.ox.ac.uk/MSDS/TE/tetrahydrofuran.html 
Hexafluoroisopropanol 1500 
1040 
Fisher 
Dupont 
https://fscimage.fishersci.com/msds/94544.htm 
http://msds.dupont.com/msds/pdfs/EN/PEN_09004a2f8062a65e.pdf 
N-Methyl-2-Pyrrolidinone 3914 
4150 
Fisher 
Whitaker 
https://fscimage.fishersci.com/msds/08690.htm 
http://www.whitakeroil.com/MSDS/COM%20td%20ehswww%20servlet%20FileStreamServlet.pdf 
 
Table A2: Oral LD50 of organic solvents for rats.  
LD50 from material safety data sheets from two online sources each. Where values differ, mean is used in thesis text. 
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Appendix B Derivation of Two Compartment Pharmacokinetic Model 
Rate equations can be determined by assuming a two compartment model (Figure 4). 
The pharmacokinetics of cisplatin can be derived from the rate equations using Laplace 
transformations (Mayersohn and Gibaldi, 1970). Converting a function into Laplace 
space allows operations to be performed on the expressions more easily than in regular 
space. The Laplace transform (equation 47) is widely used in science and engineering 
for solving integrals. 
 
( ){ } ( ) ( )dttftstfL ∫
∞
⋅−=
0
exp  (47) 
 
Complex expressions can be solved using tables of transformations. Some common 
transforms are shown in Table B1.  
 
Function: f(t) Laplace: f(s) 
1 
s
1
 
A 
s
A
 
ateA −⋅  
as
A
+
 
( )ateA −−⋅ 1  ( )ass
A
+
 
( )
( )btat ee
ab
A −− −
−
 
( )( )bsas
A
++
 
 
Table B1: Useful Laplace transforms (Mayersohn and Gibaldi, 1970). 
 
For solving pharmacokinetic problems the rate equations are generally straightforward. 
However, solving for the concentration of a compartment with several mass transfer 
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directions can be challenging. Fortunately there is a method for solving problems that 
are not tabulated. 
 
The general partial fraction theorem states that the function P(u)/Q(u) can be expressed 
as a sum of partial fractions, where P(u) is a polynomial with a lower degree in u than 
another polynomial, Q(u). General partial fraction theorem can be used to solve first 
order rate equations (Benet and Turi, 1971). 
 
( )
( )
( )
( )
( )t
Q
P
sQ
sP
L i
n
i ii
i λ
λ
λ
exp
1
1 ∑
=
− =






 (48) 
 
This method (equation 48), described as the fingerprint method (Bourne and Strauss, 
1995), states that the inverse Laplace transformation of a quotient of two polynomials of 
the form P(s)/Q(s) can be expressed as the sum of the expression with each root 
substituted in turn. This is true provided that Q(s) has a higher degree in s and contains 
the factor (s – λi) which is not repeated. ( )iP λ  is the value of the numerator for each s 
term. ( )iiQ λ  is the value of the denominator when λi is substituted for s terms apart 
from the term containing λi which is excluded. 
 
Using these Laplace transform methods the pharmacokinetics can be determined for this 
drug. Figure 4 shows a two compartment pharmacokinetic model where an initial dose, 
DW, is injected into the blood of a patient, becoming rapidly mixed throughout the whole 
central compartment with volume, V. The concentration of cisplatin in the central 
compartment, W1, is determined by the rate of transfer into, c12, and out of, c21, the 
peripheral compartment, the concentration of cisplatin in the peripheral compartment, 
W2, and the rate of elimination, cel. 
 
112
1
1221 WcWcWc
dt
dW
el−−=  
(1) 
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21
2
2112 WcWc
dt
dW
−=  
(2) 
 
In Laplace space: 
 
112)0(11 1221 WcWcWcWWs el−−=−⋅  
(49) 
 
21)0(22 2112 WcWcWWs −=−⋅  
(50) 
 
Where 1W  and 2W  are the concentrations in the central and peripheral compartments 
transformed into Laplace space. The boundary conditions are that when t = 0, W2 = 0 
and W1 = DW /V.
 
 
( ) 121 12WcWWs =⋅+  (51) 
 
Substitute 51 into 49 to give: 
 
( )
1111 12
21
1221 WcWcW
cs
cc
VDWs elW −−+
=−⋅ , or; 
 
( ) ( ) ( ){ } ( )( )211221212112211 csVDcccsccsccssW Wel +=−+++++⋅ , so; 
 
( )( )
( ) 2112212
211
cccccss
csVD
W
elel
W
++++
+
=  (52) 
 
The denominator can be factorised using two roots, αW and βW to give; 
 
( )( )
( )( )WW
W
ss
csVD
W
βα ++
+
= 211  (53) 
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where; 
 
21ccelWW =βα  (54) 
 
and; 
 
elWW ccc ++=+ 1221βα  (55) 
 
This can be transformed into real space using the fingerprint method for the inverse 
Laplace transform giving equation 56. 
 
( ) ( ) ( ) ( ) ( ){ }tctcVDW WWWW
WW
W ⋅−+−−⋅−+−
−
= ββαα
αβ
expexp1 2121  
(56) 
 
This is commonly simplified to the empirical form in equation 3 where AW and BW are 
the aggregated constants. 
 
( ) ( )tBtAW WWWW ⋅−+⋅−= βα expexp1  (3) 
 
From this model (equation 56) the pharmacokinetics of cisplatin can be calculated. 
 
 Estimate Std. Error t value Pr(>|t|) 
DW /V 3.54E+00 8.48E-02 41.7 1.30E-11 
αW 1.00E-03 9.62E-05 10.4 2.53E-06 
βW 3.96E-06 6.60E-07 6.00 2.04E-04 
c21 3.44E-04 3.91E-05 8.80 1.02E-05 
 
Table B2: Fit parameters for pharmacokinetic model of cisplatin distribution to mean 
plasma cisplatin concentration data from Erlichman, et al., 1987 using R. 
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Table B2 shows the fit parameters for mean data from Erlichman, et al., 1987. Using the 
known relationships of the roots (equations 54 and 55), cel = 1.2×10
-5 s-1 and 
c12 = 6.5×10
-4 s-1. Based on a dose of 50 mg m-2 with an estimated mean surface area of 
1.69 m2, volume of distribution in the aqueous compartment was 24 l, similar to the 
volume of distribution of 21 l reported elsewhere (Urien and Lokiec, 2004). 
 
From the two compartment model incorporating protein binding (Figure 5) the rate 
equations can be derived. 
 
1112
1
1221 UkUjUjUj
dt
dU
bel −−−=  (57) 
 
Equation 57 for unbound cisplatin is similar to equation 1 for total cisplatin but 
incorporates the protein binding effect. The concentration of unbound cisplatin in the 
central compartment can be determined as above but with different parameters since; 
 
( ) 122112 jjjjkk elbbWW −++=βα  (58) 
 
and; 
 
elbWW jjk ++=+ 122βα  (59) 
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Appendix C – Derivation of Semi-Empirical Release Models 
Appendix C Derivation of Semi-Empirical Release Models 
The equation which predicts empirical release of drug from a depot device (such as a 
PLGA microsphere or fibre) can be derived from the rate equations using Laplace 
transformations (Mayersohn and Gibaldi, 1970). Figure 15 shows the scheme of 
cisplatin release, where X1 is the amount released into solution, M2(∞) is amount of 
cisplatin in the depot which will be released after a long time and k21 is the release 
constant. From this model it can be seen that the concentration of cisplatin, X1, changes 
at a rate; 
 
2
1
21 Xk
dt
dX
⋅=  
(4) 
 
 
The concentration of cisplatin remaining in the fibre, X2, falls at a rate; 
 
2
2
21 Xk
dt
dX
⋅−=  
(60) 
 
These differential equations can be solved using the Laplace transformation. In Laplace 
space these equations have the form; 
 
( ) 2011 21 XkXXs =−⋅  (61) 
 
( ) 2022 21 XkXXs ⋅−=−⋅  (62) 
 
Here 1X  and 2X  are X1 and X2 in Laplace space. The initial conditions are X1(0) = 0 
and X2(0) = M2(∞) so therefore; 
 
( )
( )21
2
2
ks
M
X
+
∞
=  
(63) 
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Substituting this back into equation 61 gives; 
 
( )
( )21
21 21
kss
Mk
X
+
∞
=  
(64) 
 
Using an anti-Laplace transform (Table B1) to convert equation 64, which is in Laplace 
space, back into real space gives; 
 
( ) ( )tkeMX 21121 −−⋅∞=  (5) 
 
The two compartment model in Figure 15 is described by equation 5 (as long as k21 is 
kept constant by sink conditions). A single exponential is a poor fit for some 
formulations if there is a significant initial burst release. To improve the fit if a one 
compartment model is insufficient a second release pool within the device can be added. 
Physically this might represent a rapid dissolution of drug crystals in accessible pores 
near the surface of the device followed by slower release of well dispersed drug from 
the matrix. 
 
Figure 16 shows the release scheme which in physical terms these represent a surface 
pool, M3(∞), of readily released cisplatin at rate k31 and a well dispersed pool, M4(∞), 
of slowly released cisplatin at a rate, k41. The sum of drug in both pools M3(∞) and 
M4(∞) is the total drug loading. For the two compartments in the fibre the rate equation 
will be of the form; 
 
3
3
31 Xk
dt
dX
⋅−=  
(65) 
 
 
So in Laplace space; 
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( )
31
3
3
ks
M
X
+
∞
=  
(66) 
 
While for the solution compartment; 
 
43
1
4131 XkXk
dt
dX
⋅+⋅=  
(67) 
 
In Laplace space is; 
 
 
( ) ( )
41
41
31
31
43
1
ks
M
k
ks
M
ksX
+
∞
⋅+
+
∞
⋅=⋅ , or; 
 
( )( ) ( )( )
( )( )4131
31414131 431
kskss
ksMkksMk
X
++
+∞⋅++∞⋅
=  
(68) 
 
 
Equation 68 can be solved using the fingerprint method (Appendix B) The degree in s of 
the polynomial in the denominator of equation 68 is higher than the polynomial in the 
numerator and there are no repeating terms so the fingerprint method may be applied. 
The roots are found by letting each factor of the denominator be zero so s = 0, -k31 and 
-k41. To transform this into an expression in real space each root is substituted for s in 
turn (excluding the polynomial term) and then multiplied by the exponential of the 
product of time and the root, ( )tiλexp . The sum of these three values is the integrated 
function X1. 
 
{ }
( ) ( )( )
( )( )
( )
( )( )
( ) 



















⋅
+−−
+−∞⋅
+
⋅
+−−
+−∞⋅
+
⋅
∞+∞⋅
==
⋅−
⋅−−
tk
tk
e
kkk
kkMk
e
kkk
kkMk
kk
MMkk
XXL
41
31
314141
314141
413131
413131
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1
4
3
43
11 , or; 
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( ) ( ){ } ( ) ( ) tktk eMeMMMX ⋅−⋅− ⋅∞−⋅∞−∞+∞= 4131 43431  (7) 
 
The amount of drug released can be derived from the rate equations as to give the model 
shown in equation 7. 
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Appendix D – Derivation of Protein Binding Equations 
Appendix D Derivation of Protein Binding Equations 
The empirical release models can also be applied to the case where protein removes 
cisplatin from solution. The two compartment case can be solved as for no clearance of 
the drug but with rate equation 69 replacing equation 4. 
 
12
1
21 XkXk
dt
dX
b ⋅−⋅=  
(69) 
 
 
This means that in Laplace space the substituted equation becomes; 
 
( )
( )( )bksks
Mk
X
++
∞
=
21
21 21  
(70) 
 
 
When this is transformed back into real space using the fingerprint method (see 
Appendix B) the concentration is predicted by equation 8. Transforms can also be 
carried out using tables of Laplace transforms where available.  
 
( )
( )
( )
( )
tk
b
tk
b
be
kk
Mk
e
kk
Mk
X
−− ⋅
+−
∞
+⋅
+−
∞
=
21
21
21
21 221 21 , or; 
 
( )
( )
( )tktk
b
bee
kk
Mk
X
−− −⋅
−
∞
= 21
21
21 21  (8) 
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TWOCMPRF2<-nls(cispF2~ 
 k_21*M*(exp(-k_21*timpF2s)-exp(-k_b*timpF2s))/(k_b-k_21) 
,start=list(k_21=1e-5,k_b=1e-4,M=0.6)) 
 
 
Table D: Code for non-linear least squares fitting of two compartment protein binding 
model to cisplatin release data using R.  
The parameters to be estimated are M2(∞), the total drug, k21, the release constant and kb, the 
binding constant of cisplatin to BSA. 
 
This model is suitable in many situations for determining the cisplatin concentration in 
the presence of protein. In cases where the three compartment model gives an improved 
fit the model can also be derived.  
 
From the rate equations of the three compartment model (Figure 20) the amount of 
cisplatin in solution can be derived. The rate equation for the solution compartment is 
given by equation 71. 
 
143
1
4131 XkXkXk
dt
dX
b ⋅−⋅+⋅=  (71) 
 
This can be transformed into Laplace space and can be combined with expressions for 
the fibre compartments (equation 66) to give; 
 
( ) ( ) ( )
41
41
31
31
43
1
ks
M
k
ks
M
kksX b +
∞
⋅+
+
∞
⋅=+ , or; 
 
( )( ) ( )( )
( )( )( )4131
31414131 431
ksksks
ksMkksMk
X
b +++
+∞⋅++∞⋅
=  (72) 
 
In this case the roots, s = -kb, -k31 and –k41. 
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( )( ) ( )( )
( )( )
( )
( )
( )
( ) 
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−
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b
tk
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tk
bb
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e
kk
Mk
e
kk
Mk
e
kkkk
kkMkkkMk
X
b
41
31
41
41
31
31
4131
31414131
4
3
43
1  
(9) 
 
 
It should be noted that the three compartment model for protein binding (equation 9) 
introduces two additional parameters which may make the model less significant than 
the more simple equation 8. 
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Appendix E – Derivation of Higuchi Kinetics 
Appendix E Derivation of Higuchi Kinetics 
Fick’s Law can be written for an infinite slab as equation 73 where M(t) / A is the 
amount of drug released after an amount of time per unit area, D is the diffusivity, Cs is 
the limit of solubility of the drug in the bathing solution and h is the theoretical distance 
into the slab from which drug has begun eluting. 
 
( )
h
DC
dt
AtMd s=  (73) 
 
Higuchi kinetics (Higuchi, 1961) assumes that there is a perfect sink at the edge of the 
slab. The solubility of drug in the matrix (C(0)) must be much higher than its solubility 
in water (Cs). Also the drug particles must be much smaller than the layer. 
 
 
Figure E: The amount of drug released from the solid matrix of a slab into solution after 
an amount of time is determined by the loading of drug in the matrix (C(0)) and its 
solubility in water (Cs).  
This is calculated using h, the theoretical distance into the slab from which the drug has started 
to elute. Adapted from Higuchi, 1961. 
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Figure E shows that the amount of drug released from the solid matrix of a slab into 
solution after an amount of time is determined geometrically by the solubility of drug in 
the matrix (C(0)) and in water (Cs) by the relationship given in equation 74. 
 
( ) ( ) dhCdhCAtMd s2
1
0 −=  (74) 
 
This can be combined with equation 73 to give equation 75. 
 
( )
h
DC
dt
dh
C
dt
dh
C ss
2
02 =−  (75) 
 
This rearranges to: 
 
( )
dt
DC
dhCCh
s
s =
−
2
)02(
 (76) 
 
Integrating equation 76 gives: 
 
( )
tk
DC
hCC
s
s =+
−
4
)02( 2
 (77) 
 
When t = 0, h = 0, so k = 0. These boundary conditions give: 
 
( ) s
s
CC
tDC
h
−
⋅=
02
2  (78) 
 
So integrating equation 74 with respect to h and substituting equation 78 for h gives 
equation 11. 
 
221 
( ) ( )
( ) s
s
s
CC
tDC
CC
A
tM
−
⋅⋅−=
02
2)
2
1
0( , or; 
 
( ) ( ) tCCDC
A
tM
ss )02( −=  
(11) 
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Appendix F – Derivation of Release from Fick’s Second Law in 
Spherical Coordinates 
Appendix F Derivation of Release from Fick’s Second Law in Spherical Coordinates 
Fick’s first law in spherical coordinates is defined by equation 15, where C(r, t) is the 
concentration, D is the diffusivity and r is the radius. 
 
( ) ( )
r
trC
Dtrj
∂
∂
−=
,
,  (15) 
 
Fick’s second law for spherical coordinates can be derived by finite element analysis. 
By examining the flow of material through an element of the structure, the overall mass 
transfer can be determined. The volume element, ∆V, of a spherical matrix is a spherical 
shell of inner radius r, outer radius r + ∆r. The material entering ∆V during ∆t is an 
amount, inQr
∆t, which crosses the inner surface of the shell with area 4pir2 (equation 74). 
 
( ) trtrjQ tr ∆⋅=
∆ 2in 4, pi  (79) 
 
Here, j(r, t) is the radial flux at a distance r from the centre of the sphere at time t. 
Concurrently an amount, outQr
∆t, is leaving the volume ∆V across the outer surface of the 
shell with area 4pi(r + ∆r)2 (equation 75). 
 
( ) ( ) trrtrrjQ trr ∆∆+⋅∆+=
∆
∆+
2out 4, pi  (80) 
 
Therefore, the amount accumulated in the volume ∆V after ∆t, Q∆V 
∆t, is the difference 
between the two quantities (equation 81). Terms in ∆r2 can be excluded as they rapidly 
tend to zero. 
 
t
rr
t
r
t
V QQQ
∆
∆+
∆∆
∆ −=
outin  (81) 
 
( ) ( )( )( ) trrtrrjrtrjQ tV ∆∆+∆+−=∆∆ 22 ,,4pi , or 
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( ) ( ) ( )( ) trtrrjrtrrjrtrjrQ tV ∆∆∆+−∆+−⋅=
∆
∆ 2,,,4pi  (82) 
 
Assuming that the concentration profile changes slowly then j(r, t) approximates 
j(r, t + ∆t) and j(r + ∆r, t) approximates j(r + ∆r, t + ∆t). The accumulated amount of 
drug, Q∆V 
∆t, equals the change in concentration, ∆C∆t multiplied by the volume, ∆V 
during ∆t. Since ∆V = 4pir2∆r the accumulated amount of drug can be calculated from 
the concentrations in ∆V at t and t + ∆t which are C(r’, t) and C(r’, t + ∆t) respectively 
(equation 89) where r ≤ r’ ≤ r + ∆r so that r’→r, as ∆r→0. 
 
VCQ t
t
V ∆∆=
∆∆
∆  
 
( ) ( )( ) rrtrCttrCQ tV ∆⋅−∆+=
∆
∆
24,',' pi  (83) 
 
Combining equations 82 and 77 and dividing by 4pi·r2∆r∆t produces equation 84, an 
expression relating flux to concentration. 
 
( ) ( ) ( ) ( )( ) ( )




 ∆++
∆
−∆+
−=
∆
−∆+
trrj
r
trjtrrjr
rt
trCttrC
,2
,,1,','
 (84) 
 
At the limits where ∆t→0 and ∆r→0 then r’→r and j(r + ∆r, t)→ j(r, t), which reduces 
to partial derivatives (equation 16). 
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Appendix G – Derivation of Release from Fick’s Second Law in 
Cylindrical Coordinates 
Appendix G Derivation of Release from Fick’s Second Law in Cylindrical Coordinates 
Finite element analysis can be performed for cylinders. The cylinder is assumed to be 
radially homogenous for all angles of θ and along its length for all values of z. 
Therefore, concentration is treated as not being a function of z or θ so these terms are 
excluded from the concentration profile (equation 20). 
 
( ) ( )
0
,,,,
=
∂
∂
=
∂
∂
θ
θθ zrC
z
zrC
 (85) 
 
The volume element, ∆V, is a cylindrical ring of height ∆z, inner radius r, and outer 
radius r + ∆r. The change in concentration in ∆V during ∆t is an amount, inQr
∆t, which 
crosses the inner surface of the ring of radius r and area, 2pi·r∆z. This is summarized by 
equation 86. 
 
( ) tzrtrjQ tr ∆∆⋅=
∆ pi2,in  (86) 
 
Here, j(r, t) is the radial flux at a distance r from the cylinder axis at time t. Concurrently 
an amount, outQr
∆t, is leaving the volume ∆V (equation 87). 
 
( ) ( ) tzrrtrrjQ trr ∆∆∆+⋅∆+=
∆
∆+ pi2,
out
 
(87) 
 
Therefore, the amount accumulated in the volume ∆V after ∆t, Q∆V 
∆t, is the difference 
between the two quantities (equation 88). 
 
t
rr
t
r
t
V QQQ
∆
∆+
∆∆
∆ −=
outin  
 
( ) ( )( )( ) trrtrrjrtrjzQ tV ∆∆+∆+−∆⋅=
∆
∆ ,,2pi  (88) 
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Assuming that the concentration profile changes slowly then j(r, t) approximates 
j(r, t+∆t) and j(r+∆r, t) approximates j(r+∆r, t+∆t). The accumulated amount of drug, 
Q∆V 
∆t, equals the change in concentration, ∆C∆t multiplied by the volume, ∆V during ∆t. 
Since ∆V = 2pi·r∆r∆z, the accumulated amount of drug can be calculated from the 
concentrations in ∆V at t and t+∆t which are C(r’, t) and C(r’, t+∆t) respectively 
(equation 89) where r ≤ r’ ≤ r+∆r so that r’→r, as ∆r→0. 
 
VCQ t
t
V ∆∆=
∆∆
∆  
 
( ) ( )( ) zrrtrCttrCQ tV ∆∆⋅−∆+=
∆
∆ pi2,','  (89) 
 
Combining equations 88 and 89 and dividing by 2pi·r∆r∆z∆t produces equation 90, an 
expression relating flux to concentration. 
 
( ) ( ) ( ) ( ) ( )





 ∆++
∆
−∆+
−=
∆
−∆+
r
trrj
r
trjtrrj
t
trCttrC ,,,,','
 (90) 
 
At the limits where ∆t→0 and ∆r→0 then r’→r and j(r+∆r, t) → j(r, t) reducing to 
partial derivatives (equation 21). 
 
For a cylinder with a uniform initial concentration of drug the solution to equation 30 
simplifies to equation 32 (Crank, 1975) where aαn has the values shown in Table G1 for 
n = 1,…,20. 
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n aαn n aαn 
1 2.40482 11 33.77582 
2 5.52007 12 36.91709 
3 8.65372 13 40.05842 
4 11.79153 14 43.19979 
5 14.93091 15 46.34118 
6 18.07106 16 49.48261 
7 21.21163 17 52.62405 
8 24.35247 18 55.76551 
9 27.49347 19 58.90698 
10 30.63460 20 62.04847 
 
Table G1: The first twenty positive roots of the Bessel function of the first kind of zero 
order. 
Roots calculated using webMathematica (Popova, 2006). 
 
 
( ) ( )
( )
( )






−−⋅∞= ∑
∞
=1
2
2
exp
4
1
n
n
n
tD
a
MtM α
α
 (32) 
 
For a solid fibre the range of the fibre, r, extends from the origin so B in equation 28 
must be zero so that the result falls within the boundary conditions. 
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Cylinder<-nls(cisplatin~ 
 M*(1-((4*exp(-D*(2.404825558/0.024)^2*time)/2.404825558^2 
 +4*exp(-D*(5.52007811/0.024)^2*time)/5.52007811^2 
 +4*exp(-D*(8.653727913/0.024)^2*time)/8.653727913^2))) 
,start=list(M=0.4,D=1e-12)) 
 
 
Table G2: Code for non-linear least squares fitting of a third order Taylor series 
approximation of cylindrical diffusion equation to cisplatin release data using R.  
The parameters to be estimated are M, the total cisplatin, and D, the diffusivity. The radius of the 
cylinder is 0.024 cm and the Bessel zeros are from Table G1. 
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Appendix H – Modification of Fick’s Second Law for Hollow 
Cylinders 
Appendix H Modification of Fick’s Second Law for Hollow Cylinders 
Equations for heat flow in an infinite hollow cylinder (Carslaw and Jaeger, 1959) can be 
used to describe diffusion of a solute from a hollow fibre (Crank, 1975). The solid 
cylinder could be simplified because the Bessel function of the second kind in equation 
28 could not be part of the solution at r = 0. For a hollow fibre however r does not 
include the origin and so the Bessel function of the second kind is set to zero at r = 0 by 
the boundary conditions.  
 
n αn n αn 
1 3.91017 11 43.19529 
2 7.84526 12 47.12242 
3 11.77511 13 51.04952 
4 15.70356 14 54.97661 
5 19.63143 15 58.90368 
6 23.55900 16 62.83075 
7 27.48641 17 66.75780 
8 31.41372 18 70.68485 
9 35.34095 19 74.61189 
10 39.26814 20 78.53893 
 
Table H1: The first twenty positive roots of the Bessel function used for solving release 
from hollow fibres. 
Roots of the Bessel function J0(aαn)Y0(1.8αn)-J0(1.8 αn)Y0(aαn) were calculated using 
webMathematica (Popova, 2006) where 1.8 is the ratio of outer against inner radii for F9 hollow 
fibres. 
229 
 
 
Hollow_Fibre<-nls(cisplatin~ 
 M*(1-4*((((bessel_J0(97.75422897*0.040)-bessel_J0(97.75422897*0.072)) 
 /(97.75422897^2*(bessel_J0(97.75422897*0.040)+bessel_J0(97.75422897*0.072)))) 
 *exp(-D*97.75422897^2*time) 
 +((bessel_J0(196.1315516*0.040)-bessel_J0(196.1315516*0.072)) 
 /(196.1315516^2*(bessel_J0(196.1315516*0.040)+bessel_J0(196.1315516*0.072)))) 
 *exp(-D*196.1315516^2*time) 
 +((bessel_J0(294.3778788*0.040)-bessel_J0(294.3778788*0.072)) 
 /(294.3778788^2*(bessel_J0(294.3778788*0.040)+bessel_J0(294.3778788*0.072)))) 
 *exp(-D*294.3778788^2*time)))/(0.072^2-0.040^2)) 
,start=list(M=1,D=5e-11)) 
 
 
Table H2: Code for non-linear least squares fitting of a third order Taylor series 
approximation of hollow fibre diffusion equation to F9 cisplatin release data using R.  
The parameters to be estimated are M, the total cisplatin, and D, the diffusivity. The first three 
Bessel zeros from Table H1 have been divided by the inner radius, 0.040 cm. 
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Appendix I – Calculation of Diffusivity of Cisplatin in Microspheres 
using Higuchi Kinetics 
Appendix I Calculation of Diffusivity of Cisplatin in Microspheres using Higuchi Kinetics 
To estimate the surface area of a 100 mg sample of microspheres the density is needed. 
This was estimated by displacement of water. 
 
Volume (sample)   = Mass / Density 
     = 100 mg / 780 mg cm-3 
= 0.128 cm3 
Volume (one microsphere)  = 3
3
4
Rpi  
     = 1.13×10-7 cm3 
Number of microspheres (sample) = Volume (sample) / Volume (one microsphere) 
= 0.128 cm3 / 1.13×10-7 cm3 
= 1.13×106 
Surface area (one microsphere) = 24 Rpi  
     = 1.13×10-4 cm2 
Surface area (sample)   = 1.13×10-4 cm2 * 1.13×106 
= 128 cm2 
 
The surface area can be used in conjunction with the Higuchi model to estimate the 
diffusivity of cisplatin in the polymer matrix. 
 
( )
( )( )ss CVMC
Ak
D
−∞
=
2
2
 (13) 
 
The Higuchi constant, k, was 1.1±0.04×10-3 mg s-0.5 for large PLGA 50:50 
microspheres. The surface area of the sample is 128 cm2 based on an approximate mean 
radius of 30 µm and a density of 780 mg cm-3. The solubility of cisplatin, Cs, is 
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2 mg cm-3. The concentration of cisplatin in the sample is 1.2 % of the 100 mg sample 
or 0.012 mg mg-1. 
 
)cm mg 2-)cm mg 780mg mg (0.012(2 cm mg 2
 )cm 128 / s mg (0.0011
3-3-1-3-
22-0.5
⋅⋅⋅
=D  
 
Using this calculation the diffusivity of cisplatin in small PLGA 50:50 microspheres is 
estimated as 2×10-12 cm2 s-1. 
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Appendix J – Calculation of Diffusivity of Cisplatin in Fibres using 
Higuchi Kinetics 
Appendix J Calculation of Diffusivity of Cisplatin in Fibres using Higuchi Kinetics 
The surface area of a sample of fibres was estimated for each type of fibre. For example, 
for F2 fibres the surface area of the fibre was estimated from its bulk properties. 
 
Density (sample)   = Mass (sample) / Volume (sample) 
     = 41.2 mg / 0.14 cm3 
     = 290 mg cm-3 
Volume (sample)   = pi * Radius (sample)2 * Length (sample) 
Radius (sample)   
cm 75.3
cm 14.0 3
⋅
=
pi
 
     = 0.024 cm 
The volume is in agreement with the mean value measured using digital callipers. For 
5 mg fibre the typical length was 9.1 cm. 
 
Surface area (fibre)   = 2 pi * Radius (fibre) * Length (fibre)  
+ 2 pi * Radius (fibre)2 
     = 1.4 cm2 
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Appendix K – Batch Data for PLGA Microspheres and Fibres 
Appendix K Batch Data for PLGA Microspheres and Fibres 
Label L:G Ratio 
Mass PLGA 
(g) 
Mass EA (g) 
Mass Cisplatin 
(g) 
Volume PVA 
(ml) 
Cisplatin 
Loading (%) 
Homogeniser Speed 
(rpm) 
Homogenisation 
Time (min) 
M1 50:50 2.58 23.24 1.34 150 9 9500 13 
Μ3 “ 3.37 30.41 1.51 “ 2-6 “ “ 
Μ4 “ “ “ “ 125* 6-8 “ “ 
Μ7 “ 3.60 32.45 1.18 150 1-2 “ “ 
Μ8 65:35 3.61 32.57 “ “ 1-4 “ “ 
Μ14 “ 2.64 23.76 1.06 160 7 6500 11 
Μ16 “ “ “ 1.06‡ “ 0 “ “ 
Μ17 “ 2.84 25.58 1.00 “ 11 “ “ 
Μ18 “ “ 17.46 “ “ 13 “ “ 
Μ19 “ “ 12.99 “ “ 11 “ “ 
Μ20 “ “ 25.58 1.01 “ 12 “ “ 
Μ21 “ “ “ 1.00 “ 7-9 “ “ 
Μ22 “ “ “ 1.00‡ “ 0 “ “ 
Μ25 “ “ “ 1.00 “ 6 “ “ 
Μ26 “ “ “ “ “ 4 “ “ 
Μ27 “ “ 25.59 “ “ 5 “ “ 
 
Table K1: Conditions of manufacture of batches of PLGA microspheres. 
 * Twice volume of dope added to PVA. † Dichloromethane replaced ethyl acetate. ‡ Phenolphthalein replaced cisplatin. ◊ Carboplatin replaced 
cisplatin. 
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Label 
L:G 
Ratio 
Mass 
PLGA (g) 
Mass NMP 
(g) 
Mass 
Cisplatin (g) 
Flow Rate 
(ml h-1) 
Hollow 
Diameter 
(cm) 
Density 
(g cm-3) 
Cisplatin 
Loading (%) 
Water Flow 
(ml h-1) 
F1 75:25 5.54 27.7 0.6 60 N 0.044 212 0 NA 
F2 65:35 2.14 9.91 1.07 “ “ 0.048 294 10-11 “ 
F3 “ 2.15 9.98 1.11 “ “ “ 267 9-24 “ 
F4 “ 2.14 9.92 1.06 “ “ 0.052 287 15 “ 
F5 “ “ “ 0 “ “ 0.059 240 0 “ 
F6 “ “ “ 1.31◊ “ “ 0.097 271 5 “ 
F7 “ 3.21 14.87 1.61 “ “ 0.065 223 ND “ 
F8 “ 3.03 14.05 1.52‡ 50 Y 0.110 506 0 70 
F9 “ “ 14.04 1.52 200 “ 0.127 276 21-22 200 
F10 “ 5.8 26.87 2.91 “ “ 0.149 357 27-28 “ 
 
Table K2: Conditions of manufacture of batches of PLGA fibres. 
‡ Phenolphthalein replaced cisplatin. ◊ Carboplatin replaced cisplatin. 
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Appendix L – Modelling Cisplatin Release from PLGA 
Microspheres 
Appendix L Modelling Cisplatin Release from PLGA Microspheres 
Mean M3, M7 1-38 µm Mean M3, M7 38-90 µm Parameter 
Estimate St. Error Estimate St. Error 
Higuchi k (mg s-0.5) 3.41E-03*** 1.31E-04 1.11E-03*** 3.68E-05 
AIC Higuchi 45.0 -36.8 
Empirical 2 M2(∞) (mg) 4.89E+00*** 9.53E-01 1.18E+00*** 1.04E-01 
Empirical 2 k21 (s
-1) 1.40E-06** 4.27E-07 2.51E-06*** 4.37E-07 
AIC Empirical 2 54.1 -33.8 
 
Table L1: Parameters for release of cisplatin from PLGA 50:50 microspheres. 
Higuch and empirical two compartment models calculated by non-linear least squares 
regression. There was insufficient data for three compartment model and spherical Fickian 
models to converge. AIC is comparable between models not between microsphere datasets. 
Parameters are marked *** if they are significant at p < 0.001 and ** at p < 0.01. 
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Mean M14, M17-M21 Parameter 
Estimate St. Error 
Higuchi k (mg s-0.5) 1.37E-02*** 4.22E-04 
AIC Higuchi NA 
Spherical M(∞) (mg) 1.22E+01*** 3.67E-01 
Spherical D/R 2 (s-1) 2.10E-07*** 2.68E-08 
AIC Spherical 484 
Empirical 2 M2(∞) (mg) 1.14E+01*** 2.64E-01 
Empirical 2 k21 (s
-1) 4.639E-06*** 4.19E-07 
AIC Empirical 2 532 
Empirical 3 M3(∞) (mg) 3.51E+00*** 4.68E-01 
Empirical 3 M4(∞) (mg) 8.73E+00*** 4.64E-01 
Empirical 3 k31 (s
-1) 8.34E-05** 2.96E-05 
Empirical 3 k41 (s
-1) 2.22E-06*** 3.54E-07 
AIC Empirical 3 480 
 
Table L2: Parameters for release of cisplatin from six batches of PLGA 65:35 
Microspheres.  
Higuchi, spherical Fickian, two and three compartment models were fitted by non-linear least 
squares regression using R. AIC is comparable between models not between microsphere 
datasets. Parameters are marked *** if they are significant at p < 0.001 and ** at p < 0.01. 
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M21 (aged) M25 Parameter 
Estimate St. Error Estimate St. Error 
Spherical M(∞) (mg) 5.40E-01*** 7.91E-03 4.74E-01*** 4.84E-03 
Spherical D/R 2 (s-1) 1.37E-06*** 1.28E-07 1.41E-06*** 8.81E-08 
AIC Spherical -195.9 -228.6 
Empirical 2 M2(∞) (mg) 5.15E-01*** 9.37E-03 4.53E-01*** 7.32E-03 
Empirical 2 k21 (s
-1) 4.51E-05*** 4.37E-06 4.62E-05*** 3.64E-06 
AIC Empirical 2 -156.1 -170.7 
Empirical 3 M3(∞) (mg) 2.26E-01*** 2.78E-02 2.20E-01*** 1.61E-02 
Empirical 3 M4(∞) (mg) 3.24E-01*** 2.73E-02 2.64E-01*** 1.58E-02 
Empirical 3 k31 (s
-1) 1.87E-04*** 4.82E-05 1.47E-04*** 2.00E-05 
Empirical 3 k41 (s
-1) 9.71E-06*** 1.46E-06 8.88E-06*** 8.71E-07 
AIC Empirical 3 -199.4 -249.6 
 
Table L3: Parameters for release of cisplatin from aged (M21) and sieved (M25) 
PLGA 65:35 microspheres. 
Parameters calculated by non-linear least squares regression using spherical Fickian and 
empirical two and three compartment models. Higuchi model was not appropriate for this 
dataset. AIC is comparable between models not between microsphere datasets. Parameters 
are marked *** as they are significant at p < 0.001. 
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M26 M27 Parameter 
Estimate St. Error Estimate St. Error 
Spherical M(∞) (mg) 3.50E-01*** 3.43E-03 4.35E-01*** 5.92E-03 
Spherical D/R 2 (s-1) 7.86E-07*** 4.16E-08 1.40E-06*** 1.17E-07 
AIC Spherical -301.0 -203.0 
Empirical 2 M2(∞) (mg) 3.26E-01*** 5.66E-03 4.13E-01*** 7.89E-03 
Empirical 2 k21 (s
-1) 2.60E-05*** 2.53E-06 4.85E-05*** 4.61E-06 
AIC Empirical 2 -218.1 -157.7 
Empirical 3 M3(∞) (mg) 1.99E-01*** 1.11E-02 1.88E-01*** 1.74E-02 
Empirical 3 M4(∞) (mg) 1.60E-01*** 1.06E-02 2.56E-01*** 1.72E-02 
Empirical 3 k31 (s
-1) 6.36E-05*** 5.33E-06 1.84E-04*** 3.47E-05 
Empirical 3 k41 (s
-1) 4.32E-06*** 5.01E-07 9.08E-06*** 1.10E-06 
AIC Empirical 3 -327.3 -217.6 
 
Table L4: Parameters for release of cisplatin from sieved (M27, M27) PLGA 65:35 
microspheres. 
Parameters calculated by non-linear least squares regression using spherical Fickian and 
empirical two and three compartment models. Higuchi model was not appropriate for this 
dataset. AIC is comparable between models not between microsphere datasets. Parameters 
are marked *** as they are significant at p < 0.001. 
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Appendix M – Modelling Cisplatin Release from PLGA Fibres 
Appendix M Modelling Cisplatin Release from PLGA Fibres 
F2 F3 F4 Parameter 
Estimate St. Error Estimate St. Error Estimate St. Error 
Cylindrical M(∞) (mg) 1.95E+00 1.86E+00 1.18E+00*** 1.06E-01 8.27E+00 1.83E+01 
Cylindrical D (cm2 s-1) 8.60E-09 1.75E-08 3.42E-10** 1.04E-10 9.82E-13 4.40E-12 
AIC Cylindrical -275.4 0.2158 -69.14 
Higuchi k (mg s-0.5) 5.76E-04*** 1.15E-05 1.45E-03*** 5.74E-05 7.61E-04*** 3.36E-05 
AIC Higuchi -276.7 12.82 -71.30 
Empirical 2 M2(∞) (mg) 4.93E-01*** 2.00E-02 1.08E+00*** 5.57E-02 7.43E-01*** 8.41E-02 
Empirical 2 k21 (s
-1) 4.25E-06*** 4.30E-07 7.45E-06*** 1.16E-06 2.96E-06*** 7.65E-07 
AIC Empirical 2 -253.6 4.466 -66.25 
Empirical 3 M3(∞) (mg) 1.18E-01*** 2.96E-02 1.69E-01 1.10E-01 8.46E-02 5.33E-02 
Empirical 3 M4(∞) (mg) 5.54E-01*** 1.10E-01 9.54E-01*** 1.05E-01 8.32E-01** 2.40E-01 
Empirical 3 k31 (s
-1) 3.95E-05* 1.79E-05 1.64E-04 2.51E-04 1.65E-04 2.97E-04 
Empirical 3 k41 (s
-1) 1.49E-06* 6.66E-07 5.18E-06** 1.60E-06 1.64E-06 1.01E-06 
AIC Empirical 3 -274.4 3.006 -66.28 
 
Table M: Parameters for release of cisplatin from PLGA 65:35 solid fibres. 
Parameters were calculated by non-linear least squares regression using cylindrical Fickian, 
Higuchi and empirical two and three compartment models. AIC is comparable between 
models not between fibre datasets. Parameters are marked *** if they are significant at 
p < 0.001, ** at p < 0.01, * at p < 0.05 and are not marked if they are not significant. 
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Appendix N – Effect of Ethanol on Fibre Release Parameters 
Appendix N Effect of Ethanol on Fibre Release Parameters 
F9 F9 (ethanol) Parameter 
Estimate St. Error Estimate St. Error 
Hollow M(∞) (mg) 1.10E+00*** 3.51E-02 1.19E+00*** 2.27E-02 
Hollow D (cm2 s-1) 3.27E-10*** 3.18E-11 3.78E-10*** 2.60E-11 
AIC Hollow -185.8 -151.7 
Higuchi k (mg s-0.5) 1.13E-03*** 2.64E-05 1.29E-03*** 3.12E-05 
AIC Higuchi -93.45 -57.41 
Empirical 2 M2(∞) (mg) 1.04E+00*** 2.59E-02 1.15E+00*** 1.54E-02 
Empirical 2 k21 (s
-1) 5.02E-06*** 3.28E-07 5.30E-06*** 2.32E-07 
AIC Empirical 2 -177.7 -163.6 
Empirical 3 M3(∞) (mg) 1.12E-01* 5.15E-02 6.72E-02* 2.91E-02 
Empirical 3 M4(∞) (mg) 9.59E-01*** 4.76E-02 1.10E+00*** 2.83E-02 
Empirical 3 k31 (s
-1) 1.55E-04 1.59E-04 2.85E-04 4.06E-04 
Empirical 3 k41 (s
-1) 3.94E-06*** 5.30E-07 4.75E-06*** 3.05E-07 
AIC Empirical 3 -184.2 -171.0 
 
Table N1: Release parameters for release of cisplatin from PLGA 65:35 F9 hollow 
fibres before and after ethanol treatment.  
Parameters were calculated by non-linear least squares regression using cylindrical Fickian, 
Higuchi and empirical two and three compartment models. AIC is comparable between 
models not between fibre datasets. Parameters are marked *** if they are significant at 
p < 0.001, * at p < 0.05 and are unmarked if they are not significant. 
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F10 F10 (ethanol) Parameter 
Estimate St. Error Estimate St. Error 
Hollow M(∞) (mg) 1.40E+00*** 3.64E-02 1.48E+00*** 2.12E-02 
Hollow D (cm2 s-1) 2.95E-10*** 2.71E-11 5.12E-10*** 3.12E-11 
AIC Hollow -137.8 -169.0 
Higuchi k (mg s-0.5) 1.48E-03*** 2.86E-05 1.72E-03*** 4.08E-05 
AIC Higuchi -55.76 29.39 
Empirical 2 M2(∞) (mg) 1.35E+00*** 2.19E-02 1.45E+00*** 1.59E-02 
Empirical 2 k21 (s
-1) 4.78E-06*** 2.45E-07 7.86E-06*** 3.20E-07 
AIC Empirical 2 -177.0 -202.5 
Empirical 3 M3(∞) (mg) 2.53E-02 2.70E-02 6.25E-02 5.78E-02 
Empirical 3 M4(∞) (mg) 1.33E+00*** 3.11E-02 1.40E+00*** 5.56E-02 
Empirical 3 k31 (s
-1) 7.76E-04 3.47E-03 2.17E-04 4.88E-04 
Empirical 3 k41 (s
-1) 4.62E-06*** 3.03E-07 7.34E-06*** 5.26E-07 
AIC Empirical 3 -174.1 -202.7 
 
Table N2: Release parameters for release of cisplatin from PLGA 65:35 F10 hollow 
fibres before and after ethanol treatment.  
Parameters were calculated by non-linear least squares regression using cylindrical Fickian, 
Higuchi and empirical two and three compartment models in R. AIC is comparable between 
models not between fibre datasets. Parameters are marked *** if they are significant at 
p < 0.001 and are not marked if they are not significant. 
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Appendix O – Modelling Carboplatin Release from Solid Fibres 
 
Appendix O Modelling Carboplatin Release from Solid Fibres 
F6 Parameter 
Estimate St. Error 
Cylindrical M(∞) (mg) 2.46E-01*** 1.49E-02 
Cylindrical D (cm2 s-1) 6.96E-09** 2.27E-09 
AIC Cylindrical -140 
Empirical 2 M2(∞) (mg) 2.42E-01*** 1.41E-02 
Empirical 2 k21 (s
-1) 2.75E-05** 8.16E-06 
AIC Empirical 2 -141 
 
Table O: Release parameters for release of carboplatin from PLGA 65:35 F6 fibres. 
Parameters were calculated by non-linear least squares regression using cylindrical Fickian, 
and empirical two compartment models. Higuchi and three compartment models were not 
significant. Parameters are marked *** if they are significant at p < 0.001 and ** at p < 0.01. 
 
 
